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ABSTRACT
Phenylbutazone is a non-steroidal anti-inflammatory drug that 
acts by inhibiting prostaglandin synthesis. Prostaglandins are 
associated with crucial aspects of reproduction. In 5 experiments, 
mares were used to test the effects of phenylbutazone on 
reproduction. In all experiments, treatment was 2 g phenylbutazone 
or 10 ml physiological saline intravenously(control).
In Experiment I, 9 mares were phenylbutazone-treated for 180 
consecutive days and teased. Ovaries were palpated and cyclicity was 
verified by circulating progesterone concentrations. Thirty-six 
cycles were evaluated. Mares were then divided into treatment and 
control groups. Estrous mares were artificially inseminated. 
Non-surgical embryo collection was performed 7 to 8 days 
post-ovulation. Three fertilized ova were collected from control 
mares and 1 from a treated mare. Results suggested that 
phenylbutazone had no effect on estrual behavior, cyclicity or 
ovulation.
In Experiment II, 8 mares were phenylbutazone-treated daily for 
33 days. Blood samples and corresponding uterine secretions were 
obtained daily. Only purulent samples of uterine secretion were 
positive for phenylbutazone.
In Experiment III, 7 mares were placed on a switchback, 
experimental design, teased daily and cyclicity was verified by 
circulating progesterone concentrations. On day k post-ovulation, 
mares were subjected to uterine biopsy and subsequent estrous 
behavior was determined by teasing. Days from biopsy to induced
xiii
estrus for controls and treatment were significantly different 
(P<0.025). Results of Experiments II and III suggested that 
phenylbutazone accumulated in inflamed uterine tissue and inhibited 
prostaglandin synthesis.
In Experiments IV & V, 14 mares were teased daily. Estrous 
mares were mated. Treatment started on the first day of estrus and 
continued daily until embryo collection on day 10 post-ovulation. 
Embryos (blastocysts) were photographed to evaluate morphological 
development, incubated in Dulbecco's phosphate-buffered saline and 
then homogenized to determine total protein concentrations. Culture 
medium was assayed for prostaglandin synthesis. There was no 
significant difference between embryos recovered from treated or 
control mares for total prostaglandin synthesis. There was, however, 
a reduced concentration of PGF2 <x, PGE2  and PGI2  in embryos from 
treated mares compared with controls. Embryos from treated mares 
were significantly smaller(P<0.05),but contained more total protein 
than control embryos. Treatment did not affect ovulation, fertiliza­
tion or embryo viability.
xiv
INTRODUCTION
Phenylbutazone is a non-steroidal anti-inflammatory drug 
widely used in equine medicine. It is used to restore performance in 
competitive horses, to relieve musculoskeletal diseases and to 
comfort chronically sore horses, such as brood mares. Its therapeu­
tic effectiveness and toxic parameters have been clearly defined 
(Tobin, 1979a). Non-steroidal anti-inflammatory drugs (1) inhibit 
enzymes that act in the synthesis of prostaglandins and therefore 
reduce tissue prostaglandins; (2) normally accumulate in stomach, 
kidney, small intestines and inflamed tissues; (3) reduce pain, fever 
and swelling in inflamed tissues (Tobin, 1979a).
Phenylbutazone has been shown to inhibit both the cyclooxy- 
genase and hydroperoxidase enzyme systems that are necessary for the 
synthesis of prostaglandins from arachidonic acid. Prostaglandins 
actively participate in many crucial reproductive processes. When 
the non-toxic effective dose of phenylbutazone (2 g) is injected 
intravenously it takes =30 minutes to transverse the blood-brain 
barrier, distribute throughout the horse and to begin blockage of 
formation of the prostaglandins (Tobin, 1979a). In previous studies, 
it was assumed that phenylbutazone was potentially capable of 
entering uterine tissue interrupting prostaglandin synthesis and 
altering normal cyclic function of the corpus luteum. In previous 
investigations in this laboratory, researchers administered 2 g 
phenylbutazone intravenously to mares for 8 to 21 days, beginning on 
day 14 and day 1 of the estrous cycle, respectively. Results showed 
no significant differences in plasma progesterone profiles and
1
interestrous intervals between phenylbutazone-treated and physiologi­
cal saline-treated mares.
The viable embryo exerts biochemical signals to the maternal 
unit that permit development of a histotrophic uterine environment 
through the continued secretion of progesterone from the corpus 
luteum. Conceptus secretory proteins play a role in directing the 
embryo to synthesize major arachidonic acid metabolites associated 
with bovine conceptus viability, development and implantation 
(Thatcher et al., 1989). There are reports that verify production of 
prostaglandins by the harvested embryo in many farm and laboratory 
animals; however, there are no reports available for similar stage 
embryos for the mare.
Researchers have determined that prostaglandin antagonists 
administered to various species inhibited ovulation, luteolysis, ovum 
transport, blastocyst hatching, embryo implantation, embryo expan­
sion, live birth rate and sharply diminished endometrial prostaglan­
din concentration and release (see Table 6). However, there was no 
available information on the viability of the equine embryo in the 
mare being administered a non-steroidal anti-inflammatory drug.
The experiments undertaken were designed to substantiate 
previous observations and to determine if chronic administration of 
phenylbutazone significantly alters fertility in mares.
LITERATURE REVIEW
NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
Chemical Properties
Non-steroidal anti-inflammatory drugs (NSAID) are all 
aromatic-acidic compounds, sometimes referred to as "aspirin-like" 
drugs. These agents can be subdivided by general chemical structure 
into several categories: salicylates or derivatives of pyrazolon,
fenamic acid, indene or arylalkanoic acids. These agents have, to 
some degree, analgesic, antipyretic and anti-inflammatory activities. 
They have been employed in the treatment of arthritis, myositis, 
tendonitis and other soft-tissue and osseous inflammatory conditions 
(Short and Beadle, 1978).
All NSAID are carboxylic acids with a pKa of =4.5, which gives 
a very low water solubility (Snow, 1983). They are usually formulat­
ed as sodium salts, especially for parenteral administration. Sodium 
salt formation also increases the speed of absorption following oral 
administration. Their acidic nature favors accumulation in inflamed 
tissues (Snow, 1981), which also tend to be acidic (Tobin, 1981b).
The acidic nature of these drugs causes them to be between 95 and 99% 
bound to plasma proteins (Tobin, 1981b). Meclofenamic acid and 
naproxen are over 99% bound to plasma proteins (Snow, 1981).
Although the binding is readily reversible, this property limits 
NSAID distribution from plasma to other body fluids and tissues and 
has important implications in drug detection and therapy (Higgins and 
Lees, 1988). This is important because the non-protein bound or
3
free drug is associated with biological activity. Prior exposure or 
concurrent administration of other drugs that are highly protein 
bound can, because of competition for binding sites, lead to higher 
free levels of either drug (Snow, 1981). Since these drugs are 
plasma protein bound they do not pass into saliva. Therefore, saliva 
testing is not acceptable for detection of NSAID (Tobin, 1981b).
The first NSAID to be synthesized was acetylsalicylic acid 
(aspirin) at the end of the 19th Century and it is still the most 
frequently used NSAID in humans. However, it is not popular for use 
in the horse because of its short duration of action. In 1949, 
phenylbutazone (the second oldest NSAID) was introduced as a 
therapeutic agent for man and has since become the dominant NSAID 
used in the horse (Snow, 1981). Pharmaceutical companies have 
synthesized a large number of NSAID that are available to both human 
and equine medicine. A partial list of these agents is presented in 
Table 1. Only 4 are presently employed for extensive use in the 
horse (1) the fenamic acid derivative, meclofenamic acid (Arque]®; 
Snow, 1981); (2) the phenylacetic acid derivative, naproxen
(B\
(Equiproxen ; Snow, 1981); (3) the clonixin acid derivative, flunixin 
meglumine (Banamine®; Ciofalo, 1977); (4) the pyrazolone derivative, 
phenylbutazone (Butazolidin ; Burns, 1953). The chemical structures 
of these 4 popular equine NSAID are presented in Figure 1. Of these, 
phenylbutazone remains the most popular and widely used in equine 
medicine (Tobin, 1979a).
Table 1. Some non-steroidal anti-inflammatory drugs which all 
appear to share the same basic mechanism of action as 
phenylbutazone and same general pattern of toxicity
Generic Proprietary Name
Salicylates Aspirin
Phenylbutazone Butazolidin
Oxyphenbutazone Tandearil
Naproxen Equiproxen
Meclofenamic Acid Arquel
Flunixin Meglumine Banamine
Quinine -
Indomethacin Indocin
Tolmetin Tolectin
Niflumic Acid Nifluril
Ketoprofen Orudis
Ibuprofen Motrin
Ibuprofen Advil
Mefenamic Acid Ponstel
Adapted from Tobin (1981b)
6c h 2 -c h 2 -c h 2 -ch3
Phenylbutazone (Butazolidin )
COOH
CH3
Flunixin (Banamine )
OOH
N
I
H
Cl
CHi
Meclofenamic Acid (Arquel9 )
CH30
C—  COOH
Naproxen (Equiproxen9 )
Figure 1. Cheaical structure of non-steroidal anti- 
inflaamatory drugs connonly used in equine nedicine
Adapted fron Booth (1982)
Mechanism of Action
The search for a possible mechanism of action of NSAID was 
started by Piper and Vane (Vane, 1971). They discovered that lungs 
could release a previously undetected substance that they called 
"rabbit aorta contracting substance". When isolated perfused lungs 
of sensitized guinea-pigs were challenged, rabbit aorta contracting 
substance, histamine, slow reacting substance in anaphylaxis, 
prostaglandin E2  and were released. The release of rabbit aorta 
contracting substance, which could also be provoked by bradykinin and 
slow reacting substance in anaphylaxis, was antagonized by aspirin­
like drugs, as was the evoked broncho-constriction. Results of their 
experiments suggested that rabbit aorta contracting substance was a 
prostaglandin or had a structure intermediate between the prostaglan­
din precursor arachidonic acid and PGE2  or PGF2 <x (Vane, 1971).
Vane (1971) designed experiments to test the possibility that 
NSAID inhibit the enzyme(s) which generate prostaglandin. He 
incubated guinea-pig lung homogenate with arachidonic acid aerobical­
ly at 37°C and determined an increase in PGE2  and PGF2 OC synthesis.
To test for inhibition of prostaglandin synthesis, varying amounts of 
indomethacin, sodium acetylsalicylate or sodium salicylate were added 
to the incubation flasks. All 3 anti-inflammatory acids inhibited 
generation of PGF2a and PGE2 ~like activity. In all preparations, 
there was a linear relationship between percentage inhibition and log 
concentration of indomethacin or aspirin. On a weight basis, indo­
methacin was 23 times more potent than aspirin as an inhibitor of 
PGF2 OC, and on a molar basis 47 times more potent. Aspirin was more 
potent than sodium salicylate as an inhibitor of synthesis of PGF2 <x
and PGE2 ~like activity. Results of Vane's experiments determined 
that the 3 NSAID inhibited synthesis of prostaglandins, but not how 
the inhibition is brought about.
Since these pioneering reports, the inhibitory action of 
aspirin-like drugs on prostaglandin production has been amply con­
firmed and demonstrated in almost all laboratory species and many 
other biological preparations from tissues throughout the body using 
a variety of assay techniques (Ferreira and Vane, 1974). Results of 
experiments conducted by Brune et al. (1976) clearly showed that 
acidic NSAID (1) are effective in almost every biological system,*
(2) reach higher concentrations in inflamed tissue than most others 
throughout the body; (3) are found only in similarly high concentra­
tions in absorptive and excretory organs such as stomach, small 
intestine and kidney. How NSAID specifically exert their local 
anti-inflammatory action was, however, undetermined.
Mizuno et al. (1982) proposed the specific mechanism of action 
of NSAID. The biosynthesis of the prostaglandin family (Figure 2) is 
initiated by the enzyme reaction of fatty acid cyclooxygenase to con­
vert arachidonic acid to PGG2 > followed by the action of prostaglan­
din hydroperoxidase on PGG2  to form PGH2 . The former is a bis-dioxy- 
genase reaction, and the latter a peroxidase-like reaction. Mizuno 
et al. (1982) investigated the effects of various NSAID in general on 
both cyclooxygenase and hydroperoxidase activity. When tested by the 
assay of the manganese protoporphyrin-assistedproduction of PGG2  from 
arachidonic acid, all the drugs irreversibly inhibited the cyclooxy­
genase reaction. In contrast, none of the drugs except phenylbuta­
zone also inhibited the hydroperoxidase reaction. Aspirin, indometh-
9Extracellular Fluid 
Compartment
Acylhydrolases Triglycerides
Cell
membrane Phospholipids
Proteins
Phospholipase A 'Injurious Stimuli 
(chemi cal/physi cal)
ARACHIDONIC ACID
Fatty acid 
cyclooxygenase NSAID
PGG,
Prostaglandin
hydroperoxidase Phenylbutazone
PGH2
PGE PGI
Figure 2. Inhibition of prostaglandin biosynthesis by 
non-steroidal anti-inflammatory drugs (NSAID)
Adapted from Kindahl (1980), Bell 
et al. (1980) and Chand and Eyre (1977)
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acin and flurbiprofen did protect the hydroperoxidase activity from 
heat or alkaline pH inactivation. Results raised the possibility 
that NSAID might also affect the binding of enzyme and heme because 
heme is a required cofactor of the enzyme in both the cyclooxygenase 
and hydroperoxidase reactions.
In summary, the mechanism of action for NSAID is the inhibition 
of cyclooxygenase. Phenylbutazone also inhibits prostaglandin 
hydroperoxidase (Mizuno et al., 1982). The order of anti-inflamma­
tory potency of commonly used NSAID as determined in laboratory 
animals is meclofenamic acid > indomethacin > naproxen > phenylbuta­
zone > acetylsalicylic acid (Snow, 1983).
Pharmacokine tics
All NSAID appear to be metabolized to inactive metabolites 
except phenylbutazone. At therapeutic doses about 10% of phenylbu­
tazone is degraded to oxyphenbutazone, that has activity similar to 
phenylbutazone and is also used therapeutically. The metabolites are 
then excreted in urine and bile. Only negligible amounts of the drug 
are secreted in saliva. It is generally considered necessary to 
determine appropriate dosage and frequency of dosing to maintain a 
therapeutic circulating plasma level of these drugs during treatment 
(Snow, 1981). Because of the high plasma protein binding of NSAID 
and low water solubility, their rate of metabolism is the predominant 
factor responsible for declining plasma concentrations after adminis­
tration (Snow, 1983). It is probable that therapeutic concentrations 
may remain in tissues for a period of time after they are no longer 
detectable in blood, which may explain a residual effectiveness after
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therapy cessation (Snow, 1981).
The plasma half-life following intravenous administration for 
meclofenamic acid, naproxen and flunixin meglumine in the horse have 
been reported to be 1.0, 4.7 and 1.6 hours, respectively. For phen­
ylbutazone, the plasma half-life is dose dependent, possibly due to 
the effect of its active metabolite oxyphenbutazone.
Of the 4 drugs used in the horse, only phenylbutazone and 
flunixin meglumine are formulated and available for parenteral 
administration, but all 4 are marketed for oral administration in the 
form of powders or granules. Phenylbutazone is also prepared in a 
paste form in a multi-dose applicator (Snow, 1983). Plasma concen­
trations of NSAID following oral administration can be highly vari­
able (even within one animal) due to breed, age of horse and rela­
tionship to feeding time. Giving the drug on an empty stomach 
results in higher peak plasma concentration and a greater bioavaila­
bility than when it is given on a full stomach. Even though these 
compounds are acidic, most absorption occurs from the duodenum rather 
than the stomach. Presence of food in the stomach slows gastric 
emptying and therefore absorption (Snow, 1981). Studies also indi­
cate that under the same conditions, absorption of phenylbutazone and 
meclofenamic acid may be lower in pony breeds than in Thoroughbreds 
(Snow, 1983).
In summary of pharmacokinetics, all NSAID are metabloized to 
inactive metabolites (except phenylbutazone) and are excreted in 
urine and bile. All preparations are generally administered as a 
course of treatment lasting 5 to 10 days. Increasing peak plasma 
concentration is dependent on the rate of drug metabolism, dose rate,
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frequency and route of administration, breed and age of the horse and 
relationship to feed and feeding time. Parenteral administration of 
flunixin meglumine may be either intravenous or intramuscular. Phen­
ylbutazone and meclofenamic acid must be given only intravenously 
since intramuscular injection causes severe inflammation.
Toxicity
The NSAID all induce gastrointestinal irritation that often 
leads to ulceration of mucosal lining of the gastrointestinal tract 
from the oral cavity to the large intestine. Toxic effects may be 
due to inhibition of other enzyme systems. Ferreira and Vane (1974) 
proposed that inhibition of prostaglandin biosynthesis may lead to 
unwanted side effects in organs that depend upon prostaglandins for 
normal physiological function. For example, PGE inhibits gastric 
acid secretion. A locally released prostaglandin may be a mechanism 
to prevent hyperacidity, which can lead to mucosal damage. Also, the 
function of locally released prostaglandins in the stomach may be to 
increase blood flow to the mucosa. Vasoconstriction upon removal of 
this effect by NSAID may lead to ischaemia, tissue death and bleed­
ing. This proposed cytoprotection property of locally released 
prostaglandins was demonstrated by Robert et al. (1979). Pretreat­
ment with prostaglandins in rats prevented necrosis of the gastric 
mucosa when orally given acids, bases and hot water. Therefore, 
toxic doses of phenylbutazone in horses and ponies may decrease pros­
taglandin production at the mucosal level and decrease cytoprotec­
tion (MacAllister, 1983).
Prolonged bleeding time and inhibition of platelet aggrega­
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tion is caused by most NSAID (Tatro et al., 1980). Non-steroidal 
anti-inflammatory drugs also cause varying degrees of nephrotoxicity 
with some incidence of papillary necrosis. Some, like phenylbuta­
zone, lead to retention of sodium chloride and water (Ferreira and 
Vane, 1974). In a retrospective study of 16 horses in which renal 
papillary necrosis was found at necropsy, it was determined that all 
had suffered from a variety of diseases in which dehydration and 
NSAID therapy were prominent features (Gunson, 1983). Papillary 
necrosis seen in both kidneys of all horses was not associated with 
clinically apparent renal disease. It was proposed that 2 synergis­
tic etiologic factors contributed to equine renal papillary necrosis. 
First, blood volume depletion due to dehydration, hemorrhage or water 
deprivation resulted in dependence on prostaglandins for renal blood 
flow. Then, antiprostaglandin drugs were able to reduce blood supply 
to the now prostaglandin dependent vasa recta and cause ischemia of 
the renal papillae. It was suggested that horses being treated with 
NSAID must have sufficient water to balance and avoid hypovolemia.
Clinically, the early signs of toxicity are depression, anorex­
ia, weight loss, diarrhea, dehydration and sometimes oral ulceration. 
The first indication of toxicity on routine blood biochemistry is a 
progressive decline in total plasma proteins and a rise in plasma 
urea concentration. With continued treatment, areas of ulceration 
converge and impaired epithelial integrity leads to absorption of 
toxins and a terminal shock condition. Marked ulceration of the 
tongue is often noted (Snow, 1981, 1983).
Toxicity studies of 3 NSAID were conducted by Snow et al. 
(1983). Phenylbutazone, meclofenamic acid and naproxen were
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administered at the recommended dose rate and then at twice the 
normal dose. Results determined that at the therapeutic dose rate, 
phenylbutazone may cause a protein-losing gastroenteropathy in 
ponies; however, the other 2 commonly used NSAID did not exert this 
effect at either dose regimen.
Potential toxicity of NSAID in mare milk must be considered by 
the equine veterinary clinician. If a valuable but chronically 
arthritic brood mare is maintained at low doses of a NSAID, it must 
be certain that concentrations of the drug are passing into the milk. 
The NSAID will almost certainly be cleared from the body more slowly 
in nursing foals than in adult horses and this will increase 
potential toxicity (Higgins and Lees, 1988).
Clinical Use and Efficacy
All NSAID are proposed to be useful in numerous acute and 
chronic inflammatory conditions of both soft tissue and skeletal 
origin. It appears that different NSAID are more effective against 
some conditions than others. The 4 commonly used NSAID in equine 
medicine vary in efficacy in specific conditions.
Naproxen (Equiproxen ) is recommended for relief of pain, 
inflammation and lameness associated with myositis and soft tissue 
disease (Tobin, 1979b). Kilian et al. (1974) induced myositis "tying 
up" by injecting lactic acid at 8 sites into the back muscles of 
horses. These horses were treated with naproxen, which resulted in 
greatly reduced pain, lameness and tissue swelling. Jones and Hamm 
(1978) induced equine myositis using this model and proposed that 
naproxen was superior to phenylbutazone because it gave more rapid
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relief of inflammation and associated lameness. Hamm (1978) reported 
that continuous administration of naproxen in the daily feed during 
training and racing season of young colts significantly reduced the 
incidence of musculoskeletal injuries and performance days lost to 
injuries such as splints, osslets, osteoperiostitis, tendinitis, 
tenosynovitis and suspensory desmitis.
Flunixin meglumine (Banamine ) appears to be more potent than 
other equine NSAID and superior for rapid relief of equine colic 
(Tobin, 1979b). Vernimb and Hennessey (1977) reported 38% of horses 
treated for colic were improved within 15 minutes. It was reported 
that animals were eating by this time with normalization of heart and 
respiratory rates and peristalsis indicated remission of colic and
pain. The best results have been obtained in animals affected by
flatulent or spastic colic as compared with those with intestinal 
stasis or circulatory impairment. Houdeshell and Hennessey (1977) 
demonstrated that parenteral and oral flunixin meglumine is also safe 
and efficacious for alleviation of pain and inflammation associated 
with musculoskeletal disorders in the horse. Flunixin meglumine was 
also reported to be efficacious in treating endotoxic shock in ponies 
(Turek et al., 1985).
Meclofenamic acid (Arquel ) is an unusual NSAID in that its
onset of action is relatively slow, taking from 36 to 96 hours to
develop (Tobin, 1979b). It has been demonstrated to be especially 
effective in the treatment of acute and chronic equine osteoarthritis 
and certain soft tissue inflammatory conditions affecting the loco­
motor system such as navicular disease, laminitis and bony tissue 
conditions. The drug accumulates appreciably in synovial fluid,
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without altering the physicochemical properties of synovial fluid.
The tissue containing the most drug is omental fat with other sites 
being hair, spleen and articular cartilage. In comparison, meclofen­
amic acid is superior to phenylbutazone in treating equine osteo­
arthritis (Riley et al., 1971; Conner et al., 1973).
Phenylbutazone (Butazolidin ) remains the most popular and 
widely used NSAID in equine medicine. It is still the standard 
against which other drugs are compared for clinical effectiveness 
(Tobin, 1979b). This may be attributed to (1) over 30 years of 
clinical experience indicating its efficacy in a variety of 
conditions; (2) considerably lower costs for treatment, especially 
over extended periods of time; (3) low dose rates; (4) minimal 
effective blood concentration necessary; (5) establishment of 
phenylbutazone "Bute" as a household name (Snow, 1981). For these 
reasons, phenylbutazone was the drug of choice for this study.
Tobin (1979b) summarized that these 4 equine NSAID (1) are 
safe and effective when given at therapeutic doses; (2) they have a 
number of broadly similar characteristics in that dosages are 
approximately equivalent from drug to drug; (3) their time courses of 
action are broadly similar; (4) their detection in blood and urine is 
not particularly difficult; but (5) there are subtle differences in 
clinical effectiveness against certain conditions, that make specific 
NSAID the drugs of choice for specific conditions. A summary of 
NSAID properties is presented in Table 2. Pharmacological 
characteristics of NSAID are summarized in Table 3.
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Table 2. Summary of non-steroidal anti-inflammatory drug properties
1. Acidic drugs that accumulate in acidic, inflamed tissues
2. Highly protein bound in plasma
3. Easily detected in urine and plasma; undetectable in saliva
4. Restore normal performance, not a central nervous system 
stimulant or depressant
5. Safe and effective at therapeutic doses
6. May be used in competitive horses
7. Inhibit enzymes which form prostaglandins and therefore 
reduce tissue pain and inflammation
8. Reduce fever (antipyretic)
9. Accumulate in stomach, kidney and gastrointestinal tract 
and tend to produce lesions in these tissues if toxic 
doses are given
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Table 3. Pharmacological characteristics of non-steroidal
anti-inflammatory drugs commonly used in equine medicine3
Drug Route Daily dose 
(mg/kg)
Half-life
(hours)
Detection in 
Urine Plasma 
(hours) (hours)
Phenylbutazone IV 2.2 to 4.4 3.5 96b 24-48b
(Butazolidin® ) Oral 4.4 to 8.8 6
Flunixin meglumine IV,IM 1.1 1.6 48 8
(Banamine ®) Oral 1.1
Naproxen IV 5.0 4 48 48
(Equiproxen® ) Oral 10.0
Meclofenamic acid IV 2.0 6-8 96° 24c
(Arquel® ) Oral 2.2
?Adapted from Booth (1982) 
Gabel et al. (1977) 
cMaylin (1977)
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Use of Non-steroidal Anti-inflammatory Drugs in Competing Horses
Various equestrian federations throughout the world have 
determined their own regulations governing the use of NSAID in 
competition horses. The NSAID do not have central nervous system 
stimulant or depressant actions and therefore are unlikely to affect 
the optimal performance of a horse. It is accepted that these agents 
both by their analgesic and anti-inflammatory activities are able to 
improve performance impaired due to tissue damage (Snow, 1981).
The NSAID are included in a group of drugs referred to as drugs 
of controlled medication. The goal of a controlled medication 
program is to smooth out the minor health and musculoskeletal 
problems that are common to all athletes and to insure that horses 
are presented at the starting gate fit to race at their best. By 
allowing specific therapeutic medications to be used, controlled 
medication programs avoid driving trainers and veterinarians to more 
extreme, difficult and damaging measures such as freezing, denerving, 
nerve blocking and intra-articular corticosteroid injections without 
rest. These are the drugs that many racing commissioners in the 
1960s and 1970s chose to allow to be used in performance horses under 
controlled conditions (Tobin, 1981c).
These drugs are extremely valuable therapeutic agents in 
performance horses when properly used. Under the proper circumstan­
ces, NSAID have the ability to enable a horse to perform more 
consistently at its innate ability. Therefore, these drugs are of 
great economic importance in racing. Proponents for the use of NSAID 
suggested that if their use were restricted, the number of horses 
that race and compete in shows would be markedly reduced (Tobin,
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1981c).
Therapeutic medication consists of administering an agent to a 
horse which controls a condition that is interferring with the 
performance of that horse. The justification for this type of 
medication is that it allows a horse to run up to its form but not 
beyond its innate ability. Therefore, a horse with joint or muscle 
pain may be given a NSAID to control inflammation and pain. The 
horse trainer's and veterinarian's objective is to keep their horses 
in the competition. Proper medication can be a critical factor of 
this objective (Tobin, 1981c).
In January, 1989, the American Horse Show Association (AHSA) 
Board of Directors unanimously approved a major amendment to the 
Medications Rule, placing restrictions on the use of NSAID at AHSA 
recognized competitions. The ammendment effective date was December 
1, 1989. The purpose of the ammendment is to protect the fairness of 
competition by preventing abuses of drugs and to safeguard the health 
and well-being of horses and ponies by accommodating the treatment of 
illness and injury (Lengel, 1989).
This ammendment rules (1) when a NSAID is needed, either 
phenylbutazone or flunixen meglumine should be administered, but not 
both; (2) when phenylbutazone is administered, not more than 2 g/450 
kg body weight/day should be administered, not closer than 12 hours 
prior to competing and not more than 5 successive days; the dose for 
a pony is to be reduced accordingly; (3) when flunixen meglumine is 
administered, not more than 500 mg/450 kg body weight/day should be 
administered, not closer than 12 hours prior to competing and not 
more than 5 successive days; the dose for a pony is to be reduced
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accordingly; (4) if both phenylbutazone and flunixen meglumine were 
administered to a horse or pony during the 7 days prior to competing, 
then one or both must have been administered no closer than 48 hours 
prior to competing, in order to achieve an acceptably low trace level 
(Lengel, 1989).
According to international racing jurisdictions, only the 
United States and the Rio de Janeiro Jockey Club permit use of NSAID 
in racing horses. Medication rules regulating use of NSAID vary 
among states. Each state that permits horse racing determines its 
own regulations. Some states do not permit any use of NSAID. In 
many states, there is no permitted medication for 2-year-old horses, 
but there is restricted use of NSAID in adult horses. Restrictions 
determine the accepted maximum post-race blood and urine levels of 
permitted NSAID and the accepted time of administration. Regulations 
may vary between harness racing and runners (Drug Control Service 
Policy Review, 1988).
The Louisiana State Racing Commission does not permit any 
medication for racing 2-year-olds. Of the NSAID, only phenylbutazone 
and oxyphenbutazone are permitted for use. Post-race urine and blood 
levels for both drugs are 165 yg/ml and 5 yg/ml, respectively, 
regardless of time of administration (Louisiana State Racing 
Commission, 1986).
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PHENYLBUTAZONE IN HORSES
Introduction
Phenylbutazone was first synthesized in 1946 by H. Stengyl in 
Switzerland and was later marketed as Butazolidin® by J.R. Geigy, 
A.G., as a therapeutic agent to treat rheumatic diseases (Jeffcott, 
1977). Phenylbutazone was widely used in human medicine until it was 
restricted because it caused deaths from aplastic anemia and agranu­
locytosis. However, an extensive veterinary market developed to 
treat equine musculoskeletal disorders, colic and inflammation 
(Tobin, 1979a). Phenylbutazone has been approved for use in racing 
horses in most American states. Horses are allowed to be medicated 
with phenylbutazone while competing in Federation Equestre Interna­
tionale shows providing a limit of 4 pg/ml of plasma (Tobin et al., 
1986). Phenylbutazone is not a naturally occurring compound 
(Schubert, 1967) and is classified as a non-steroidal anti-inflamma­
tory drug (Tobin, 1979a).
Chemistry
Chemically, phenylbutazone is a pyrazolidine with 2 nitrogen and 
3 carbon atoms. It has an acidic nature with a pKa of 4.5, making it 
soluble in aqueous solutions of pH > 6.0 (therefore also in body 
fluids). It forms colorless crystals which melt at 104.5 to 106.5°C. 
It is sparingly soluble in usual organic solvents. Phenylbutazone is 
rather susceptible to oxidation, the first step being the formation 
of a hydroxyl group at the 4 position. It has a well defined ultra­
violet light spectrum and infrared absorption (Schubert, 1967).
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Physically, phenylbutazone is a white or light yellow powder 
with a bitter taste. It is poorly soluble in water (Barragry, 1973).
Safety
Phenylbutazone is a safe drug if administered within therapeutic 
doses (Tobin et al., 1986). Finocchio et al. (1970) administered the 
clinically recommended dose of 2 g/450 kg phenylbutazone intravenous­
ly to 11 Thoroughbreds and determined that hemoglobin concentration, 
packed cell volume, serum protein fractionation, serum creatinine 
concentration and urine pH, osmolarity and creatine concentration 
were not significantly changed from normal values.
Recommended Dose and Route of Administration
The optimal effect can be achieved by 2 g/450 kg (average size 
horse) intravenously/day or 4 g/450 kg orally/day. Daily dosing is 
required since the anti-inflammatory effect is not good for more than 
about 24 hours (Tobin, 1979a). The American Association of Equine 
Practitioners has recommended that the dose for racing horses be not 
greater that 2.2 mg/kg intravenously each day, with the last dose 
occurring not more than 24 hours before post time (Tobin et al., 
1986).
First response to the drug can be seen a few hours after 
administration. Optimum effect is variable but occurs approximately 
12 hours after administration. Intravenous injection appears to 
speed the onset of action on the average by 2 to 4 hours compared 
with oral use. Onset of action is variable after oral administration 
depending on whether the horse eats before or after the drug is
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given. Optimal clinical effect appears to continue for a variable 
time, usually for < 48 hours after the last dose, depending on the 
dose and length of treatment course (Gabel et al., 1977).
Researchers determined that clinical efficacy of doubling the 
recommended dose of phenylbutazone as a loading dose should be 
limited to the first 1 or 2 days of treatment only. In this treat­
ment regimen, overall clinical response was good to excellent with no 
overt signs of phenylbutazone toxicity in any horse (Lees et al., 
1983; Taylor et al., 1983a).
Intramuscular injection of phenylbutazone is used in some 
countries although it is not recommended. Intramuscular injections 
into the neck region of 2.5 mg/kg phenylbutazone induced heat, 
tenderness and swelling around the injection site which persisted up 
to 5 days (Sullivan and Snow, 1982).
For standardization and predictability purposes, 2 g of phenyl­
butazone intravenously administered daily was chosen for all 5 exper­
iments in this study.
Half-life
The half-life of phenylbutazone is highly variable depending 
upon dose, dosing regimen, age of recipient and species. In the 
horse, despite its size, phenylbutazone has approximately the same 
half-life as in smaller experimental animals.
Usually, the half-life is approximately 3 hours intravenously or 
6 hours orally. If the daily dose is increased and the phenylbuta­
zone accumulates in body tissues, the half-life also increases and 
toxicity can result (Tobin, 1979a). An intravenous dose of 4.4 mg/kg
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phenylbutazone results in a plasma half-life of 3 to 4 hours. Dou­
bling the dose almost doubles the half-life (Snow, 1983). Concurrent 
intravenous administration of phenylbutazone and another related 
drug, isopyrin (Tomanol ) also results in prolongation of both drugs 
due to competition for the metabolizing enzymes responsible for their 
degradation (Snow, 1981).
Phenylbutazone exhibits dose-dependent kinetics in the horse.
The elimination half-life increases from 3.5 hours at 4.4 mg/kg body 
weight to 8.6 hours at 10 mg/kg. A possible reason for this could be 
accumulation of phenylbutazone in the body when high doses are 
administered. Accumulation of phenylbutazone within the body might 
partially explain why doses only 1.5 to 2 times the recommended 
maximum can produce a fatal protein-losing enteropathy in ponies 
within 10 to 14 days, whereas recommended dose rates seem to be well 
tolerated clinically by most horses for months or even years (Lees et 
al., 1985).
Maylin (1974) demonstrated an increase in half-life of phenyl­
butazone in a daily dosing regimen. He administered 4.4 mg/kg body 
weight phenylbutazone intravenously to horses daily for 4 days. The 
half-life of phenylbutazone in plasma was 5.1, 5.3, 5.5 and 6.1 hours 
following the first, second, third and fourth doses, respectively.
Other reports of the half-life of phenylbutazone being dose 
dependent include (1) 3.5 hours with 4.4 mg/kg to 6 hours with 17.8 
mg/kg (this may reflect saturation of liver enzymes at high dose 
levels); (2) doubling the dose from 2.2 to 4.4 mg/kg phenylbutazone 
raised plasma levels by 33%; (3) quadrupling the dose from 2.2 to 8.8 
mg/kg phenylbutazone raised the plasma concentration by 300%
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(Gerring, 1981).
Phenylbutazone has demonstrated a wide range in reported half- 
life among various mammalian species. Phenylbutazone is metabolized 
in man at a very slow rate with a plasma half-life averaging 3 days. 
However, in the monkey, dog, rabbit, rat, guinea pig and horse the 
drug is rapidly metabolized. The half-life of phenylbutazone in the 
goat and cattle falls in the moderate range (Burns, 1968)(Table A).
In cattle, elimination half-life changes considerably depending on 
route of administration. Three administration routes were compared 
using a cross-over design. The half-life of phenylbutazone was 36,
44 and 51 hours for intravenous, oral and intramuscular administra­
tion, respectively (Lees et al., 1988a).
In the horse, the half-life of oxyphenbutazone is approximately 
the same as that of the parent drug, phenylbutazone (Gandal et al., 
1969; Barragry, 1973; Lees et_ al., 1986; Gerken and Sams, 1988). In 
comparison, the plasma half-life reported for phenylbutazone in the 
horse has ranged from 3.5 to 10.9 hours, increasing with the adminis­
tered dose (Soma et al., 1983; Tobin et al., 1986). The plasma 
half-life of oxyphenbutazone has been reported to be 2.8 to 6.0 hours 
for doses from 4.4mg/kg to lOmg/kg (Gandal et al., 1969; Lees et al., 
1986b; Gerken and Sams, 1988). The plasma half-life of phenylbuta­
zone is increased in horses following administration of oxyphenbuta­
zone. A similar finding has been reported in other species and 
suggests that oxyphenbutazone contributes to the overall effect of 
phenylbutazone and inhibits metabolism of phenylbutazone in horses 
(Booth, 1982; Lees et al., 1986b).
Urinary pH has little effect on the plasma half-life of
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phenylbutazone, which is determined mainly by hepatic metabolism and 
possibly by biliary secretion (Tobin et al., 1986)
Table 4. Species differences in the elimination of phenylbutazone
Species Half-life (hours)
Man 72a
Cattle 31, 36, 39b
Goat 15°
Monkey 8a
Dog 6a
Horse 3.5d, 6a
Rat 6a
Guinea Pig 5a
Rabbit 3a
Pig 2e, 6a
? Burns (1968)
De Backer et al. (1980); Lees et al. (1988a); Martin et al. (1984) 
Boulos et al. (1972)
Piperno (1968) 
e Booth (1982)
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Absorption
Oral administration of phenylbutazone is often the preferred 
route because of ease of administration and the irritant action of 
the drug when injected intravenously and/or perivascularly. A 
portion of orally administered phenylbutazone is rapidly absorbed 
from the stomach via diffusion and ion trapping. Since phenylbuta­
zone is a weak acid of high lipid solubility, its absorption would be 
favored by acid conditions in the stomach and early small intestine 
of the horse (Traub, 1983; Lees et al., 1986a; Maitho et al., 1986). 
Gerring e_t al. (1981) reported detection of phenylbutazone in the 
plasma of ponies 10 minutes after oral dosing. The most rapid ab­
sorption appears to occur from the small intestine, that is likely 
due to the greater surface area of the intestinal mucosa when com­
pared with the gastric mucosa (Traub, 1983).
Variability has been noted when phenylbutazone is administered 
orally under similar conditions. Phenylbutazone absorption is 
subject to marked inter- and intra- animal variations. The rate of 
absorption may vary both from horse to horse and with the amount and 
type of food consumed in relation to the time of phenylbutazone 
administration (Gerring et al., 1981; Lees et al., 1986a).
Rose et al. (1982) investigated the bioavailability of two 
different oral preparations of phenylbutazone and the effect of the 
state of stomach contents on the absorption of phenylbutazone. They 
administered 8.9 mg/kg phenylbutazone in a paste or a traditional 
powder form either before or after a meal. Ration consisted of a 
full feed of lucerne chaff, wheaten chaff and bran or partial feed of 
a small bran mash. Both the paste and powder forms of phenylbutazone
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administered before a meal appeared to be almost completely absorbed. 
Phenylbutazone paste administered after feeding or phenylbutazone 
powder given in a full feed resulted in lower peak plasma phenylbuta­
zone concentration compared to administration on an empty stomach or 
relatively empty stomach (small bran mash). They concluded (1) the 
oral route has a disadvantage of unpredictable absorption even though 
it is the most convenient; (2) the paste has the advantage to ensure 
the horse receives the entire dose; (3) the amount of food present in 
the stomach at the time of phenylbutazone administration has an 
important effect on absorption; (4) complete absorption of phenylbu­
tazone can be anticipated when given as a powder in a small bran mash 
or in paste before feeding.
In vitro studies have shown that phenylbutazone adsorption onto 
hay does occur and, therefore, may affect absorption of the drug. 
Large doses of phenylbutazone generally produce ulcers in the caecum 
and colon, rather than the stomach. Therefore, delayed absorption 
might be due to adsorption of phenylbutazone onto roughage in the 
feed, with subsequent release in the large intestine as a result of 
fermative digestive processes (Maitho et al., 1986; Tobin et al., 
1986; Lees et al., 1988).
Maitho £t al. (1986) orally administered a powdered form of 
phenylbutazone to ponies that had access to hay after dosing. Double 
peaks in the plasma concentration-time curve were frequently 
observed. A tentative hypothesis concerning the phenylbutazone 
absorption was proposed. The administered dose probably dissolved 
first in the gastrointestinal fluids and a proportion was then 
available for rapid absorption. This dose portion comprised the
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first peak. Then, a variable proportion of the administered dose 
rapidly became adsorbed onto the hay components and subsequent 
release did not occur until breakdown of the fibrous, cellulose 
constituents of the diet that took place by fermentation in the 
caecum and colon. This phase comprised the second peak.
Three plasma concentration peaks were usually obtained when the 
experiment was repeated using a phenylbutazone paste formulation.
The third peak was proposed to be a feature of the oil:water emulsion 
of the product. It was proposed that the administered dose became 
divided into a number of boluses. Dispersal and dissolution of the 
phenylbutazone would presumably occur at different rates. The 
erratic absorption from an emulsion would be a consequential concern 
when phenylbutazone is administered before a competitive equine sport 
(Lees et al., 1986a).
Sullivan and Snow (1982) studied the absorption of orally 
administered phenylbutazone (5 mg/kg) in 10 Thoroughbreds, 8 ponies 
and 4 pony foals. Large variations in area under curve (AUC) and 
peak plasma concentrations were found both within an animal and 
within groups of animals. Administration of phenylbutazone (5 mg/kg) 
following an overnight fast resulted in no difference in AUC (0 to 24 
hours) among the 3 groups of animals: mean (± SD) values were 132 +
68, 107 + 48 and 98 ± 6, respectively. Feeding before phenylbuta­
zone administration decreased AUC and peak plasma concentration and 
extended the range of time taken to reach the latter. Repeated, 
twice daily administration of phenylbutazone (5 mg/kg) resulted in 
more rapid absorption following the morning than afternoon dose.
Sullivan and Snow (1982) indicated factors that may contribute
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to slower absorption of phenylbutazone in horses fed prior to oral 
administration of phenylbutazone. Slower gastric emptying time is a 
major factor. Consistency of the roughage (grass versus hay) affects 
emptying time. Partially digested feed in the stomach interferes 
with passage of the drug into the small intestine. When horses were 
fed after oral phenylbutazone administration, most of the drug may 
have already passed into the small intestine.
When phenylbutazone is injected intravenously, it is rapidly 
distributed taking approximately 30 minutes to disperse throughout 
the horse (Tobin, 1979a). Phenylbutazone is capable of transversing 
the blood-brain barrier (Tobin, 1981a).
Sullivan and Snow (1982) also reported absorption was slower 
with intramuscular injections of phenylbutazone (2.5 mg/kg) than 
after oral administration in the fasted animal. They postulated the 
slower absorption may be caused by the precipitation of the drug into 
an environment of neutral pH and the presence of only small amounts 
of fluid restricting redissolution. This slower absorption is in 
contrast to most drugs which are absorbed more rapidly following 
intramuscular than oral administration.
After intramuscular administration, peak plasma levels are 
achieved in 6 to 10 hours. This slower rate is explained by the fact 
that after intramuscular administration, phenylbutazone is fixed to 
muscle protein and consequently its absorption is delayed (Barragry, 
1973).
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Distribution
Tissue concentrations of phenylbutazone had not been investigat­
ed until studies conducted by Lees et al. (1987a). Tissue residue 
and body fluid concentrations of phenylbutazone and oxyphenbutazone 
were determined 6 hours after intravenous and 6, 12 and 24 hours 
after oral dosing with 4.4mg phenylbutazone/kg. Tissue cage fluid, 
peritoneal fluid and synovial fluid concentrations were generally 
one-third to two-thirds of corresponding concentrations in plasma. 
Tissue concentrations were even lower, indicating that no tissue 
cumulation of phenylbutazone or oxyphenbutazone occurred. Concentra­
tions in the adipose tissue could not be determined accurately. The 
highest phenylbutazone and oxyphenbutazone concentrations were pre­
sent in kidney tissue and the lowest were detected in muscle and 
tendon. Intermediate levels were in heart, liver and lung tissue.
These tissue concentration may merely reflect organ blood flow 
differences rather than tissue differences in binding affinity.
There was no tendency for phenylbutazone and oxyphenbutazone to 
accumulate in high concentrations in any particular tissue. Most 
tissues were shown to contain undetectable residue levels (< O.lpg/g) 
24 hours after oral dosing with phenylbutazone. Only lung, liver and 
kidney contained higher concentrations at that time. The relatively 
good penetration into tissue fluids presumably reflects the ready 
reversibility of the high degree of plasma protein binding (Lees et 
al., 1987a).
Plasma Concentration with Intravenous Administration
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Maylin (1974) administered 4.4 mg/kg phenylbutazone intravenous­
ly to horses daily for 4 days. Plasma concentrations were determined 
by gas liquid chromatography. Plasma concentrations increased from 
18.2 to 31.1 ug/ml 1 hour after the first and fourth doses, respec­
tively. Twenty-four hours after the first and fourth doses, plasma 
concentrations increased from 0.8 to 2.4 pg/ml, respectively.
Piperno et al. (1968) administered a single dose of 2 g/450 kg 
phenylbutazone intravenously to 6 horses. Mean plasma concentrations 
declined from approximately 20 pg/ml a half-hour after administration 
to about 4 ug/ml 9 hours after administration. They also gave 1 
horse 2, 4 and 8 g/450 kg phenylbutazone intravenously in a series. 
With the 1 hour post-administration value as a reference point, a 2- 
fold increase in dose (2 to 4 g level) produced a 33% increase in 
plasma level. A 4-fold increase (2 to 8 g) in dose caused a 300% 
rise in plasma concentration. Repeated daily doses of 4 g/450 kg 
phenylbutazone intravenously were given to 5 horses for 3 days. In 
all horses, slight to moderate elevations in plasma levels occurred. 
In all experiments by Piperno et al. (1968) peak phenylbutazone 
plasma concentrations after intravenous administration occurred =1 
hour post-administration.
Metabolism
The liver is the principle site of phenylbutazone metabolism. 
Biotransformation of phenylbutazone occurs via hepatic mixed-function 
oxidase activity. No glucuronide metabolites have been found in the 
horse. The 4-glucuronide of phenylbutazone has been reported in man
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and, therefore, is a potential metabolite in the horse (Tobin et al., 
1986).
The 2 major metabolites are hydroxylated derivatives, oxyphenbu- 
tazone and y-hydroxyphenylbutazone. The latter is referred to as the 
"alcohol metabolite". The 1 minor hydroxylated metabolite is y-hy- 
droxyoxyphenbutazone. Ring hydroxylation occurs on oxyphenbutazone 
and side chain hydroxylation occurs on y-hydroxyphenylbutazone. Side 
chain and ring hydroxylations occur on y-hydroxyoxyphenbutazone 
(Traub, 1983; Tobin et al., 1986; Lees et al., 1987a)(Figure 3). 
Oxyphenbutazone is an active metabolite which shares many of the 
pharmacologic actions of phenylbutazone; however, rather high doses 
(6 to 12 mg/kg; Gerring et al., 1981) are required for effect. 
Gamma-hydroxyphenylbutazone and y-hydroxyoxyphenbutazone are presumed 
to be inactive metabolites. These 3 metabolites are secreted into 
urine (Traub, 1983; Tobin e_t al., 1986; Lees et al., 1987).
Because y-hydroxyphenylbutazone is less tightly bound than 
either phenylbutazone or oxyphenbutazone it is readily excreted in 
urine and is the principle metabolite found in urine (14%) after a 
single intravenous dose of 4.4 mg/kg phenylbutazone. However, if 
dosing was continued, the proportion of y-hydroxyphenlybutazone 
excreted dropped to 6% of the dose. This change in proportion of 
different metabolites in the urine as dosing proceeds is likely 
related to the dose-dependent kinetics of phenylbutazone due to 
inhibition of drug metabolism by one of its metabolites (Maylin, 
1977).
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Figure 3. Chemical structure of phenylbutazone and its 
oxidative metabolites; oxyphenbutazone, y-hydroxyphenyl- 
butazone and y-hydroxyoxyphenylbutazone
Adapted from Traub et al. (1983) 
and Tobin et al. (1986)
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Oxyphenbutazone has been shown to inhibit the metabolism of 
phenylbutazone in the rat and horse (Maylin, 1977). It was proposed 
that a metabolite of phenylbutazone (probably oxyphenbutazone) 
becomes bound to and inhibits liver microsomal drug metabolism 
enzymes and alters both the metabolite pattern of phenylbutazone and 
its plasma half-life (Maylin, 1977). It is also possible that 
phenylbutazone itself saturates mixed function oxidase to inhibit its 
own metabolism (Tobin ejt al., 1986).
Piperno et al. (1968) determined that horses were remarkably 
uniform in their rate of metabolism of phenylbutazone as indicated by 
small standard errors (0.2 to 0.6 mg/liter) in plasma concentrations. 
The greatest variability existed in the first hour after dosing, when 
decay rate was accelerated. After this time, the decay rate was 
uniform and logarithmic.
Several studies confirmed that plasma disposition follows a 
bi-exponential decline (Lees et al., 1983; Lees and Taylor, 1985;
Lees et al., 1986; Maitho et al., 1986). By using a sensitive 
chromatographic method and a frequent blood sampling schudule up to 
72 hours, Lees et al. (1987a) investigated but did not observe a 
third, slower phase of decreasing plasma concentration. Therefore, 
it seems improbable that phenylbutazone will achieve very high 
concentrations in tissues since this would be likely to provide a 
further phase of slower plasma elimination (Lees et al., 1987).
Sex differences did not appear to affect metabolism rate 
(Piperno et al., 1968), but breed differences appear to affect phen­
ylbutazone metabolism rate. Chay et al. (1984) determined population 
distributions of phenylbutazone and oxyphenbutazone after oral and
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intravenous dosing in Thoroughbred, Standardbred and half-bred horses 
at pasture. The plasma concentrations of phenylbutazone in half-bred 
horses were only one-third of those observed in the Thoroughbred and 
Standardbred horses. Chay ejt al. (1984) proposed 1 possible inter­
pretation is that phenylbutazone is metabolized more rapidly in half- 
bred horses; because phenylbutazone is more toxic in ponies than in 
Thoroughbred horses (Lees and Mitchell, 1979; Snow et al., 1979,
1980, 1981, 1983; Gerring, et al., 1981; Rose et al., 1982; 
MacAllister, 1983; Snow and Douglas, 1983), this data may suggest 
that it is a metabolite of phenylbutazone rather than phenylbutazone 
itself which is the toxic species.
Feeding times relative to dosing time appear to affect phenylbu­
tazone metabolism. Recovery of phenylbutazone and its metabolites 
from urine was significantly reduced in the first 24 hours after dos­
ing when horses had free access to hay. This was probably a result 
of markedly delayed absorption because this did not occur in animals 
deprived of food for a few hours before and after dosing (Lees et^  
al., 1987a).
Finocchio et al. (1970) suggested various individual factors may 
affect metabolism of phenylbutazone in the horse. For example, liver 
microsomal enzyme systems have been shown to be subject to nutrition­
al inadequacy, hepatic glycogen content, stage of pregnancy, stage of 
enzyme development, circulating hormone concentrations, liver dis­
ease, presence of exogenous chemicals and simultaneously administered 
drugs. Any one or combination of factors may be present in a parti­
cular horse such as variations in training, diet and prior or simul­
taneous drug treatment.
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Excretion
Although the pharmacological action of phenylbutazone is over 
within 24 hours, the time for the horse to eliminate phenylbutazone 
is much longer (Tobin, 1981b). Phenylbutazone is excreted in the 
urine in an unchanged form and/or as its 2 major metabolites, oxy­
phenbutazone and y-hydroxyphenylbutazone (Maylin, 1974). Renal 
clearance of phenylbutazone is influenced by the drug being 98X 
plasma bound and its pKa of 4.5. The acidic nature of phenylbutazone 
will tend to reduce its reabsorption from the renal tubules, if the 
tubular luminal fluid is alkaline (Tobin et al., 1986). Only the 
unbound drug is available for glomerular filtration (Moss, 1973) and 
the pH of the urine affects excretion rate (Piperno, 1968).
Clearance is also affected by the age of the horse (Lees, 1985) and 
route of administration (Moss, 1972).
Moss (1972) reported that route of administration is an 
important factor in determining the phenylbutazone excretion pattern. 
Generally after oral or intravenous administration, plasma levels 
return to "zero” after about 24 hours, but phenylbutazone persists in 
the urine for at least 36 hours and its metabolites for more than 48 
hours. After intramuscular administration, phenylbutazone appears to 
persist in urine a much longer and variable period of several days.
Moss (1972) reported that Thoroughbreds during training and 
certainly after a race produce an acidic urine, but produce a more 
alkaline urine at rest and light exercise. Moss and Haywood (1973) 
investigated the significance of urinary pH on phenylbutazone drug 
clearance time. They administered an oral dose of 5 mg/kg phenyl­
butazone daily to a pony for 3 days under both alkaline (normal) and
under a condition that induced acidic urine. In alkaline urine,
phenylbutazone was detected by a routine screening procedure up to 11
hours after administration and oxyphenbutazone up to 48 hours after
dosing. In the acidic urine experiment using the same pony and dose,
phenylbutazone was detected up to 48 hours and oxyphenbutazone up to
57 hours. A more exhaustive solvent extraction of the urine detected
oxyphenbutazone for 54 and 88 hours in alkaline and acidic urine,
respectively. They repeated the experiment dosing 3 ponies with 5
14mg/kg phenylbutazone containing 10 microcuries of C. In 1 pony, 
radioactive material was detected 6 days later in acidic urine. Moss 
and Haywood (1973) concluded aciduria in the horse prolongs clearance 
time of phenylbutazone and/or its metabolites.
Houston et al. (1983) determined the effect of urine pH on 
detection of oxyphenbutazone in racing horses. Urine pH in racing 
horses may range from pH 4.5 to 10. Distribution tends to be 
bimodal, with peaks at approximately pH 5 and pH 8. They measured 
blood and urinary levels of oxyphenbutazone in post-race samples from 
Thoroughbred horses racing in Kentucky. Data showed that oxyphenbu­
tazone levels in equine blood are not significantly influenced by 
urine pH, but urine concentrations of oxyphenbutazone are highly 
dependent on urine pH and may vary up to 500-fold, depending largely 
on whether the urine is acidic or basic. If the pH of urine was < pH 
6, blood and urinary concentrations of oxyphenbutazone were compara­
ble: if the sample pH was > 8, the urinary concentrations of 
oxyphenbutazone approached 100 pg/ml, while the plasma levels of 
oxyphenbutazone remained low. Houston et al. (1983) suggested their 
results represented a classic example of "ion-trapping" phenomenon;
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as an acidic drug, the concentrations of oxyphenbutazone are high in 
basic urines and low in acidic urines.
Houston et al. (1985) conducted a similar experiment to 
determine the effect of urine pH on detection of phenylbutazone and 
its metabolites in plasma and urine of Thoroughbred race horses. 
Analysis of the pH of these post-race urine samples again showed a 
bimodal frequency distribution. The pH values ranged from 4.9 to 
8.7, with peaks at about pH 5.25 and 7.25. This bimodal pattern of 
urinary pH values was consistent with observations of parallel 
studies of race horses in England and Japan.
Urinary pH influenced the concentrations of phenylbutazone and 
its metabolites oxyphenbutazone and y-hydroxyphenylbutazone found in 
the urine samples. The concentration of these metabolites found in 
alkaline urines were 32 to 225 times greater than those found in 
acidic urines. Again, research by Houston et al. (1985) demonstrated 
that as acidic drugs, these agents will be largely in their ionized 
forms at alkaline urinary pH values, and will, therefore, tend to 
trap in alkaline urine. Plasma concentrations of phenylbutazone and 
its metabolites, however, were not affected by urinary pH (Houston et 
al., 1985).
Lees et al. (1985) determined that age affects elimination rate 
of phenylbutazone in horses. A clinical dose of 4.4 mg/kg phenylbu­
tazone was administered intravenously or orally to 6 ponies. In 3 
ponies, 3-years-of age, drug clearance after intravenous administra­
tion was almost twice as rapid as in 3 ponies 8 to 10 years-of-age. 
After oral administration, plasma concentrations were greater in the 
older ponies, the area under the plasma concentration time curve
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being almost twice as high as that of the younger ponies. These 
researchers stated that this did not result from more efficient 
absorption but from slower plasma clearance (as demonstrated in the 
intravenous study). They added that in very young animals (< 8 weeks 
of age) the plasma clearance of most drugs is slow (as in the older 
ponies) but is due to immature mechanisms of metabolism in the liver 
and excretion in the kidney.
Lees et al. (1985) results indicated that only 25% of the 
administered dose was accounted for by excretion in the urine over 24 
hours, the greatest fraction being excreted as oxyphenbutazone and a 
slightly smaller fraction as y-hydroxyphenylbutazone. Only 2% of the 
dose was present in urine as unchanged drug. The remaining 75% 
remained unaccounted. They speculated that other fates of phenyl­
butazone may be (1) formation of other unidentified metabolites; (2) 
excretion via non-renal pathways such as bile; (3) storage of phenyl­
butazone in tissues with a subsequent slow release which suggests a 
further elimination phase will occur. Unpublished data of J.B.
Taylor and P. Lees (see Tobin et al., 1986) indicated a third phenyl­
butazone metabolite in horse urine; however, the quantities present 
were not large and would add only a few percentage points to the 24 
hour urinary excretion level (Lees ej^  al., 1985). This third metabo­
lite has been named y-hydroxyoxyphenylbutazone (Tobin et al., 1986).
Lees e^t al. (1987a) determined a lack of acumulation of phenylbu 
tazone and oxyphenbutazone in tissues and body fluids and a limited 
recovery in urine. The fate of at least 50% of the administered 
intravenous dose of phenylbutazone remained undetermined. Lees ejt 
al. (1987a) porposed that up to half of the administered oral and
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intravenous doses were probably passed into the gastrintestinal tract 
as phenylbutazone or metabolites with eventual excretion in feces. 
This could arise by active secretion in fluids such as bile or by 
simple passive diffusion across the blood-gastrointestinal tract 
barrier (Lees et al., 1987a).
Lees et al. (1985) considered that possibly the slower 
phenylbutazone clearance in 8 to 10-year-old ponies could be related 
to the 35% greater body weight of the older ponies as compared to the 
3-year-old ponies. However, these researchers suggested that this 
was improbable since data from their laboratory showed that mean AUC 
values were higher in ponies than in Thoroughbreds weighing 
approximately twice as much.
Gerring et al. (1981) determined via high performance liquid 
chromatography the urinary excretion pattern of phenylbutazone and 
its metabolites after orally dosing horses: doses ranged from 1.1 to
13.2 mg/kg. Analysis of urine specimens demonstrated concentrations 
of phenylbutazone were similar to or more than those in plasma. 
However, the concentrations of both metabolites were very much higher 
in urine than plasma. Gerring et al. (1981) suggested the slow 
excretion of phenylbutazone may result from tubular reabsorption of 
the drug, but it is also attributed largely, possibly entirely, to 
the high degree of plasma protein binding, that limits the amount of 
phenylbutazone filtered at the glomerulus to a small fraction of the 
total plasma concentration. Gerring et al. (1981) stated their 
results made it clear that tubular secretion of phenylbutazone does 
not occur in the horse (although it has been reported in laboratory 
animals); however, the hydroxylated phenylbutazone metabolites must
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be secreted as suggested by their urineiplasma concentration ratios.
Maylin (1974) administered 4.4 mg/kg phenylbutazone intravenous­
ly daily for 4 days. He determined the excretion of phenylbutazone 
remained relatively constant following 4 consecutive doses. Total 
percent recovery of phenylbutazone for 24 hours post-administration 
was 0.9%, 1.7%, 2.1% and 1.6% of the first, second, third and fourth 
doses, respectively. Concentration of oxyphenbutazone decreased 
after each successive dose from 14.2%, 10.1%, 8.2% and to 6.4% of the 
first, second, third and fourth doses, respectively.
Concentration of oxyphenbutazone increased after the second and 
third doses but decreased after the fourth dose. It accounted for 
9.6%, 14.0%, 14.0% and 10.5% of the first, second, third and fourth 
doses, respectively. The concentration of y-hydroxyphenylbutazone 
was greater than oxyphenbutazone for approximately 12 hours after 
each dose whereas the oxyphenbutazone concentration exceeded that of 
y-hydroxyphenbutazone beyond 18 hours. Total urinary excretion of 
phenylbutazone, oxyphenbutazone and y-hydroxyphenbutazone accounted 
for 24.7%, 25.8%, 24.3% and 18.6% of the dose after the first, 
second, third and fourth doses, respectively. An additional 6.3% of 
the dose was recovered 24 to 48 hours post-administration.
Toxicity
When phenylbutazone is used in the horse in recommended doses 
for the recommended period of time, it is a very safe drug. The 
number of doses administered to horses over approximately 30 years 
must be infinite but the incidence of reported toxicity is small 
(Tobin, 1981b). Horses have been kept on the usual maintenance dose
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of 2 g/450 kg/day for up to 2 and 3 years with no detectable toxic 
effects (Gabel, 1977).
Toxicity has been reported most frequently in pony breeds (Lees 
and Mitchell, 1979; Snow et al., 1979, 1980, 1981, 1983; Gerring et 
al., 1981; Rose et al., 1982; MacAllister, 1983; Snow and Douglas,
1983). The reason why phenylbutazone produces toxicity at relatively 
low dose rates in ponies is unknown (Snow and Douglas, 1983).
Because ponies were reported to be a phenylbutazone toxicity risk, 
horse mares were used in all 5 experiments in this study.
The paste preparation is considerably more toxic than the powder 
preparation. The reason for this is unknown (Snow, 1982). It has 
been suggested that the bioavailability was greater for the paste 
and, therefore, would more readily produce toxicity (Snow and 
Douglas, 1983; Tobin et al., 1986). A lower dose schedule is 
recommended if the paste preparation is used. Higher dose rates 
should not be instituted if there is a lack of clinical response 
(Snow, 1982; Lees and Higgins, 1987).
The principle dangers with phenylbutazone are associated with 
improper injection. If phenylbutazone is accidentally injected 
perivascularly it may cause severe inflammation, abscessation and 
eventual sloughing of the jugular vein (Tobin, 1981b). Rapid 
intravenous injection of undiluted phenylbutazone (5£ solution) will 
cause phlebitis with fibrosis and sometimes occlusion of the jugular 
vein. Phenylbutazone should be injected slowly and diluted with 
saline solution. Since blood levels reached following oral adminis­
tration are similar to those after intravenous injection, intravenous 
use of the drug can be justified only in cases when it is important
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to attain a more rapid onset of action than via oral administration 
such as severe trauma, severe pain and selected colic cases (Gabel,
1977) or when standardization and predictability are necessary for 
drug studies. If phenylbutazone is accidentally injected directly 
into the carotid artery, the horse immediately becomes excited, 
prostrated and may die (Tobin, 1981b).
An extensive review of the literature shows there have been few 
reports of phenylbutazone toxicity in horses. The published reports 
of phenylbutazone toxicity occurred when researchers elected to give 
higher than usual doses of phenylbutazone to study its effects 
(Tobin, 1981b). These reports all conclude that toxic doses of 
phenylbutazone cause lesions in the entire gastrointestinal tract, 
liver and kidney. All case reports list the same clinical signs of 
toxicity: central nervous system depression, anorexia, diarrhea,
listlessness and oral ulcerations. The 2 following studies (one 
involving ponies and one involving horses) are examples of all toxic 
cases reviewed.
Snow et al. (1980) studied the toxic effects of phenylbutazone 
by oral administration of 12 mg/kg/day for 8 days to ponies. Blood 
samples were taken at frequent intervals and necropsies were per­
formed on all ponies. The only consistent clinical biochemical find­
ing was an approximate 25% decrease in total plasma protein. Plasma 
protein concentration seems to be the best biochemical indicator of 
phenylbutazone toxicity in the horse (Lees and Higgins, 1986).
Hypoproteinemia was investigated by injecting "^CrCl^-labeled 
plasma proteins and calculating the loss. Labeled chromic oxide was 
given orally and was concentrated in the feces. The results clearly
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showed that the phenylbutazone-treated ponies had very high fecal 
radioactivity compared with the untreated controls indicating a mas­
sive loss of plasma protein into the gastrointestinal tract. Necrop­
sies revealed ulceration of the large colon and caecum in varying 
degrees from few to massive ulcerations. All ponies had tongue 
ulcerations. Radioactive determinations of gut contents indicated 
that the site of plasma protein loss was variable throughout the 
gastrointestinal tract. The plasma protein loss was associated with 
the gastrointestinal ulceration (Snow et al., 1980).
Gabriel and Martin (1962) chronically administered phenylbuta­
zone to Thoroughbred and Standardbred horses. Necropsies showed 
ulcerative lesions in the intestines of horses given 8 and 16 g 
phenylbutazone/day. Ulcerations were also found in the oral mucosa 
and stomach. Extensive necrotic phlebitis was found in the portal 
veins and liver degeneration was evident. Autolysis of all tissues 
submitted at necropsy in a horse given 16 g phenylbutazone/day was so 
extensive that no definite conclusion could be reached as to the 
extent of the involvement.
In summary, necropsy reports were extensive, but there was no 
indication that the phenylbutazone caused any degeneration of the 
reproductive tract of males or females. It may be assumed that 
phenylbutazone does not normally accumulate in the reproductive 
tract.
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Phenylbutazone and Inflammation
The acidity of phenylbutazone enables it to accumulate in acidic 
inflamed tissues (Tobin, 1979a). The primary role of phenylbutazone 
in treating inflammation in horses is to inhibit a massive prosta­
glandin synthesis thus reducing the erythema, edema, hyperalgesia and 
fever of inflammation. Accumulation of phenylbutazone in inflamed 
tissue is slow. The anti-inflammatory action of phenylbutazone 
develops slowly because first the preformed tissue prostaglandin 
concentration must be significantly reduced before phenylbutazone can 
start blocking synthesis of new prostaglandins (Brune, 1976). After 
the 30 minutes distribution of an intravenous injection of phenylbu­
tazone in the horse, it then takes =3 to 4 hours for the preformed 
prostaglandin concentration to decline by its own biodegradation 
followed by the phenylbutazone blockage of newly synthesized prosta­
glandins. Loss of the signs of inflammation may take up to 12 hours
or more. When the plasma level of phenylbutazone declines, the
concentration of prostaglandins in inflamed tissues builds back up
again and signs of inflammation reappear. Then, it is time for
another daily therapeutic dose of phenylbutazone (Tobin, 1979a).
Accumulation of phenylbutazone into cells of inflamed tissues is 
highly influenced by the variation of pH in both the extracellular 
and intracellular spaces. Table 5 shows that the normally alkaline 
pH of the extracellular space (7.4) becomes acidic (6.8) in inflamed 
tissues and the normally neutral intracellular pH (7.0) becomes 
slightly alkaline pH (7.2) in cells of inflamed tissue. Therefore, 
there is a considerable shift of acidic phenylbutazone into a more 
favorable alkaline pH in cell membranes and intracellular spaces
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(Brune, 1976).
Two experimental equine models of acute non-immune inflammation 
have been developed to enable studies of the biochemical composition 
and cellular content of exudates. Both are based on the creation of 
a mild, reproducible and reversible inflammatory reaction that is 
free from uncontrolled incidental factors and that causes minimal 
distress to the ponies. The polyester sponge model involves the 
insertion of small polyester sponge strips soaked in sterile 
carrageenan solution into subcutaneous neck pouches and their serial 
removal. The tissue-cage model is based on the initial insertion of 
a sperical tissue-cage subcutaneously in the neck and the subsequent 
stimulation with carrageenan of the granulation tissue that lines and 
permeates the cage. Relationships between prostaglandin formation at 
the site of inflammation and leucocyte accumulation, enzyme release, 
total protein content of exudates and the temperature of the lesions 
have been investigated (Higgins et al., 1987a).
Development of the equine model of acute inflammation facilitat­
ed studies of the action of NSAID in horses (Higgins and Lees, 1983; 
Lees e_t al., 1986b; Higgins et al., 1987b; Lees et al., 1987b). 
Higgins and Lees (1983) determined a highly significant (P < 0.001) 
reduction in prostaglandin levels in inflammatory exudates from 
phenylbutazone-treated ponies compared to untreated ponies. Lees and 
Higgins (1986) determined that phenylbutazone paste significantly 
reduced skin temperature over the site of the inflammatory lesion for 
24 hours and inhibited prostaglandin synthesis for at least 12 hours. 
There were no significant differences in exudate protein concentra­
tion and leukocyte numbers between phenylbutazone-treated and control
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ponies. Phenylbutazone was cleared more slowly from exudate than 
from plasma. Lees et al. (1986b) utilized this model to determine 
that phenylbutazone and oxyphenbutazone readily passed into the 
inflammatory exudate and then were slowly cleared from the exudate.
Table 5. Influence of variation of pH on the relative concen­
trations of phenylbutazone (PBZ) in neighboring cell­
ular compartments
Situation Extracellular
space
Cell membrane Intracellular
space
pH PBZ PBZ pH PBZ
Normal 7.4 1.0 5.8 7.0 0.5
Inflamed 6.8 1.0 15.8 7.2 2.0
The values were defined by equilibrium distribution of phenylbutazone 
between citrate buffers (ionic strength 0.15 M) of different pH 
values and octanol. The phases were always saturated against each 
other.
(Adapted from Brune, 1976)
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INFLAMMATION AND PROSTAGLANDINS
Inflammation Defined
Inflammation has been defined as "the reaction of living tissue 
to injury, which comprises a series of changes of the terminal 
vascular bed, of the blood and of the connective tissue that tends to 
eliminate the injurious agent and to repair the damaged tissue." The 
reaction which follows interaction between antigen and antibody in an 
animal which has been in contact with that particular antigen is 
referred to as "allergic inflammation" (Chand and Eyre, 1977). 
Inflammation is a fundamental defense mechanism of the body against 
physical, chemical or infectious injury. Despite its protective 
nature, the resulting tissue changes may be excessive and damaging 
(Jones, 1977).
The chemical mediators of inflammation include (1) biogenic 
amines (histamine, serotonin and catecholamines); (2) vasoactive 
polypeptides (kinins, cationic proteins, anaphylatoxins, connective 
tissue activating peptide); (3) lysosomal enzymes; (4) vasoactive 
lipids (prostaglandins, endoperoxides, thromboxanes, rabbit aorta- 
contracting substance, slow-reacting substance of anaphylaxis); (5) 
phospholipid (platelet activating factor); (6) chemotactic substances 
(eosinophil and neutrophil chemotactic factors of anaphylaxis). The 
type of principle chemical mediator(s) involved in a particular in­
flammatory condition depends upon the underlying cause of inflamma­
tion and the species (Chand and Eyre, 1977).
Many of these chemical mediators produce, directly or indirect­
ly, inflammation characterized by redness, heat, swelling, pain and
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loss of function. Pharmacological agents which inhibit the excessive 
defense reactions (e.g. fever, pain and inflammation) have been 
called "anti-defense" drugs. The NSAID inhibit inflammation and 
fever and are therefore known as "anti-defensive" agents (Chand and 
Eyre, 1977).
Inflammation Process
The process of inflammation can be initiated in any vascular­
ized part of the body by an injury or insult to living tissue. Then, 
the synthesis of eicosanoids is stimulated (Higgins, 1985).
Eicosanoids are derived from naturally occurring eicosapolyen- 
oic acids, of which arachidonic acid is the most common in domestic 
animals. Arachidonic acid is either obtained from the diet or is 
synthesized from linoleic acid. It is widely distributed in the body 
and is usually stored, covalently bound in its esterified form, in 
the phospholipid fraction of cell membranes of most body cells 
(Higgins, 1985).
Following an inflammatory stimulus, an acyl hydrolase and 
phospholipase A  ^ (and possibly others) act to release the arachidonic 
acid from its phospholipid pool. This free arachidonate is either 
immediately re-esterified or metabolized by 1 of 2 enzyme pathways 
(Figures 4 and 5). The cyclooxygenase enzyme system (Figure 4) will 
convert the arachidonate to a cyclic endoperoxide PGG2 , which is 
acted upon by another enzyme to yield P G ^  (a cyclic hydroxyendoper- 
oxide) which subsequently gives rise to the primary prostaglandins 
(PGD2 , PGE2  and PGF2 «x) as well as PG ^  (prostacyclin) and the non- 
prostanoate thromboxanes A 2  (TXA2 ) and TXI^. Members of this group
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of eicosanoids have been implicated in every phase of inflammation 
(Higgins, 1985).
Prostaglandins induce the signs of inflammation and sensitize 
tissue including hypothalamus to pain provoking and fever inducing 
effects of other substances. Sensitivity to the kinins is especially 
enhanced. They cause exudation of fluid into the inflamed area and 
intense leukocyte migration due to chemotactic factors (Jones, 1978).
Prostaglandins in Basal Conditions
Prostaglandins are crucial to many body functions and influence 
the production and release of each other. They modify blood pressure 
and cardiovascular control. In the lung, prostaglandins influence 
both circulation and ventilation and may well match the delivery of 
air and gas to provide gaseous exchange. In the newborn, prostaglan­
dins are instrumental in termination of umbilical blood flow and in 
diversion of venous blood to the lung. They are involved in many 
facets of reproduction and regulation of growth hormone. They in­
crease intestinal fluids and gut mobility, often resulting in diar­
rhea and cramps (Jones, 1978).
Prostaglandins are usually present in the central nervous 
system and have been implicated in the function of both the central 
and autonomic systems, especially in mediation or modulation of 
chemical and other stimuli. Prostaglandins depress behavior and 
enhance barbiturate action, mediate response to pyrogens, modify food 
intake, influence cerebral blood flow and modify neurotransmission 
(Jones, 1977).
None of the synthesized prostaglandins persist long at their
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site of formation. They rapidly diffuse to other sites or are con­
verted to various derivatives. Most prostaglandins do not survive 
one passage through the lungs. Therefore, they do not usually reach 
the systemic circulation for redistribution (Jones, 1978).
Prostanoids (prostaglandins, prostacyclin and thromboxanes) are 
not stored in tissues and are very unstable (Higgins, 1985). In 
aqueous solution at pH 7.5 and 37°C, half-life of the cyclic endoper- 
oxides PGG2  and P G ^  was found to be 4 and 3.5 minutes respectively, 
before they are converted to primary prostaglandins. The half-life 
of PGI2  was 4 minutes and that of TXA2  was 32 seconds. These short 
half-life values require that PGI2  and TXA2  are measured as their 
degradation products 6-keto-PGF^a and TXl^, respectively. These 
products have been found to be biologically less active but 
relatively stable. In vivo, prostaglandins have been shown to be 
rapidly metabolized to urinary metabolites. More than 95% of infused 
PGE2  was inactivated after one circulation through the lungs 
(Higgins, 1985). Only 3% of tritiated PGE2  remained unchanged in the 
plasma 90 seconds after intravenous administration (Higgins, 1985).
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Prostaglandins and Erythema
Prostaglandins E^, E£ and (at higher concentrations) have a 
direct vasodilating ability that may be responsible for characteris­
tic erythema in inflamed tissue (Short and Beadle, 1978). Erythema 
results from a local blood pooling due to relaxation of smooth 
muscles in walls of arterioles and venules (Ferreira and Vane, 1974). 
This is a long-lasting effect in cutaneous vessels and superficial 
veins, but lasts only a few minutes in other vascular beds. Prosta­
glandins may also cause vasodilation by inhibiting the release of 
adrenergic mediator (Short and Beadle, 1978). They have the ability 
to counteract the vasoconstriction caused by substances such as 
norepinephrine and angiotensin (Ferreira and Vane, 1974).
Prostaglandins and Edema
Prostaglandins Ej, and A2  can directly cause some degree of 
localized edema, that is likely caused by increased vascular permea­
bility resulting from contraction of venular endothelial cells. This 
effect is additive in the presence of other mediators such as hista­
mine and bradykinin. Therefore, prostaglandins have an indirect 
sensitizing action on the wheal-forming potential of other agents 
(Short and Beadle, 1978). Experiments have clearly demonstrated that 
prostaglandin E can sensitize blood vessels (at postcapillary and 
collecting venules) to the permeability-increasing effects of other 
edema mediators locally released (Ferreira and Vane, 1974).
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Prostaglandins and Pain
Prostaglandins directly induce headache and long-lasting pain 
when injected in man. They can induce hyperalgesia. Low concentra­
tions of prostaglandins as released in inflammation, alone usually do 
not invoke pain. However, the addition of histamine or bradykinin 
causes intense pain. Furthermore, neither histamine nor bradykinin 
injected alone has been shown to induce pain (Short and Beadle,
1978). It appears prostaglandins must act synergically with 
histamine and/or bradykinin to cause sensitivity to pain receptors.
Prostaglandins causes long-lasting pain and is 10 times more 
potent than PGE2 . Injections of PGF2 0 1  cause an initial brief pain 
effect followed by a delayed gradual increase over 4 hours. Subder- 
mal PGE^ infusions mimicking continuous release of mediators at an 
injury site showed that hyperalgesic effects of prostaglandins were 
cumulative, since they depended on concentration plus duration of 
infusions (Ferreira and Vane, 1974).
Prostaglandin E^ must act with histamine to cause pruritus.
When infused with bradykinin, there was pain induction rather than 
itching (Ferreira and Vane, 1974).
Fatty acid hydroperoxides can also induce pain in man.
Intensity of pain produced by injections of hydroperoxides of 
arachidonic, linoleic and linolenic acids was greater than that 
induced by either the parent fatty acids or PGE^, acetylcholine, 
bradykinin or histamine. Thus, lipoperoxides formed during 
prostaglandin biosynthesis may also be important pain-producing 
substances (Ferreira and Vane, 1974).
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PROSTAGLANDINS
I. SENSITIZE PAIN RECEPTORS TO PAIN AGONISTS  
N O R M A L  IN F L A M E D
PAIN
RECEPTOR ,< 51
t
PAIN /  PROSTAGLANDIN RECEPTOR -  AGONIST  
AGONIST PROSTAGLANDIN C OM PLEX
2. INCREASED PROSTAGLANDIN LEVELS (INJECTION OR WITH 
IN FL A M M A TIO N  ) CAUSES HYPERALGESIA.
3. BLOCK PROSTAGLANDIN SYNTHESIS : TISSUE RETURNS TO 
NORMAL (SLOWLY -  PROSTAGLANDINS FORMED MUST BREAK DOWN )
Figure 6. Schematic representation of the pain-sensitiz­
ing action of prostaglandins. Pain is mediated by cer­
tain chemicals which interact with pain receptors. The 
prostaglandins appear to act by increasing the sensitiv­
ity of pain receptors to pain agonists, here represented 
as a locking of the pain agonists onto the pain receptors. 
In an inflamed tissue the increased levels of prostaglandin 
cause the hypersensitivity characteristic of inflamed tis­
sues. Once prostaglandin formation is blocked, the high 
tissue levels of prostaglandin have to decay over a number 
of hours before the tissue returns to normal. This is 
the reason many non-steroidal anti-inflammatory drugs often 
take several hours to act.
Tobin (1981b)
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Prostaglandins and Fever
Prostaglandin E^, PGF^a and PGA^ are potent pyretic agents. 
Prostaglandin is the most potent pyrogen known when injected into 
the cerebral ventricle or the anterior hypothalamus (Short and 
Beadle, 1978). The hyperthermic effect is dose-dependent, almost 
immediate and lasts for about 3 hours. Prostaglandin E^ or E 2  causes 
fever acting on the same region on which monoamines and pyrogens act 
to affect temperature. Fever occurs during induction of human abor­
tion with PGF2 <x, but it is rather ineffective in cats and rabbits.
The pyrogenic action of PGE2  is greater than that of PGF2 <x in ani­
mals. Generation of a PGE2 ~like substance in the central nervous 
system has been measured during fever. Concentrations in the cere­
bral spinal fluid rise after intravenous pyrogen by 2.5 to 4-fold, 
sometimes to as much as 35 ng/ml (Ferreira and Vane, 1974). Fever 
and pain are the first signs of inflammation to be relieved by 
antiprostaglandin therapy. Edema and erythema are alleviated more 
slowly (Jones, 1977).
Prostaglandins and Leukotaxis
Prostaglandin E^ has been observed to cause an initial 
migration of polymorphonuclear (PMN) leukocytes followed by an 
invasion of mononuclear cells into an area of inflammation.
Inhibitors of prostaglandin synthesis have been found to greatly 
reduce the emigration of monocytes from blood vessels in the 
inflammatory site in an acute inflammatory reaction (Short and 
Beadle, 1978). Significant inhibition of polymorphonuclear and 
mononuclear leukocyte locomotion was produced by indomethacin,
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flunixin, phenylbutazone and oxyphenbutazone (Dawson et al., 1987; 
Sedgwick et al., 1987). Leukotaxis is also demonstrated by other 
arachidonic acid derivatives, the thromboxanes and hydroxyeicosate- 
traenoic acid (Short and Beadle, 1978).
Leucocytes enhance eicosanoid-mediated aspects of the inflamma­
tory reaction and its maintenance. During phagocytosis, arachidonic 
acid metabolites are released. These products mediate inflammatory 
responses and may be chemotactic for more leucocytes. This cycle of 
phagocytosis and leucotaxis may continue for as long as debris or the 
inflammatory stimulus is present (Higgins, 1985).
Prostaglandins and Anti-inflammatory Actions
Prostaglandin F2 CX is a potent vasoconstrictor in many vascular 
beds. It is possible that in some tissues the PGE:PGF ratio deter­
mines the degree of inflammation. Some antiprostaglandin drugs alter 
this ratio in favor of the F series. Prostaglandin and PGE2  have 
proven to be effective at low concentrations as inhibitors of hista­
mine release in basophils. Lysosomal enzyme release by neutrophils 
has also been shown to be inhibited at higher levels of PGE^. Pros­
taglandin E^ and E 2  will also inhibit lymphokine secretion by lympho­
cytes. The development and regression of inflammation probably de­
pend partly upon relative concentrations of pro- and anti-inflamma­
tory prostaglandin activity and possibly on feedback inhibitory 
mechanisms (Short and Beadle, 1978).
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PROSTAGLANDINS AND FEMALE REPRODUCTION FROM 
CYCLICITY TO EARLY EMBRYONIC DEVELOPMENT
Introduction
Prostaglandin F2 OC, PGE2  and PGI2  have been documented having an 
important role in directing estrous cycles, ovulation, fertilization 
and uterine environment of females. Embryos depend on prostaglandins 
for hatching, expansion, development and implantation. Researchers 
have demonstrated these aspects of prostaglandins in female reproduc­
tion by administering prostaglandin antagonists and recording various 
antifertility effects (see Table 6).
Ovulation
Espey (1980) described ovulation as an inflammatory reaction.
It was hypothesized that an ovulatory surge of gonadotropin induced 
an inflammatory condition in mature follicles that brought about the 
rupture of the ovarian surface. This theory gives prostaglandins the 
central role as mediators of the inflammatory process. The principle 
modifications in the ovarian vascular system include an increase in 
local blood flow (vasodialation) and edema, both effects documented 
to be caused by PGE. Within minutes of an ovulatory surge of lutein­
izing hormone there is a significant increase in ovarian circulation 
associated with the hyperemic condition developed in follicles.
These vascular changes cause the follicle to become edematous 
to the time of rupture. At the time of ovulation, thecal fibroblasts 
migrate into the stratum granulosum laying down collagenous support 
for the mass of developing lutein tissue. Prostaglandins promote 
fibroblast proliferation. In addition, fibroblasts themselves are a
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common source of prostsglandins.
It is well known the ovulatory surge of luteinizing hormone 
activates the adenylate cyclase system and stimulates cyclic adeno­
sine monophosphate (cAMP) synthsis in follicle cells. Subsequently, 
cAMP stimulates prostaglandin synthesis by stimulating an acyl hydro­
lase, which liberates arachidonic acid. Mature follicles begin a 
cAMP mediated increased secretion of steroids, specifically estrogens 
that may contribute to the ovulatory process by increasing 
prostaglandin synthsis (particularly PGF2 0 O (Espey, 1980).
Prostaglandin F reaches a maximum level in the follicle by 
ovulation time and then rapidly declines, but PGE continues to be 
produced for several hours after ovulation (Espey, 1980). Granulosa 
cells produce significant amounts of prostaglandins, but so do thecal 
cells that generate PGF. It has been suggested that causes
rupture of the follicle by increasing ovarian contractility and then 
vasoconstriction, thus diminishing blood flow to the ovary during the 
luteal phase of the cycle (Espey, 1980).
There is evidence that mature ovarian follicles contain proteo­
lytic enzymes that have been implicated in inflammatory processes. 
Fibrinolytic activity increases in the follicle during the hours 
preceding ovulation. This is associated with production of plasmino­
gen activator in the follicle during ovulation. Cyclic AMP and PGE^ 
and E2  are also capable of stimulating follicular cells to produce 
plasminogen activator, which leads to plasmin formation. Plasmin 
stimulates production of collagenase that is necessary for collagen 
degradation resulting in the follicle wall becoming flaccid and 
distensible. The decomposition of follicular connective tissue
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accelerates rapidly during the final hour preceding ovulation (Espey, 
1980). Prostaglandin F and E appear in the follicular fluid the last 
few hours before ovulation (Stabenfeldt and Eqvist, 1984). Prosta­
glandins may contribute to the formation of the collagen decomposi­
tion cascade since they are known to stimulate collagenase activity 
in fibroblasts and related cells (Espey, 1980).
This hypothesis encourages the evaluation of anti-inflammatory 
agents as potential antifertility agents (Espey, 1980). The Espey 
hypothesis describing roles of prostaglandins in the mechanism of 
mammalian ovulation appears to be unchallenged at this time (Lipner, 
1988).
Luteolysis
Prostaglandin is considered to be the substance that 
initiates regression of the corpus luteum. Numerous studies have 
demonstrated that increased PGF2 <x levels in blood due to either 
exogenous administration or physiological synthesis and release was 
concomitant with corpus luteum regression. Prostaglandin F2 «x is 
released episodically beginning approximately 14 days after ovulation 
in large domestic species. Individual surges average 5 to 6 hours in 
duration with approximately the same interval intervening between 
surges. Functional luteolysis, involving a decline in progesterone 
secretion, usually begins 3 to 6 hours after the initiation of PGF2 OC 
release. Regression of the corpus luteum is usually complete within 
24 to 48 hours in farm animals except in the sow, which has increased 
amounts of PGF2 C* several days before the initiation of functional 
luteolysis (Stabenfeldt and Edqvist, 1984).
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Prostaglandin F2 <* is synthesized in the uterus and released in 
a series of pulses, each lasting about an hour with a frequency of 
about 6 hours (McCracken, 1984). It may pass via general systemic 
circulation to reach the ovary or be transferred from the utero-ovar- 
ian vein to the ovarian artery via local countercurrent type exchange 
(Stabenfeldt and Edqvist, 1984). The local transfer permits only 
small amounts of PGF2 « (=1%) to reach the ovary directly (McCracken, 
1984). A local route has been found in the ewe and cow and appears 
to be general circulation in swine and mares. The general route 
indicates that each uterine horn can influence the life span of the 
corpus luteum on the contralateral ovary (Stabenfeld and Edqvist,
1984).
Chronic inflammatory processes in the mare uterus (often 
resulting in pyometra) often results in destruction of the endometri­
um and loss of ability to synthesize PGF2 <x. Depending upon the 
amount of uterine damage present, luteal function may be prolonged 
for variable periods of time (days to months) or may be extended 
indefinitely in cases of severe obliterative endometritis. Most cows 
and many mares with pyometra have a persistant corpus luteum. The 
condition does not necessarily lead to a poor fertility prognosis in 
the cow (Archbald, 1976), but it does in the mare because tissue 
damage is usually more extensive in the mare compared with the cow. 
The accumulation of fluid in the uterus in the ewe and cow can also 
result from a prolonged luteal phase. In general, in large domestic 
species, abnormalities in estrous cycle lengths are usually related 
to uterine dysfunction (Stabenfeldt and Edqvist, 1984).
Naturally occurring prolongation of luteal activity in the
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nonpregnant mare is one of the most primary causes of infertility.
The cause is a failure to release adequate amounts of PGF2 « at =14 
days post-ovulation. Some release often occurs with dampening
of luteal activity, but not complete luteolysis. Luteal function can 
persist for months with return to cyclic ovarian activity when the
uterus regains the capacity to synthesize and to release PGF2 «. In a
mare with a pyometra, continual luteal activity has been noted for 
over a period of 613 days. The usual treatment for such cases is 
administration of exogenous PGFjix (Stabenfeldt et al., 1980).
Zavy et al. (1978) measured PGF2 « concentrations in uterine 
flushings in cycling mares and demonstrated an abrupt peak on day 14 
of the estrous cycle coinciding with the onset of luteal regression. 
Results showed a 45-fold increase in the amount of PGF2 « in uterine 
flushings from day 4 to day 14 of the estrous cycle. A 3-fold
increase was noted from day 12 to day 14 of the cycle.
Prostaglandin is luteolytic in the mare when administered after 
day 5 of diestrus via either uterine infusion or subcutaneous injec­
tion (Douglas and Ginther, 1972; Noden et al., 1974).
Luteotropic Effects of Prostaglandins
Evidence of the luteotropic role of P G ^  during the early 
development of the bovine corpus luteum was determined by (1) 
injection of P G ^  directly into the corpus luteum at mid-cycle, which 
produced a prolonged increase in peripheral plasma progesterone 
concentrations; (2) P G ^  stimulated progesterone synthesis by luteal 
cells in vitro; (3) PGI2  synthesis by luteal cells was greatest 
during the period of early luteal tissue development (days 5 to 10 of
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the estrous cycle) and reached a low level by day 15 and remained low 
during the remainder of the cycle (Hansel and Convey, 1983).
Hansel and Convey (1983) infused either PGE^ or PGE2  (both bind 
to PGI2  receptors) into either the ipsilateral or contralateral 
uterine horn of unilaterally ovariectomized ewes and concluded both 
compounds had antiluteolytic effects. Both PGE^ and PGE2  have been 
shown to inhibit the luteolytic effects of estradiol. Infusions of 
PGE2  directly into ovaries transplanted to the neck inhibited the 
luteolytic effects of concurrently infused PGF2 « (Henderson et al., 
1977; Hansel and Convey, 1983). Multiple intra-uterine infusions of 
PGE2  also resulted in an increase in peripheral progesterone concen­
trations and a delay of 2 days in the time at which plasma progester­
one declined in the sow although estrous cycle lengths were unaffect­
ed (Schneider et al.,1982; Hansel and Convey, 1983).
Antifertility Effects of Non-steroidal Anti-inflammatory Drugs
Many studies that implicate prostaglandins in reproductive 
processes are based on the determination of a response to the admin­
istration of prostaglandin synthetase inhibitors and the reversal of 
that effect by prostaglandin administration. Prostaglandin synthe­
tase inhibitors prolong gestation, inhibit ovulation, reduce gonado­
tropin releasing hormone release from the hypothalamus and reduce 
pregnancy and live birth rates (Seeley, 1983). Antifertility effects 
have been reported when NSAID are administered to various mammalian 
species (Table 6). Results of these experiments suggest involvement 
of prostaglandins in these reproductive functions.
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Table 6. Antifertility effects of non-steroidal anti-inflammatory 
drugs (NSAID) administered to various female mammalian 
species
Function of 
fertility inhibited NSAID Animal Reference
1 . Ovum transport, 
implantation
IND Rabbit Hodgson, 1976
2. Blastocyst expansion IND Rabbit Hoffman et al., 1978
3. Fetal development IND Rabbit Hoffman, 1978
4. Live birth rate IND Deermice Seeley, 1983
5. Blastocyst hatching MF, PA Mouse Baskar et al., 1981
6. Implantation MF,PA Mouse Biggers et al., 1981
7. Corpus luteum develop IND Cow Hansel & Convey, 1983
8. Pregnancy IND Pig Kraeling et al., 1985
9. Endometrial PG 
synthesis & release
IND,
ASA
Sheep Lacroix & Kann, 1982
10. Luteolysis IND Sheep Lacroix & Kann, 1986
11. Luteolysis FM Pony Berglund & Sharp,1983
IND = Indomethacin 
MF = Meclofenamic acid 
PA = Prostynoic acid 
ASA = Acetylsalicylic acid 
FM = Flunixen meglumine 
PG = Prostaglandin
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EMBRYO PROSTAGLANDIN SYNTHESIS IN FARM ANIMALS
Introduction
The viable conceptus (embryo and extraembryonic membranes) 
exerts a biochemical dialogue with the maternal unit to prolong life 
of the corpus luteum. This dialogue continues the secretion of 
progesterone essential for a uterine histotroph production. Concep­
tus secretory proteins direct the synthesis of major prostaglandins 
that relate to conceptus viability (Thatcher et al., 1989). There 
are publications on the production of prostaglandins by the harvested 
embryo in farm animals (Table 7). No reports are presently available 
in the mare.
Ovine Embryo Prostaglandin Synthesis
Marcus (1981) collected intact embryos from pregnant ewes on
day 12 or day 15 of gestation. Embryos were incubated in 1 ml tissue
culture medium-199 (TCM-199) containing 10% fetal calf serum and 
14C-arachidonic acid for 3 to 10 hours in a shaking water bath at 
37°C. The medium was analyzed by thin layer chromatography. Day 12 
embryos synthesized approximately equal quantities of PGE2 , P G ^  and 
PGF2 OC, with PGI2  being the principle product. It was concluded that 
maternal recognition of pregnancy in the ewe occurs at least by day 
12 post-coitus and involves synthesis of PGI2  and PGE2 .
Hyland et al. (1982) collected intact embryos from pregnant
ewes on days 13, 14 and 15 of gestation. Embryos were homogenized in
ice-cold saline or were incubated in Dulbecco's phosphate-buffered 
saline with 10% normal sheep serum in Dubnoff shaking incubators at
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Table 7. Summary of farm animal embryo prostaglandin (PG) 
synthesis
PG Major
Reference Animal Day assayed for PG
Marcus et al. 
(1981)
Ewe 12
15
E« »I9 > E9
E2’I2’F2
p g i9,e „
PGlJ
Hyland et al. Ewe 13,14,15 PGF9a
(1982)
z
Lacroix & Kahn Ewe 14 E9» ^ 2 PGF„a
(1982) 23 E2’F2 pg e2
Lewis & Waterman Sow 16 E2,E2 PGE„
(1983a)
z
Shemesh et al. 
(1979)
Cow 13,15,16 E2,P2 PGF2a
Lewis et al. 
(1982)
Cow 16,19 e2,f2 PGF2a
Lewis & Waterman Cow 19 E2 ’ E2 PGF„a
(1983b)
z z z
Lewis (1984) Cow 19 E2,F2 PGF2a
Hwang et al. 
(1988)
Cow > 12 
13
E2 *F9 » 9^
E2,F2, ly
PGE„*
p g e;,f2
> 15 E2,F2 ,lj pgi2
Only PGE2 was detected
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37°C for 0.5, 4.5 or 8.5 hours. Strips of endometrium were also 
cultured and prostaglandin E£ and PGF2 <x synthesis was determined by 
RIA. Prostaglandin F2 <x release rates were consistently higher than 
those of PGE2  at all incubation stages. Prostaglandin E and PGF2 <x 
output by embryos on a weight basis was up to 200 and 1000 times 
higher than that from cultured endometrium, respectively. Prosta­
glandin release declined as the incubation proceeded.
Hyland et al. (1982) stated (1) that the production of higher 
amounts of PGF than PGE by embryos at a time when luteal maintenance 
was crucial to pregnancy is difficult to rationalize though similar 
findings have been recorded; (2) if PGE2  is a potential anti-luteo- 
lysin as suggested in the ewe, its production by embryos may be
accompanied by a non-specific increase in PGF secretion; (3) if so,
PGE2  could perhaps counteract the luteolytic effects of PGF2 <x at this 
time.
Lacroix and Kann (1982) incubated ovine day 14 and day 23
intact embryos for 2 hours at 25°C in 1 ml of incubation medium
(Krebs-HEPES) under an atmosphere of 95% 5% CO2  bubbling in the
incubation medium. Prostaglandin F2 OC and E 2  synthesis was deter­
mined by RIA. Day 14 embryos produced a high prostaglandin 
concentration of PGF2 0 1  and PGE2 , with PGF2 <x being much greater than 
PGE2 * Day 23 embryos produced much lower concentrations of prosta­
glandins with PGE2  being dominant.
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Porcine Embryo Prostaglandin Synthesis
Lewis and Waterman (1983a) recovered day 16 blastocysts from 
pregnant gilts and incubated them in a petri dish containing 15 ml 
minimum essential medium (MEM) incorporated with radiolabeled 
arachidonic acid. Incubates were placed into a culture chamber on a 
rocking platform for 24 hours at 37°C in an atmosphere of 50% Nj:45% 
02^5% C02* Aliquots of medium were transferred to storage vials and 
the tissue was homogenized. Prostaglandin synthesis was determined 
by high performance liquid chromatography (HPLC). Prostaglandin E2  
was the predominant arachidonic acid product. Blastocysts metabo­
lized 79.8 ± 1.8% of the arachidonic acid added to the MEM. Of the 
arachidonic acid that was not metabolized by blastocysts during the 
24 hour incubation period, 80.2 ± 2.5% was found in the blastocyst 
homogenates.
Bovine Embryo Prostaglandin Synthesis
Shemesh et al. (1979) collected bovine blastocysts on days 13, 
15 and 16 post-mating. Blastocysts from each superovulated cow were 
placed (1) in 1 ml uterine flushing medium (O.lM-sodium phosphate 
buffer with 0.1% glucose and bovine serum albumin, 5 mg/ml) and 
stored at -20°C or (2) in 1 ml TCM-199 supplemented with 5% fetal 
calf serum and incubated in an incubator at 37°C and continuously 
flushed with 95% air and 5% saturated with water. Prostaglandin
F and PGE were determined by RIA. There was a steady rise in PGF and 
PGE concentrations with increase of embryo age. The prostaglandin 
concentrations of cultured blastocysts were 4 to 17 times greater 
than those of uncultured blastocysts. At all 3 gestation ages, PGF
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concentration was considerably greater than that of PGE.
Lewis et al. (1982) recovered bovine blastocysts on days 16 and 
19 post-mating. Blastocysts were placed in 15 ml MEM and incubated 
in a culture chamber on a rocking platform for 24 hours at 37°C in an 
atmosphere of 50% ^ :45% COj. Culture medium was assayed for
blastocyst prostaglandin synthesis by RIA. Results concurred with 
those of Shemesh et al. (1979) in that blastocyst production of PGF2 « 
and PGE2  increased with day of pregnancy and the quantity of PGF2 « 
was much greater than PGE2 *
Lewis and Waterman (1983b) recovered day 19 bovine blastocysts 
and incubated them in 15 ml MEM containing arachidonic acid for 24 
hours at 37°C in an atmosphere of 50% ^ ^ 5 %  02^5% C02* Metabolism 
of arachidonic acid was determined by HPLC. Results show a 3-fold 
increase in PGF2 « synthesis as compared with PGE2 . Lewis (1984) 
repeated this procedure except blastocysts were incubated in 10 ml 
MEM and prostaglandins was quantified via RIA. Again there was 
approximately a 3-fold increase in PGF2 <x synthesis as compared with 
PGE2.
Thatcher et al. (1984) reported that day 16 bovine conceptuses 
produced approximately 4 times the amount of PGF2 a as compared with 
PGE2 . This concurs with other studies indicating bovine conceptuses 
produce PGF2 0 1  and PGE2  and that production increased with day of 
pregnancy. It was proposed that these prostaglandins may be sequest­
ered and compartmentalized within the uterine lumen.
Hwang et al. (1988) determined the profile of arachidonic acid
metabolites synthesized by bovine embryos recovered on days 6 through
3
17. Embryos were incubated in MEM with H-arachidonic acid for 15
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hours at 37°C in a humidified atmosphere of 5% CO2  in air. To
evaluate the time course of prostaglandin synthesis, day 15 embryos
were incubated for 24 hours in 5 ml MEM, but without arachidonic
acid. An aliquot of medium was taken at 0, 2, 4, 6, 8, 12, 15 and 24
hours and assayed for PGE2  and 6-keto-PGF^a (metabolite of PG^) by
RIA. Formation of PGE2  and PGI2  increased linearly during the 24
hour incubation. Analysis of embryo samples incubated with 
3
H-arachidonic acid was determined by HPLC. Embryos collected on 
days 6 through 10 metabolized arachidonic acid primarily to PGEg.
Day 13 embryos metabolized arachidonic about equally to PGE2  and 
PGF2 «. The appearance of PGF2 <x peaks in other embryo samples 
occurred between days 12 and 15. The enhanced ability of embryos to 
synthesize PGF2 « tended to coincide with rapid development of 
trophoblastic tissue surrounding the embryonic disc. Embryos 
harvested after day 15 metabolized arachidonic acid to PGI2  in 
addition to PGE2  and PGF2 «. Results indicate there are distinct 
transitional changes in arachidonic acid metabolism during early 
stages of development by bovine embryos.
A summary of embryo prostaglandin synthesis studies in ewes, 
gilts and cows is presented in Table 7. Embryos ranging in age from 
day 6 to day 23 of gestation were incubated in these studies. 
Incubation medium was TCM-199, Dulbecco's phosphate-buffered saline 
or MEM and incubation times ranged from 2 to 24 hours. Prostaglan­
din synthesis was determined via RIA, thin layer chromatography or 
HPLC. All embryos were incubated intact, except Hyland et al. (1982) 
who homogenized one group of embryos. In most studies, research­
ers also homogenized and cultured endometrial tissue to compare
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prostaglandin synthesis. Endometrial prostaglandin synthesis was 
negligible as compared with that of similar stage embryos.
These findings suggest that endometrial cells harvested with 
the embryos did not affect prostaglandin concentrations. Hwang et 
al. (1988) was the only researcher to report washing embryos before 
incubation. Only Marcus et al. (1981) and Hwang et al. (1988) also 
assayed for P G ^  synthesis. There was no absolute pattern of prosta­
glandin synthesis for various ages of embryos across the species. 
Embryo prostaglandin synthesis appeared to have transitional changes. 
The dominant prostaglandin changed as the embryos progressed through 
the early stages of development.
MARE ESTROUS CYCLE
Introduction
The reproductive cycle of the mare and its related phenomena 
are unique. Because the mare is susceptible to environmental 
changes, many so called "normals" that are reported for the mare may 
actually fluctuate month by month. Such variations deem it necesary 
to consider every mare as an individual (Belling, 1983).
Breeding Season
Most mares are seasonally polyestrous. Summer is the physio­
logical breeding season when the mare has normal-length cycles, 
follicular development with ovulations and full uterine growth. 
Approximately 85 to 95% of all mares exhibit estrus and ovulate 
regularly in the summer (Ginther, 1979a; Neely, 1983a).
Most mares become anestrus during the cold season because 
decreased daylight (photoperiod) decreases ovarian activity due to 
the melatonin effect (Ginther, 1979a). High levels of melatonin 
secreted by the pineal gland are promoted by darkness and decrease 
gonadal activity. Only 15 to 25% of all mares are in estrus and 
ovulate during the months of December, January and February (Ginther, 
1979a).
Spring is a transitional period when there is a slow increasing 
ovarian response to increasing day length. Mares are emerging from 
winter anestrus. Follicles may or may not ovulate and cycles are 
often irregular. Uterine epithelium changes from a thin lining of 
simple cuboidal epithelial cells to a thicker lining due to an 
increase in height, diameter and number of cells (Ginther, 1979a;
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Neely, 1983a; Banks, 1986).
In the Fall there is a slow decrease in ovarian activity due to 
decreasing day length (Ginther, 1979a). Cycles become irregular, 
ovarian activity usually terminates in October or November and 
uterine epithelium regresses and becomes thin again due to a decrease 
in height, diameter and number of cells (Ginther, 1979a; Banks,
1986).
Some mares cycle all year long, especially those living closer 
to the equator. A more pronounced period of anestrus is exhibited in 
mares living at higher latitudes (Ginther, 1979a).
Estrous Cycle
An estrous cycle is defined as the time between the first day 
of estrus of one cycle and the beginning of estrus of the subsequent 
cycle whether or not accompanied by ovulation (Ginther, 1979a). The 
average estrous cycle is 21 days with the normal range reported as 18 
to 24 days (Day, 1940). Ranges in estrous cycle have been reported 
from 12 to approximately 40 days (Belling, 1983).
Estrus is defined as the period when the mare accepts teasing 
and mounting by the stallion and is normally associated with 
follicular development and ovulation (Ginther, 1979a; Neely,1983a). 
The normal range is 4 to 8 days with ranges from 1 to 40 days 
reported. The average length of estrus is 5 days (Belling, 1983).
Diestrus is defined as the time between 2 estrous periods when 
the mare will not accept teasing and mounting by the stallion. It is 
highly variable due to the life-span of the mare corpus luteum 
(Ginther, 1979a). The normal range for diestrus is 11 to 17 days
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with a range of 2 to 59 days reported (Belling, 1983).
The normal mare estrous cycle is diagramed in Figure 7.
Relative endocrine and PGF2 <* levels are represented in Figure 8.
Ovulation
Ovulation may occur on any day of the cycle, any time of day, 
may be single or multiple and may vary within a mare from cycle to 
cycle. Mares may ovulate throughout the year. Ovulation normally 
occurs 1 to 2 days prior to the end of estrus; however, it may occur
on the first or last day of estrus, or the first or second day after
the end of estrus (post-estrous ovulation). Ovulation may occur 
during diestrus in about 5% of cycles without signs of estrus. Most 
mares ovulate during the night or early morning. Multiple ovulations 
occur about 20% of the time, may be from the same or both ovaries and 
may be simultaneous or at intervals (Belling, 1983; Neely, 1983a).
Ovulation occurs only at the ovulation fossa. The ensuing 
corpus luteum has approximately a 12 day lifetime, with abrupt 
termination after an increase in PGF2 OC from the uterus (Ginther, 
1979a; Neely, 1983a).
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ENDOMETRIAL BIOPSY IN THE MARE
Induced Luteolysis in the Mare
Arthur (1970, 1975) and Neely et al. (1975, 1979) reported 
intrauterine saline infusion in the early diestrous cyclic mare 
shortened the interestrous interval by inducing premature luteolysis. 
Plasma progesterone levels decrease within 1 day after infusion and 
declined to < 1 ng/ml within 4 days. Then, mares returned to estrus.
Arthur (1975) infused mares in prolonged diestrus that showed ovula­
tory estrus within 3 to 9 days. In these experiments, infusion 
during estrus or late diestrus had no significant effect. It was
postulated that the luteolytic effect of early diestrus intrauterine
saline was induced by a premature release of uterine PGF2 OC.
Hurtgen (1975) reported that uterine and/or cervical manipula­
tions caused alterations of the estrous cycle. Several experiments 
were conducted to evaluate these observations in cycling mares. 
Hurtgen (1975), Hurtgen and Whitmore (1978) and Hurtgen and Ganjam 
(1979) tested the effect of specific procedures versus day of estrous 
cycle it was performed. He grouped estrous cycles as follows (1) 
control cycles included no cervical or uterine manipulations; (2) 
cycles included endometrial biopsy and uterine culture (passing a 
cotton swab through the cervix and rolling it against uterine endome­
trium) on day 4 post-ovulation; (3) cycles included biopsy and cul­
ture on the first and third days after ovulation; (4) cycles included 
manual dialation of the cervix with the gloved index finger 4 days 
after ovulation. Serum progesterone concentrations were measured by 
RIA in all experiments.
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In summary, in the first group endometrial biopsy and culture 4 
days after estrus resulted in early regression of the corpus luteum 
that was evidenced by a sharp decline in serum progesterone concen­
tration and a significantly shortened interestrous interval. Estrous 
cycle length was decreased although the duration of the subsequent 
estrus was increased. The second and third groups also demonstrated 
sufficient stimulus to shorten diestrus and lengthen estrus, though 
the effect was less stimulating than endometrial biopsy when compar­
ing experimental parameters. Double ovulation that required 2 cor­
pora lutea to regress responded in the same manner. Uterine culture 
on day 4 post-ovulation did not significantly alter estrous cycles. 
Hurtgen and Whitmore (1979) did induce estrus and ovulation by 
endometrial biopsy in mares with prolonged diestrus suggesting that 
regression of persistant luteal tissue was caused by stimulating the 
release of endogenous PGF2 <x.
Baker (1981) verified earlier results and also determined that 
endometrial biopsy (1) during estrus had no effect on the cycle; (2) 
on day 4 post-ovulation induced premature luteolysis; (3) signifi­
cantly reduced length of diestrus. Baker (1981) questioned whether 
luteolysis was induced by the biopsy procedure or by an induced 
uterine infection because premature luteolysis had been previously 
induced by bacterial infections (Hughes, 1969), saline infusions 
(Arthur, 1975; Neely, 1975), cervical manipulation (Hurtgen, 1979a) 
and exogenous PGF2 « (Noden, 1974). Therefore, Baker (1981) cultured 
endometrial swabs taken before and after the biopsy procedure. No 
bacterial contamination was apparent or detected by culturing the 
uterine swabs. These results suggested luteolysis was induced by the
biopsy procedure and was not due to uterine infection.
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Luteolysis in Mares Induced by Endometrial Biopsy
Hurtgen (1975), Hurtgen and Whitmore (1978), Hurtgen and Ganjam 
(1979), Hurtgen and Whitmore (1979) and Baker et al. (1981) postulat­
ed that endometrial biopsy could potentiate an acute inflammatory 
response caused by the biopsy and, thus, increase endogenous release 
of uterine luteolysin PGF2 « and cause subsequent premature luteal 
regression. The equine corpus luteum was shown not to be sufficient­
ly mature to respond to the luteolysin until day 4 post-ovulation.
Technique for Performing Endometrial Biopsy in the Mare
The mare is restrained in an equine stock as for rectal examina­
tion. The gauze-wrapped tail is tied aside and feces are removed 
manually from the rectum. The perineum and vulvar lips are thorough­
ly washed 3 times with Betadine surgical scrub, each wash being 
followed by a thorough rinse with clean, warm water, taking care to 
wash and rinse the vulvar orifice (Ricketts, 1975; Kenney, 1978).
The tissue specimen is taken with a biopsy punch having alliga­
tor-type jaws with a basket 20 x 4 x 3 mm and an overall length of 70
2
cm (Kenney, 1978). This instrument provides a specimen 2 cm , which
2
is on average 0.2% of the entire (850 to 1350 cm ) endometrium 
(Kenney, 1975). A hand is covered first with a plastic sleeve and 
covered with a sterile disposible glove lubricated with a sterile, 
surgical jelly (Kenney, 1978). The tip of the sterile biopsy instru­
ment is placed in the palm of the gloved hand.
The vulva lips are spread and the gloved hand cupping the biopsy
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punch (jaws closed) is passed through the vagina. The index finger 
is inserted through the cervix and the instrument passed along the 
index finger into the uterus. While maintaining the forceps in 
position, the gloved arm is then withdrawn from the vagina and passed 
into the rectum where the instrument is palpated and positioned to 
the desired sites (Ricketts, 1975).
To avoid penetrating the entire uterine wall if a straight bite 
is taken, the biopsy punch is laid on its side, and the endometrium 
is pushed into the side of the open jaws and pinched off by closing 
the jaws. There is usually hemorrhage (1 to 2 ml) at the biopsy site 
(Kenney, 1978). Endometrial biopsy may be performed any time of the 
year (Shideler, 1982) and at any stage of the estrous cycle (Kenney, 
1978).
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HIGH PERFORMANCE LIQUID CHROMATOGRAPHY 
AS A METHOD TO ASSAY PHENYLBUTAZONE IN BODY FLUIDS
Introduction
Phenylbutazone was first synthesized in 1946 by H. Stengyl in 
Switzerland and was later marketed by J. R. Geigy, A.G. (Jeffcott and 
Coles 1977). This compound was not detected in biological material 
until 1953 (Burns, 1953). Indiscriminate use of phenylbutazone at 
race tracks and high performance equestrian events has stimulated 
interest in devloping a fast, reliable, specific method for phenylbu­
tazone detection in various equine biological materials such as 
plasma, urine and sweat. Since phenylbutazone is almost completely 
metabolized in the horse, recovery rates are low (Maylin, 1977) and 
detection can be difficult, inaccurate or even missed. In separate 
studies, only 3.7£ of a 2 g/450 kg intravenous dose was recovered in 
the first 24 hours (Piperno, 1968).
In another study, only 1 to 2% of the parent drug was recovered 
in the urine of the horse when dosing 2 g/450 kg intravenously at 
consecutive 24-hour intervals (Maylin, 1974). The principle 
metabolites in the horse, oxyphenbutazone and y-hydroxyphenylbuta- 
zone, together accounted for only about 25% of the phenylbutazone 
administered. The remaining 75% of the parent drug was undetected by 
gas liquid chromatography (Maylin 1974; Maylin, 1977).
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Chromatography History
Burns et al. (1953) pioneered the method for estimating the 
concentration of phenylbutazone in body fluids. They isolated 
phenylbutazone from acidified human plasma and urine by extraction 
into heptane. The drug was then extracted from the heptane solution 
with aqueous alkali and the phenylbutazone concentration was measured 
at 265 nm in an ultraviolet spectrophotometer.
Burns et al. (1953) also designed a tissue procedure by 
homogenizing up to 2 g of tissue in 10 ml of 1^0 that followed the 
same method used for plasma and urine except that it used heptane 
containing 3% isoamyl alcohol. This is the technique that many 
equine phenylbutazone researchers have used primarily for 2 to 3 
decades (Gabriel, 1962; Piperno, 1968; Gandal, 1969; Finocchio, 1970; 
Quijano, 1979).
Stevens (1970) developed a faster extraction of phenylbutazone 
from blood, plasma and liver. He used formic acid to deproteinize 
the material, hexane instead of heptane for extraction and 263 nm 
instead of 265 nm to perform the spectrophotometric assay. A 95% 
recovery yield was reported from plasma and =45% from whole blood or 
liver. This new method extracted phenylbutazone from water with a 
99% yield. It was concluded that the poorer recoveries from biologi­
cal fluids resulted from plasma protein binding.
Stevens (1970) also collected a blood sample from a human 
receiving phenylbutazone treatment and divided it into 2 equal 
portions and estimated the phenylbutazone concentration by both the 
Burns et al. (1953) method and his own. The same result was obtained 
by each method, but the Burns et al. (1953) procedure lasted 45 to 50
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minutes and the Stevens method could be completed in only 10 to 15 
minutes. Equine researchers then started using the Stevens method to 
estimate phenylbutazone concentration in biological tissues and 
fluids (Sullivan and Snow, 1982; Rose et al., 1982).
Gas Liquid Chromatography Analysis of Phenylbutazone
Modern advances in chromatography broadened the field to 
include detection of therapeutic and doping agents. Gas liquid 
chromatography and high performance liquid chromatography (HPLC) have 
become popular with equine researchers for phenylbutazone analysis as 
easier and more specific methods than ultraviolet spectrophotometry.
Bruce et al. (1974) used gas liquid chromatography to measure 
phenylbutazone concentration in plasma and urine after giving a 
single, oral dose (8.9 mg/kg) of phenylbutazone to horses either as 
tablets or granules. Samples were obtained at 0.5 to 72 hours post­
administration. The plasma half-life was =4 hours. Measurable 
concentrations of phenylbutazone were present in some horses for 48 
hours in plasma and urine. They concluded that gas liquid chromato­
graphy analysis of blood and urine for phenylbutazone and oxyphenbu- 
tazone is simple, specific and adaptable to analysis of race horses 
suspected of doping.
Maylin (1974) also used gas liquid chromatography to study the 
metabolism and pharmacokinetics of phenylbutazone in the horse.
Horses were given 4.4 mg/kg phenylbutazone intravenously daily for 4 
days. It was reported that (1) phenylbutazone and its metabolites 
are chemically unstable and decompose readily; (2) urine and blood 
samples improperly refrigerated or analyzed usually contain several
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impurities or decomposition products that must be distinguished from 
phenylbutazone and metabolites; (3) plasma metabolites could not be 
assayed accurately at all intervals although they could be detected 
in most samples; (4) total percent recovery of phenylbutazone in 
urine for 24 hours post-administration was 0.9%, 1.1% 2.1% and 1.6% 
of the first, second, third and fourth doses, respectively; (5) 
plasma concentrations increased from 18.2 ug/ml 1 hour after the 
first dose to 31.1 Ug/ml 1 hour after the fourth dose and increased 
from 0.8 to 2.4 ug/ml 24 hours after the first and fourth doses, 
respectively.
High Performance Liquid Chromatography Analysis of Phenylbutazone 
Pound et al. (1974) pioneered the analysis of phenylbutazone 
and its major metabolites in plasma by HPLC. Results of his study 
demonstrated that HPLC is a sensitive procedure for determination of 
phenylbutazone concentration in plasma that also offers high speci­
ficity, since it differentiates the parent drug from oxyphenbutazone 
and y-hydroxyphenylbutazone. Analysis time was less than 7 minutes. 
No extraneous interfering compounds were extracted from plasma by 
using n-hexane. Neither of the 2 known metabolites, oxyphenbutazone 
and y-hydroxyphenylbutazone, were detected. The output of the ultra­
violet detector was linear thus allowing quantitation of phenylbuta­
zone by electronic integration and peak-height measurements. The 
limit of detection was approximately 0.2 ug/ml of phenylbutazone.
Data determined by integration and peak-height measurements showed 
straight lines over the concentration range of 1.8 to 41.7 ug/ml.
Mean recovery values of 99.9 + 1.1% and 99.3 ± 3.1% were obtained by
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integration and peak-height measurement, respectively. It was noted 
that refrigerated plasma samples containing phenylbutazone were 
stable for several weeks.
Pound et al. (1974) tested their procedure by doing a compara­
tive analysis of phenylbutazone in plasma using 3 established methods 
(1) ultraviolet spectrophotometry; (2) gas liquid chromatography; (3) 
their own HPLC procedure. The overall difference between HPLC and 
ultraviolet methods was 8.2X and that between gas liquid chromatogra­
phy and HPLC 8.9%. The ultraviolet method would not distinguish 
between any side-chain hydroxy- metabolite present and the parent 
drug. They concluded that their HPLC procedure was a more specific 
and sensitive method for measurement of phenylbutazone and its major 
metabolites than classical methods and could form the basis for a 
method for metabolic studies.
Alvienerie (1980) developed a specific and precise reversed- 
phase HPLC assay that detected minute quantities of phenylbutazone in 
horse plasma, urine, saliva and sweat. Recovery from the extraction 
procedure for both plasma and sweat was 65 ± 2% with a concentration 
of 100 ng to 10 yg. Concentrations as low as 50 to 100 ng/ml of 
phenylbutazone in 0.5 to 1.0 ml of body fluids were determined. This 
reverse-phase HPLC method detected the lowest concentrations of 
phenylbutazone in horses to date.
Although Pound et al. (1974) did not report detecting oxyphen­
butazone or y-hydroxyphenylbutazone, they developed the method that 
was the basis for analysis of phenylbutazone and its metabolites 
utilizing HPLC. Taylor et al. (1981) made modifications and improve­
ments on the Pound method. Their limits of detection were 0.01, 0.05
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and 0.10 yg/ml and mean recovery rates in spiked equine plasma were 
100.08 + 1.4%, 90.4 ± 0.9% and 59.74 + 1.4% for phenylbutazone, 
oxyphenbutazone and y-hydroxyphenylbutazone, respectively. Taylor et 
al. (1981) also reported that phenylbutazone is relatively stable in 
frozen plasma and urine, but less stable (plasma) and very unstable 
(urine) when stored at 4°C.
Gerring et al. (1981) tested the Taylor method to determine 
levels of phenylbutazone and its metabolites in plasma and urine with 
regard to time and clinical doses administered orally to horses. 
Gerring et al. (1981) concluded that HPLC is a simple and sensitive 
method and achieved good recoveries for phenylbutazone and oxyphenbu­
tazone.
During the 1980's, HPLC methods were developed proving to be 
superior to previously reported methods. Phenylbutazone is quantita­
ted for forensic purposes by HPLC. The variability of this method 
within a laboratory is reported to be < 5%, however, between differ­
ent laboratories it is + 25% (Tobin et al., 1986).
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PREVIOUS EXPERIMENTS LEADING TO FIRST HYPOTHESIS
The basic hypothesis and experiments for studying the effects 
of chronic administration of phenylbutazone on reproduction in the 
mare were proposed and undertaken by Dr. Louis F. Archbald and his 
graduate student Lawrence M. Olsen, Department of Veterinary Clinical 
Sciences, School of Veterinary Medicine, Louisiana State University, 
Baton Rouge, Louisiana. They conducted 2 preliminary experiments 
during the 1979 and 1980 breeding seasons.
Prostaglandins, specifically PGF2 «, have been shown to be 
luteolytic in the mare. It has been suggested that the synthesis and 
release of PGF2 0 1  from the uterus is the primary cause of cyclic 
luteolysis and consequently controls the estrous cycle of the mare 
(Stabenfeldt et al., 1980). Archbald (1980) postulated that since 
phenylbutazone inhibits the cellular synthesis of PGF2 O1, it could 
prolong the life span of the corpus luteum and subsequent length of 
the estrous cycle. Furthermore, it was proposed that prolonged 
luteal function might alter the uterine environment due to an 
extended production and circulation of progesterone.
The immunologic competence of the mammalian uterus appears to 
be steroid hormone-dependent. The progesterone-dominated bovine 
uterus is more susceptible to bacterial infections than the estrogen- 
dominated uterus (Black et al,1953; Rowson et al., 1953). It may be 
assumed that prolonged luteal function would cause the uterus to be 
more susceptible to infections. Clinical records indicate that 
following retirement from the racetrack many mares experience varying 
degrees of infertility. The possibility exists that previous phenyl­
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butazone medication may have been involved in luteal tissue dysfunc­
tion, resulting in increased susceptibility of the uterus to infec­
tious organisms. The primary objectives of the first 2 experiments 
at this station were to evaluate expression of estrual behavior, 
peripheral plasma progesterone concentration and uterine luminal 
PGF2 « concentrations in mares parenterally treated with phenylbuta­
zone (Archbald, 1980).
Tobin (1979a) reported that in average horses (500 kg body 
weight) an intravenous dose of 2 to 3 g phenylbutazone daily produces 
an optimal anti-inflammatory effect. Therefore, in both preliminary 
experiments and all subsequent experiments, each mare was given 
intravenously 2 g phenylbutazone which was proposed to be sufficient 
phenylbutazone to inhibit prostaglandin synthesis (Archbald, 1983).
In the first experiment, 5 mares of mixed breeding between 3 
and 4 years of age and 450 to 500 kg body weight were maintained as 
an experimental group. All mares were teased daily with a stallion 
to determine onset of estrus (day 0) and rectally palpated daily 
during estrus to evaluate ovarian follicle development and day of 
ovulation. Hares were monitored for 2 untreated estrous cycles.
Then, each mare served as treatment and control using a switchback 
experimental design. Between days 13 to 14 of the third estrous 
cycle each mare was given a daily intravenous dose of either 2 g 
phenylbutazone as treatment or 10 ml of physiological saline as 
control until estrus. Blood samples were obtained daily via jugular 
venipuncture from each mare prior to the daily injection of phenylbu­
tazone or physiological saline. Progesterone concentrations were 
determined by RIA.
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In the second experiment, 8 mares averaging 3 to 4 years-of-age 
and 450 kg body weight were maintained as an experimental group. All 
procedures were the same as the first experiment except that treat­
ment began on the first day of estrus and was continued daily until 
mares exhibited estrus. Also, uterine secretions were collected via 
cervical approach from each mare on days 0, 4, 8, 12, 14, 16, 18 and 
20 of the treatment estrous cycles. Samples were stored at -19°C 
until assayed for PGF2 <x concentration by RIA.
Results of the first experiment determined that there was no 
significant difference in estrous cycle lengths within individual 
mares or across all cycles of all physiological saline-treated mares. 
Saline-treated estrous cycles were similar in length to pretreatment 
cycles of each mare. When mean estrous cycle lengths of saline- 
treated mares were compared with mean estrous cycle lengths of phen­
ylbutazone-treated mares having normal length cycles, no significant 
differences were noted between the mean cycle lengths of each treat­
ment group. However, signs of estrus were not observed in 2 mares 
for 34 days during phenylbutazone treatment. Treatment with 5 mg 
PGF2 OC induced overt estrus in these 2 mares on days 2 and 4 post­
injection. Estrous cycle lengths of these same 2 mares while being 
first treated with physiological saline on the switchback design were 
24 and 22 days (Archbald, 1980).
Results of the second experiment showed no significant differ­
ences in estrous cycle lengths in 15% of the mares treated with 
physiological saline. The estrous cycle lengths were shorter (cycle 
was 14 days for each mare) in the 2 remaining mares while treated 
with physiological saline. However, estrous cycle lengths of normal
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duration (cycle was 20 days for each mare) were noted when these 2 
mares were treated daily with phenylbutazone in their subsequent 
cycles (Archbald, 1980).
Prolongation of estrous cycle lengths was recorded for 3 mares 
following phenylbutazone treatment. However, signs of estrous 
behavior were observed at the end of the extended cycles in these 
mares unlike the pattern observed in the 2 mares in the first 
experiment where estrus was induced with PGF2 « following phenylbu­
tazone treatment.
Plasma progesterone profiles determined that 37.5% of the 
phenylbutazone-treated mares failed to exhibit overt estrus at their 
predicted time, although progesterone levels had decreased to < 1 
ng/ml. The expected time of estrus was based on previous estrous 
cycle lengths during physiological saline treatment.
In both treatment groups, mean (± SEM) PGF2 <x concentrations of 
uterine flushings were between 3.10 + 0.33 and 3.34 + 0.40 ng/ml on 
the first day of estrus, decreased on day 4 and then increased to 
between 2.71 + 0.33 and 3.49 ± 0.55 ng/ml on day 14. Values for 
mares treated with saline then increased on days 16 (3.27 ± 0.22 
ng/ml) and 18 (3.47 ± 0.19 ng/ml). These mares exhibited estrus on 
days 20 to 22 of the saline-treated cycle. In phenylbutazone-treated 
mares, PGF2 «x concentrations were significantly lower on days 16 and 
18 (< 1 ng/ml) when compared with corresponding days of saline-treat­
ed mares. The phenylbutazone-treated cycles from these same 3 mares 
were 5, 6, and 8 days longer than expected, respectively. Progester­
one values of these mares decreased on days 16 and 18 of phenylbuta­
zone-treated cycles, but then increased again before the decline
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preceding overt estrus (Archbald, 1980)
Results of the second experiment indicated that there were no 
significant differences in interestrous intervals between (1) 
control mares; (2) treatment versus pretreatment cycles of control 
mares; (3) mares treated with phenylbutazone (mean = 23.1 ± 0.24 
days) versus those given saline (20.7 ± 0.28 days). Plasma proges­
terone profiles of treated mares showed no significant difference 
compared with controls. Results suggest there was no effect on 
ovarian cyclicity and plasma progesterone concentration in mares 
treated with 2 g phenylbutazone intravenously for 21 days. There was 
no apparent carryover effect of phenylbutazone on subsequent estrous 
cycle lengths when mares were totally removed from treatment 
(Archbald, 1983).
Results of these earlier experiments suggested validity in 
pursuing the effects of parenteral phenylbutazone treatment in mares 
because some phenylbutazone-treated mares (1) exhibited prolonged 
cycles; (2) exhibited shortened cycles; (3) did not express estrual 
behavior even though progesterone concentration was < 1 ng/ml.
Because phenylbutazone treatment did significantly decrease uterine 
PGF2 OC concentrations on days 16 and 18 of the estrous cycle, it was 
presumed that phenylbutazone may be able to concentrate in the uterus 
and alter the estrous cycle of the mare.
Perhaps the phenylbutazone (1) was not potent enough to cause 
significant luteal tissue dysfunction; (2) did not accumulate in the 
ovaries or uterus; (3) caused incomplete luteolysis with subsequent 
recovery of the corpus luteum; (4) did not effectively cause luteal 
dysfunction when administered for 8 to 21 days.
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Therefore, because results of phenylbutazone-treated mares were 
varied and questions were not answered regarding why the phenylbuta­
zone may not have acted according to the hypothesis, 5 additional 
experiments were conducted by this research station.
EXPERIMENT I
Estrual Behavior, Ovulation and Fertility of Mares 
After Chronic Administration of Phenylbutazone
INTRODUCTION
Results of previous experiments conducted in this laboratory 
suggested that some of the mares receiving short-term phenylbutazone 
treatment apparently responded to the treatment by exhibiting pro­
longed cycles and/or failed to exhibit overt estrus. However, other 
mares receiving the same treatment did not appear to be affected by 
the treatment because they exhibited normal cycles and estrual 
behavior (Archbald, 1980; Archbald, 1983). It was then proposed that 
possibly long-term phenylbutazone treatment may alter the mare 
estrous cycle.
OBJECTIVES
The objectives were (1) to test the hypothesis that chronic 
use of phenylbutazone can cause infertility in mares by inhibiting 
prostaglandin synthesis; (2) to substantiate previous data collected 
by this laboratory suggesting that short-term (8 to 21 days) phenyl­
butazone treatment affected mare fertility; (3) to determine the 
effects of chronic (182 days) administration of phenylbutazone on 
estrual behavior, ovulation, luteal function and fertilization in 
mares; (4) to confirm cyclicity in the mares by using results of 
progesterone assays used to validate a new commercial, solid-phase,
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no-extraction I progesterone radioimmunoassay kit (Appendix III).
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MATERIALS AND METHODS
Nine mares of mixed breeding, ranging from 3 to 4 years of age 
and weighing 450 to 500 kg were purchased and maintained under exper­
imental conditions at the Louisiana State University School of Veter­
inary Medicine. Each mare was given a thorough physical examination 
before purchasing. Complete reproductive histories of these mares 
were unknown. All mares tested negative for equine infectious anemi- 
a. They were fed 8 liters of mixed grain concentrate/mare/day and 
free-choice hay and water from December 1, 1980 until August 15,
1981.
On December 1, 1980, each mare was given intravenously 2 g 
phenylbutazone (Butazolidin , D-M Pharmaceuticals, Inc., Rockville, 
MD). This treatment was continued daily until May 31, 1981.
Beginning on February 12, 1981, all mares were teased daily by an 
androgenized gelding, estrous mares were palpated per rectum to 
evaluate ovarian activity and a heparinized blood sample was collect­
ed daily via jugular venipuncture to be used for determination of 
progesterone concentration via RIA (Appendix III).
Cyclicity (estrus versus diestrus) was confirmed by the 
progesterone assays outlined in Appendix III. Estrus as detected by 
teasing was confirmed by correlation with progesterone concentrations 
< 1 ng/ml.
By June 1, 1981, 8 mares had exhibited at least 2 estrous 
cycles of normal duration (18 to 24 days). Mares were assigned to 
one of 2 groups as follows. The first mare to display estrus was a 
phenylbutazone treatment and the second mare physiological saline.
The experimental design for Experiment I is presented in Figure 9.
Mares were alternated via this pattern of grouping until all 9 mares 
were placed into either the treatment or the control group. The 
treated group continued to receive 2 g of phenylbutazone daily until 
the day of embryo collection. The control group received 
physiological saline treatment.
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Phenylbutazone-Treated 
(n = 5)
109 days73 days
PS controls
a December 1, 1980, to February 11, 1981, 9 mares were 
daily administered 2 g phenylbutazone intravenously.
k On February 12, 1981, phenylbutazone treatment continued daily 
for the same 9 mares plus daily teasing, blood collection and 
ovarian palpation of estrous mares.
c June 1, 1981, the same 9 mares were randomly assigned to 
either continuation of daily phenylbutazone-treatment or 
physiological saline (PS) control treatment. Teasing and 
palpation continued and estrous mares mated. Non-surgical 
embryo collection was performed day 7 or 8 post-ovulation.
Figure 9. Schematic representation of the experimental design 
for Experiment I
100
All mares were teased daily for signs of estrual behavior. Any 
mare of either group that exhibited estrus was artificially insemi­
nated with semen from a fertile stallion. With standard artificial 
insemination techniques each mare was inseminated on the second day 
of estrus and on alternate days until no signs of estrus were evi-
g
dent. A standard dose of 500 x 10 motile spermatozoa from the same 
stallion was used for all the mares. Within 5 to 10 minutes after 
insemination, each mare received an intrauterine infusion of 20 ml 
semen extender prepared as previously described (Pickett and Back, 
1973).
The day of ovulation (day 0) was determined by ovarian palpa­
tion. Starting 7 to 8 days after ovulation, fertilized ova were 
collected using an established non-surgical embryo collection 
technique (Imel et al., 1981). A 30 French Foley catheter with a 
30-ml inflatable cuff was manually inserted through the cervix. To 
ensure a snug fit against the internal os of the cervix, the cuff was 
inflated with =30 ml sterile water and pulled caudally. Both uterine 
horns were filled by gravity flow with 1,000 to 1,500 ml Dulbecco's 
phosphate-buffered saline solution (Appendix I). The uterus was 
manipulated per rectum and the medium was collected by gravity flow 
into an embryo concentrating filter device positioned on top of a 
sterile 2 liter graduated cylinder. This flushing procedure was 
performed twice and/or until a fertilized ovum was recovered. If the 
procedure was successful, the embryo could be detected macroscop- 
ically in the filter device. If an embryo was not located macro- 
scopically, the collection medium was searched under low magnifica­
tion through a dissecting microscope (lOx).
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Embryos were transferred to a sterile petri dish containing 
fresh PB-1 holding medium (Appendix II). Subsequently, embryos were 
stained with fluorescein diacetate using the procedure previously 
described by Looney et al., 1981.
Percentages were calculated for normal, extended and shortened 
cycles, embryo recovery rate and embryo flushing medium recovered. 
Mean (± SEM) cycle length was determined for each treatment mare.
RESULTS
One mare (No. 5) did not exhibit signs of estrus or ovarian 
activity until June (180 days). The remaining 8 mares exhibited 
initial signs of estrus between February 12 and February 24, 1981. 
From February 12 to June 15, 1981, (124 days) 36 cycles were observed 
(Table 8). Of these, 21 cycles (58.3%) were within the normal range 
of 18 to 24 days as reported by Belling (1983). Mean cycle length 
was 23.6 ± 0.98 days. Ten cycles (27.8%) were slightly extended (25 
to 28 days) and 3 cycles (8.3%) were very extended (> 30 days). Two 
cycles (5.6%) were shortened (< 18 days). Thirty-eight ovulations 
were recorded from 9 mares and of these, 4 mares had double ovula­
tions.
Percentage of Dulbecco's phosphate-buffered saline solution 
recovered from the uterus during attempts to recover the embryos was 
91.7 ± 1.6. An embryo was collected from only 1 of the 5 mares 
treated with phenylbutazone during the breeding cycle (Table 9). Of 
the 4 treated mares that an embryo was not collected, 2 had a muco­
purulent vaginal discharge when collection was attempted. One con­
trol mare also had a mucopurulent vaginal discharge at the time of
attempted collection. An embryo was not recovered from this mare. 
However, one embryo was recovered from each of the other 3 mares in 
the control group. In summary, embryos were recovered from 4 of 9 
mares (44.4%). Control mares contributed 75% and treated mares 25% 
of the total embryos recovered.
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Table 8. Cyclicity and ovulatory results determined by teasing 
mares with an androgenized gelding and by palpation of 
ovaries per rectum of phenylbutazone-treated mares 
between February 12 and June 15, 1981
Mare
no.
No. of days/ 
estrous cycle
No. of 
ovulations Cycle comment
1 18b, 25, 24, 20 3 3 N, 1 SE
2 26, 17, 19, 18 5a 2 N, 1 SE, 1 S
3 25, 22, 24, 21, 20 6a 4 N, 1 SE
4 40*, 21, 23, 18 4 3 N, 1 VE
5 ---- 21b
**active ovaries
0 1 N,
6 21, 28, 25, 23, 22 6a 3 N, 2 SE
7 20, 28, 23, 26 4 2 N, 2 SE
8 44***, 19, 33, 27 5a 1 N, 1 SE, 2 VE
9 28, 19, 15, 26, 19 5 2 N, 2 SE, 1 S
Total= 36 cycles 38 21 N, 2 S, 10 SE, 3 VE
N = normal cycles (18 to 24 days)
S = short (< 18 days)
SE = slightly extended (25 to 28 days)
VE = very extended (> 30 days)
* 25 days of estrus and 15 days diestrus 
** 65 total days of estrus and 29 total days diestrus (no cyclicity)
*** 6 days estrus, 38 days diestrus
fdouble ovulation 
follicle regressed
Note: The first cycle recorded is on the left of each row and then
sequentially across the row to the right.
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Table 9. Embryo collection data for individual mares, intravenous 
treatment, embryo recovery results and the percent of 
embryo flushing medium recovered
Mare No. Treatment
Embryo
recovered
Clinical
evaluation
1 PBZ No PM,94%
2 PS No PM,95%
3 PBZ No 88%
4 PS Yes 87%
5 PS Yes 93%
6 PS Yes 90%
7 PBZ Yes 94%
8 PBZ No 84%
9 PBZ No PM,100%
PBZ = daily treatment with 2 g of phenylbutazone 
PS = daily treatment with 10 ml physiological saline 
PM = pyometra noted at embryo collection 
% = percent return of embryo collection medium
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DISCUSSION
The decision to administer phenylbutazone to all mares was the 
result of a limited number of mares and a limited budget. Because 
results with short-term treatments from previous studies had not been 
very consistant, it was decided that it might require all of the 
available mares to find some that might respond to phenylbutazone 
by demonstrating altered cycles. Results were to be evaluated on the 
basis of cycles outside of an accepted norm (21 ± 3 days). In 
retrospect, it is questionable that having control mares would have 
added much to that information gained.
Mare No. 5 did not exhibit estrual behavior or ovarian activity 
for several months during the experimental period. It probably was 
not an effect of treatment with phenylbutazone because when this mare 
was placed in the experimental herd, it was very thin. However, 
after being fed grain on a regular basis and since pasture grass was 
abundant in the spring, it gained weight. This mare exhibited a 
normal-length cycle at the end of the experimental period and 
produced a viable control embryo from a typical uterus (Table 9).
During the first part of the experimental period, the intervals 
between estrus were irregular and erratic. This effect was assumed 
to reflect the transition period between winter anestrus (when cycles 
are often longer than later in the year) and the breeding season. 
Subsequently, the interval between estrus for these 9 mares during 
the entire period of study was 23.6 + 0.98 days, which is slightly 
longer than the reported average of 21 days (Ginther, 1979a; Belling, 
1983). However, this cycle mean was within the normal range of 18 to 
24 days as reported by Day (1940). Therefore, it was assumed that
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administration of phenylbutazone for 180 days (December 1, 1980 to 
May 31, 1981) did not have a significant effect on the initiation or 
regularity of estrous cycles.
The mean recovery rate for embryo flushing medium was 92% and 
was similar to recovery rates reported previously with 93% and 96% by 
Imel et al. (1981), 97% by Oguri and Tustsumi (1972) and 92% by 
Douglas (1979). Therefore, the low embryo recovery rate was probably 
not due to inadequate flushing technique. Medium recovery rates 
tended to be higher for mares exhibiting pyometra. This was asssumed 
due to other fluid accumulated in the uterus due to inflammation. 
Active vasodialation with increased permeability of blood vessels 
resulting in accumulation of a protein-rich fluid and leukocytes 
making up the inflammatory exudate is a major feature of inflammation 
(Higgins and Lees, 1984; May et al., 1987).
Embryo recovery rate (44%) was considerably less than those 
reported in previous reports with 72% and 83% by Imel et al. (1981), 
90% by Oguri and Tsutsumi (1974) and 65% and 56% by Douglas (1979). 
The recovery rate was comparable with the 47% recovery rate reported 
by Oguri and Tsutsumi (1972), but greater than the 39% recovery rate 
reported by Allen and Rowson (1975).
The cause of the mucopurulent vaginal discharge was not 
ascertained. A review of utero-ovarian palpation records did not 
give any indication that there was an obvious pyometra during the 
cycle prior to the cycle that they were mated. Because no abnormal­
ities were observed in the vagina or cervix on vaginoscopic examina­
tion, the source of the discharge was likely the uterus. The fact 
that no embryos were recovered from these mares may have been due to
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uterine infection and/or lack of fertilization. However, uterine 
infection does not necessarily interfere with fertilization in cattle 
(Archbald, 1976). Forty percent of the treated mares had vaginal 
discharge. It may or may not have been caused by phenylbutazone 
because all mares had received phenylbutazone for an extended period 
of time. Also, semen collection and insemination equipment may have 
been inadequately sterilized by the methods used (placed in Nolvasan 
solution and air dried).
The low percentage of embryos recovered could also be stallion 
related. At the beginning of the experimental breeding season, the 
stallion was given a complete fertility examination and was consi­
dered acceptable. This procedure was not conducted again. There­
after, each semen collection was simply visualized to evaluate dens­
ity and measured in a graduated cylinder to estimate semen dose per 
mare. If only 1 mare was mated per day, artificial insemination was 
still used to maintain the same protocol for every mare. Possibly, 
stallion fertility was lowered to less than acceptable for some un­
known reason. Others have reported a difference in fertility between 
stallions (Douglas, 1979).
The low embryo recovery rate (20%) from phenylbutazone-treated 
mares may also be related to ovum transport. Inhibition of ovum 
transport in rabbits treated with indomethacin was reported by 
Hodgson (1976). Possibly the ovum in treated mares did not reach the 
uterus.
Figure 13 shows an example of an embryo (blastocyst) recovered 
from one of the mares in this study. The same blastocyst is 
presented after staining with fluorescein diacetate (Figure 14).
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This stain has been used to assess the viability of cell lines 
cultured in vitro because living mammalian cells take in fluorescein 
when exposed to fluorescein diacetate (fluorochromasia). Fluorochro- 
masia occurs because fluorescein diacetate, being nonpolar, can 
readily pass into the cell. There, it is hydrolyzed by esterases to 
yield fluorescein, which cannot readily cross the cell membrane and, 
therefore, accumulates intracellularly. The test is a measure of 
esterase enzyme activity, cell membrane integrity and, indirectly, 
cell viability (Rotman and Papermaster, 1966).
The fluorescein diacetate stain has been reported not to be 
detrimental to embryos recovered from other species. Exposure of 
2-cell mouse embryos to fluorescein diacetate and ultraviolet light 
did not alter the rate of implantation or post-implantation develop­
ment in vivo (Mohr and Trounson, 1980). Also, the fluorescein diace­
tate viability assay did not inhibit development of hamster and 
bovine preimplantation embryos (Looney et al., 1981; Hoppe and 
Bavister, 1983;1984). In this study, all 4 blastocysts recovered 
were positive by the fluorescein diacetate test.
The results of this study suggest that chronic treatment with 
phenylbutazone had little if any effect on estrual behavior, estrous 
cycle length or ovulation. In addition, it appears that blastocysts 
from phenylbutazone-treated mares may be viable when recovered from 
the uterus between 7 and 8 days after ovulation.
Figure 10. Blastocyst recovered from a mare on 
day 8 post-ovulation (x40). The red stain is 
derived from the phenol red in PB-1 embryo 
holding medium.
Figure 11. Blastocyst (Figure 10) stained with 
fluorescein diacetate (x40). The green stain 
suggests embryo viability.
EXPERIMENT II
Analysis of Phenylbutazone in Plasma and Uterine Secretions 
of Mares by High Performance Liquid Chromatography
INTRODUCTION
Since phenylbutazone distributes throughout the horse (Tobin, 
1979a) and is capable of traversing the blood-brain barrier (Tobin, 
1981a) it was assumed in Experiment I that phenylbutazone was poten­
tially capable of entering uterine tissue following parenteral admin­
istration. However, results of Experiment I did not support the 
hypothesis that long-term phenylbutazone therapy would interfere with 
prostaglandin synthesis in the uterus and consequently disrupt 
estrous cycle length in the chronically-treated mare. It was then 
proposed that possibly phenylbutazone did not have any receptor sites 
in the mare uterus and did not accumulate there. Consequently, it 
was decided to evaluate if phenylbutazone was being concentrated in 
the uterine fluids.
The appearance of a mucopurulent vaginal discharge when embryo 
collection was attempted in Experiment I prompted the investigation 
to determine if circulating progesterone concentrations affected the 
incidence of uterine inflammation. The progesterone-dominated bovine 
uterus is more susceptible to bacterial infections than the 
estrogen-dominated uterus (Black et al., 1953; Rowson et al., 1953; 
Archbald, 1980). Therefore, it was decided to determine if circulat­
ing progesterone concentrations affected the incidence of uterine 
inflammation in the mare.
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OBJECTIVES
The objectives were (1) to test the hypothesis that phenylbu­
tazone accumulates in the normal and/or pathological equine uterus by 
determining concentrations of phenylbutazone in uterine secretions; 
(2) to determine if progesterone levels affected incidence of uterine 
inflammation; (3) to determine phenylbutazone concentrations in 
circulating blood at the time the uterine samples were collected.
MATERIALS AND METHODS
Seven mares of mixed breeding (4 to 6 years-of-age) averaging 
450 kg bodyweight were housed in large pens at the Louisiana State 
University School of Veterinary Medicine and fed good quality grass 
hay, trace mineral salt and water ad libitum. Four mares were each 
given 2 g phenylbutazone (Butazolidin , 200 mg/ml; D-M Pharmaceuti­
cals, Kansas City, MO.) intravenously (treated group) and 3 mares 
were given 10 ml sterile physiological saline intravenously daily 
(control group).
Uterine secretions were obtained 1 day prior to treatment 
(December 21, 1981) and daily until January 20, 1982. They were 
obtained by a modified non-surgical collection technique described by 
Zavy et al., 1978. After perineal washing (Pickett, 1973) a sterile 
long-sleeved glove was used to insert a 30 French Foley catheter with 
a 30-ml inflatable cuff through the cervix. To ensure a snug fit 
against the internal os of the cervix, the cuff was inflated via a 
sterile syringe with =30 ml air and pulled caudally. Sixty ml of 
sterile physiological saline were infused through the catheter via a 
sterile syringe into the uterine lumen. The uterus and uterine horns
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were manipulated per rectum for 5 minutes after which the flush 
containing the uterine secretions was slowly massaged out of the 
uterus, through the catheter and collected by gravity flow into a 
sterile 60 ml syringe case. Samples were immediately refrigerated 
standing upright in the syringe case. All of the mares were collect­
ed following the same sequence at the same time each day. Collection 
time was recorded and then each mare was immediately administered 
intravenously 2 g phenylbutazone or 10 ml physiological saline.
Visual examination of the recovered uterine flushing was then 
conducted and catagorized as follows (1) clear, appeared to have no 
uterine particles and looked like the physiological saline infused 
into the uterus; (2) cloudy, had diffuse white or slightly yellow 
particles and some sediment; (3) purulent, had a thick white or 
yellow sediment.
The uterine flushes were allowed to stand overnight in the 
refrigerator. Every morning the entire volume of each uterine 
flushing was measured, the supernatant was poured into another 
sterile 60 ml syringe case for storage at -20°C until analysis and 
the sediment was discarded. Percent of flushing medium recovered was 
calculated and recorded.
For the current experiment, sodium heparin and ethylenediamino- 
tetraacetate (EDTA) anticoagulant vacutainers were utilized to 
harvest jugular blood samples from mares. Ethylenediaminotetraace- 
tate samples were designated to confirm circulating phenylbutazone 
levels. Sodium heparinized samples were designated to determine 
circulating progesterone concentrations, but they were also utilized 
to run duplicate plasma samples because there was a shortage of EDTA
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plasma for the experiment. During the process of assaying plasma 
samples for phenylbutazone concentrations, it was noted there was a 
distinct chromatographic peak height difference between EDTA and 
sodium heparin blood samples even though they were collected one 
right after the other from the same mare. Therefore, a concurrent 
experiment evolved to determine if plasma from the 2 anticoagulants 
gave different phenylbutazone concentration values (Appendix IV).
Heparinized and EDTA blood samples were collected daily from 
each mare via jugular venipuncture. Progesterone concentrations were 
analyzed by the solid-phase, no extraction Coat-A-Count assay kit 
described in Appendix III.
Two preliminary studies were conducted in our laboratory. The 
first one determined that removing the organic extraction solvent in 
a stream of air instead of nitrogen did not adversely affect the 
determination of phenylbutazone concentrations in uterine secretions 
or plasma (Appendix V). The second one determined that phenylbuta­
zone concentrated in the supernatent rather than the sediment 
(Appendix VI).
Concentrations of phenylbutazone in uterine samples were 
determined by HPLC as described for plasma samples by Taylor et al. 
(1981). The following modifications were made (1) the organic 
solvent was removed in a stream of air instead of nitrogen; (2) 25 ml 
aliquots of uterine flushing were used instead of 2 ml; (3) 2 ml 10% 
(w/w) hydrochloric acid was used instead of 1 ml; (4) residue was 
dissolved in 50 yl of tetrahydrofuran instead of 150 yl.
A Waters Associates 254 Model-440 liquid chromatograph was used 
with a prepacked Whatman Partisil PXS 10/25 Column No. IB separation
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column and an HC Pellosil CKS1 guard column.
Statistical analysis was performed using an unpaired Student's 
t-test (Snedecor and Cochran, 1980) to determine if there was a sig­
nificant difference in percent of uterine flushing medium recovered 
from inflamed versus normal uteri in both treated and control groups. 
A Chi-Square analysis (SAS, 1988) was used to determine if there was 
a significant difference in incidence of uterine inflammation between 
phenylbutazone-treated and physiological saline control mares.
RESULTS
A total of 109 samples of uterine secretions were collected 
from treated mares (n = 4) and were monitored for phenylbutazone. Of 
these, 53, 28 and 28 secretions were catagorized as clear (48.6%), 
cloudy (25.7%) and purulent (25.7%), respectively. Nine samples were 
positive for phenylbutazone. Of these, 6 and 3 samples were from 
purulent and cloudy secretions, respectively. Percentage of secre­
tions positive for phenylbutazone content from phenylbutazone-treated 
mares was 8.33% (Table 10). Two phenylbutazone positive samples 
demonstrated a trace estimated at =40 and 120 parts per billion, 
respectively. Concentrations of phenylbutazone in the other 7 
uterine secretion samples that tested positive were 3.0, 3.5, 6.0, 
12.0, 13.0, 25.0 and 31.5 pg/ml, respectively.
A total of 122 uterine secretion samples from physiological- 
saline control mares were analyzed for phenylbutazone content and 
none of these were positive for phenylbutazone. Of the total, 99 
(81.1%), 14 (11.5%) and 9 (7.4%) were catagorized as clear, cloudy 
and purulent, respectively (Table 10).
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More uterine secretion samples from control mares were analyzed 
than from treated mares because pretreatment samples were collected 
from each mare to be used to run standard curves and preliminary HPLC 
studies (Appendix VIII).
Mares with cloudy and purulent secretions were thought to have 
uterine inflammation. Inflammation was also evaluated by measuring 
the volume of secretion recovered. Secretions were grouped as normal 
uterus (clear) and inflamed (cloudy + purulent). More fluid was 
recovered from inflamed uteri than the 60 ml physiological saline 
infused, suggesting fluid accumulation. Means (± SEM) uterine fluid 
volume recovered from control mares were 45.6 ± 0.2 ml and 129.7 ±
9.8 ml for normal and inflamed uteri, respectively. Mean uterine 
fluid volume recovered from phenylbutazone-treated mares was 47.5 + 
14.5 ml and 125.4 + 2.5 ml for normal and inflamed uteri, respective­
ly (Table 11).
Volume of uterine secretions recovered from inflamed uteri was 
larger (P < 0.01) than from normal uteri in both treatment and con­
trol groups (Table 11). Chi-Square analysis determined there was a 
greater (P < 0.001) incidence of uterine inflammation in mares being 
treated with phenylbutazone compared with saline-treated control 
mares.
Results of the progesterone assay determined that 2 of 4 
control and 2 of 4 treated mares had active corpora lutea (progester­
one values > 1 ng/ml). Two control and 2 treated mares did not have 
active corpus lutea as determined by progesterone values < 1 ng/ml.
Of the 9 uterine secretion samples that were phenylbutazone positive, 
7 had a concurrent progesterone value of < 1 ng/ml and 2 had
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progesterone values of 17.94 and 18.50 ng/ml, respectively.
Table 10. Results of visual examination of uterine secretions
recovered from phenylbutazone-treated and physiological 
saline (PS) control mares and of high performance liquid 
chromatography (HPLC) analysis for phenylbutazone (PBZ) 
content
Treatment HPLC
analysis
Visual Saline PBZ PBZ positive
appraisal no. % no. % (treated mares)
Clear 99 81. 1 53 48.6* 0
Cloudy 14 11. 5 28 25-7b 3
Purulent 9 7.4 28 25.7b 6
Total 122 109 9 (8.3%)
cL b’ Percents with different superscripts within column are signifi­
cantly different (P < 0.001)
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Table 11. Mean percent and volume of uterine flushing medium
recovered from phenylbutazone-treated and physiological 
saline (PS) control mares
Uterine
treatment condition (n)
Recovered flushing medium/mare 
Percent (%) Volume(ml)^
Saline
Normal 99 75.6a 45.6
Inflamed 23 176.8 129.7
Phenylbutazone
Normal 53 78.3a 47.5
Inflamed 56 180.3 125.4
^ Flushing significantly different (P < 0.01) between conditions 
60 ml of physiological saline was infused into the uterus
DISCUSSION
Phenylbutazone was detected only in cloudy and purulent uterine 
secretions from phenylbutazone-treated mares. Results suggested that 
phenylbutazone accumulated in detectable amounts (HPLC) only in mares 
with an inflamed uterus. Inflammation was appraised in phenylbuta­
zone positive secretions by presence of a mucopurulent sediment and/­
or a volume of recovered medium greater (P < 0.01) than that which 
was infused into the uterus, which suggested accumulation of other 
fluids in the uterus as described by Archbald (1976), Higgins and
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Lees (1984) and May et al. (1987).
Results show there was a 2 and 3-fold increase in the number of 
uterine samples catagorized as cloudy and purulent, respectively, for 
phenylbutazone-treated mares when compared with cloudy and purulent 
samples from control mares. Results suggest that phenylbutazone 
treatment enhances (P < 0.001) the chances of uterine infections in 
mares. This possiblity was also suggested in Experiment I because 
40% of the phenylbutazone-treated mares exhibited pyometra at the 
time of embryo collection when compared to 25% of the control mares.
Results showed a doubling (6 versus 3) of the number uterine 
fluids samples in which phenylbutazone accumulated in detectible 
amounts in purulent flushes (indicating heavy inflammation) compared 
with cloudy flushes (suggesting slight inflammation). An explanation 
of this finding may be that phenylbutazone adhered to the leucocytes 
found in the sediment because phenylbutazone is 98% protein bound 
(Tobin, 1981b).
Phenylbutazone accumulated in detectible amounts in only 9 of 
the 56 (16.1%) uterine flushings appraised as those from inflamed 
uteri. This suggests that phenylbutazone does not necessarily 
accumulate at all times in all mares exhibiting a uterine infection 
even though it appears that phenylbutazone potentiates a uterine 
inflammatory condition.
During the course of the experiment, 50% of the treated and 50% 
of the control mares had active corpora lutea (progesterone > 1 
ng/ml). Therefore, it appeared that phenylbutazone had no affect on 
luteal function.
Progesterone concentrations determined that phenylbutazone
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accumulated in inflamed uteri under both high and low progesterone 
concentrations. Seven of 9 (77.7%) phenylbutazone positive uterine 
flushings had concurrent progesterone values of < 1 ng/ml while 2 of 
9 (22.2%) had high progesterone concentrations. Phenylbutazone 
accumulation in the inflamed uterus appeared to be associated with 
low peripheral progesterone concentrations. This finding is unex­
plained at this time. This phenomenon may or may not have had a 
physiological basis. It is contrary to that reported in the cow 
where the progesterone-dominated bovine uterus is more susceptible to 
uterine infections than the estrogen-dominated uterus (Black e_t al., 
1953; Rowson et al., 1953).
The source of the uterine inflammation was not ascertained. It 
appeared that it was the result of daily manipulation and intubation 
of the uterus. All pretreatment samples were clear and the amount of 
flushing medium recovered was less than that which was infused, which 
concurred with uterine secretions from normal uteri. This finding 
confirmed that all uteri were normal before that daily saline infu­
sions started. Therefore, uteri became inflamed due to the daily 
intubation procedure and was potentiated (P < 0.001) by chronic phen­
ylbutazone treatment.
EXPERIMENT III
Effect of Phenylbutazone on Luteolysis 
Induced by Uterine Biopsy in the Mare
INTRODUCTION
Results of Experiment I demonstrated that chronic administra­
tion of phenylbutazone to mares exhibiting a nonpathological uterus 
did not affect estrual behavior, ovulation or length of estrous 
cycle. Results of Experiment II suggested that phenylbutazone accum­
ulated primarily in the inflamed uterus of the mare. It was then 
proposed that parenterally administered phenylbutazone will accumu­
late in an inflamed uterus, interrupt prostaglandin synthesis and, 
therefore, extend the estrous cycle of the mare.
The method chosen to specifically inflame the uterus was endo­
metrial biopsy. Uterine biopsy performed on day 4 post-ovulation 
shortened the estrous cycle of mares by inducing an inflammation that 
stimulated an increased synthesis and release of uterine prostaglan­
dins resulting in premature luteolysis (Hurtgen, 1975; Hurtgen and 
Whitmore, 1978; Hurtgen and Ganjam, 1979; Baker et al., 1981).
OBJECTIVES
The objective of this experiment was to test the hypothesis 
that parenterally administered phenylbutazone in the mare will 
accumulate in the uterus that has been inflamed by biopsy and inhibit 
uterine PGF2 OC synthesis. Consequently, to evaluate if the phenyl­
butazone treatment will block the luteolysis induced by the uterine 
biopsy performed on day 4 post-ovulation and will extend the estrous
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cycle.
MATERIALS AND METHODS
Seven mares of mixed breeding, between 4 and 6 years of age and 
averaging 450 kg body weight, were purchased and maintained as an 
experimental group at the Louisiana State University School of Veter­
inary Medicine. Each mare was given a thorough general physical and 
breeding soundness examination prior to purchase. Prior to and dur­
ing the period of study (March through mid-August) mares were fed 8 
liters of mixed grain concentrate/mare/day, grass hay and water free 
choice. All mares were in good body condition at the beginning of 
treatment and were subsequently maintained in large pasture lots with 
native grass cover during the study.
Mares were teased every morning with an androgenized gelding to 
determine the onset of estrus and each estrous mare was rectally pal­
pated to evaluate ovarian structures on a daily basis. Mares were 
monitored for estrual activity during untreated estrous cycles start­
ing in mid-February. After mares had exhibited 2 normal length 
estrous cycles (18 to 24 days), they were allotted to treatment on 
the first day of the third cycle. On the first day of the treatment 
estrous cycle each mare was administered intravenously 2 g phenylbu­
tazone (Butazolidin , 200 mg/ml; D-M Pharmaceuticals, Kansas City, 
MO.) in Treatment A. On the first day of the control estrous cycle 
each mare was administered intravenously 10 ml of sterile physiologi­
cal saline in Treatment B.
Treatments were continued daily until each mare exhibited an 
estrous response. Mares were treated with phenylbutazone or physio-
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logical saline using a switchback experimental design alternating 
between Treatment A and Treatment B on successive estrous cycles.
The first mare exhibiting a third estrus received phenylbutazone, the 
second received physiological saline. Remaining mares were alternat­
ed into treatments in this manner. Assignments were made until the 
end of the cyclic season in mid-August. The switchback treatment 
design was used to aid in reducing individual animal variability 
within the experiment by allowing each treated mare to also serve as 
her own control.
The day of ovulation (day 0) was determined by rectal palpation 
and later verified by peripheral plasma progesterone levels. On day 
4 post-ovulation all mares were subjected to uterine biopsy using the 
instrument and methods previously described (Hurtgen and Whitmore, 
1978; Baker et al., 1981). Following uterine biopsy, mares were 
teased each morning (0800 hours) and then either Treatment A or 
Treatment B was continued on a daily basis. Estrual behavior was 
evaluated from the response of each mare to the androgenized gelding 
and later verified by plasma progesterone concentrations.
Blood samples were collected prior to administration of Treat­
ment A or Treatment B on a daily basis via jugular venipuncture. 
Circulating progesterone levels on the first day of estrus, on the 
day of presumed ovulation, on the day of biopsy and on the day of 
induced estrus verified follicular development, a functional corpus 
luteum and ensuing luteal regression. Plasma progesterone concentra­
tions were determined by a no-extraction solid-phase RIA (Appendix 
III). Coefficient of variation for both intra-assay and inter-assay 
analysis was 5.8Z and 7.2%, respectively, for all plasma samples
123
evaluated in this study.
Mean plasma progesterone levels for specific days and mean 
number of days from uterine biopsy to the next estrous period for 
both treated and control cycles were compared for significance using 
a Student's paired t-test (Snedecor and Cochran, 1980).
RESULTS
A total of 19 estrous cycles (10 treated and 9 control cycles)
were evaluated (Table 12). Mean number of days (+ SEM) from uterine
biopsy to the next estrous period was 9.20 ± 0.34 days for treatment 
cycles and 5.00 + 0.16 days for control cycles. These mean intervals 
to estrus were significantly different (P < 0.025) with phenylbuta­
zone treatment cycles longer than control cycles.
Plasma progesterone concentrations verified low concentrations 
(< 1 ng/ml) at ovulation and at the estrus after uterine biopsy 
(Figure 12). Ovulation and the presence of functional luteal tissue 
at the time of uterine biopsy (day 4) were also verified by 
progesterone levels (> 5 ng/ml).
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Table 12. Mean intervals from biopsy to estrus and plasma proges­
terone (P^) concentrations in mares treated daily with 
either phenylbutazone (PBZ) or physiological saline (PS)
Item
Treatment3
A B 
2 g PBZ daily Saline daily
No. of cycles evaluated*5 10 9
Mean interval from biopsy
to estrus (days) 9.20c 5.00°
±0.34 ±0.16
Mean plasma P^ concentra­
tions at day 0 (ng/ml) 0.98 0.88
±0.34 ±0.34
Mean plasma P, concentra­
tions at day 4 (ng/ml) 15.56 14.21
±1.72 ±1.77
Mean plasma P^ concentra­
tions at induced estrus (ng/ml) 0.75 0.44
±0.37 ±0.25
aMean (± SEM)
^A total of 7 cyclic mares allotted to a switchback design 
c ci’ Means with different superscripts in rows were 
significantly different (P < 0.025)
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Figure 12. Plasma progesterone profiles for a typical 
experimental mare (No. 7) for treatment cycles 2 and 3 
using the switchback design. During treatment cycle 
number 2 this mare was administered 2 g of phenylbutazone 
(PBZ) daily until it exhibited an estrous response. On the 
first day of treatment cycle number 3 this mare was adminis­
tered physiological saline until the subsequent estrus.
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DISCUSSION
Results support the hypothesis presented in the objectives of 
this experiment indicating that treatment with phenylbutazone can 
delay luteolysis induced by uterine biopsy on day 4 post-ovulation.
It seems reasonable to assume that acutely inflamed uterine tissue, 
resulting from the biopsy, sequestered phenylbutazone in adequate 
concentrations to inhibit synthesis of uterine prostaglandins. In 
this regard, it has been previously shown that phenylbutazone does 
accumulate in inflamed tissues (Brune et al., 1976; Tobin, 1979a). 
This finding agrees with the results of Experiment II, which showed 
measurable levels of phenylbutazone in uterine flushings collected 
from phenylbutazone-treated mares that exhibited an inflamed uterus. 
Results of Experiment II showed that uterine flushings from phenyl­
butazone-treated mares containing purulent material also contained 
measurable levels of phenylbutazone. Uterine flushings from treated 
and control mares in which there was no evidence of uterine inflamma­
tion did not have a detectable level of phenylbutazone.
The occurrence of estrus at 5.0 days following uterine biopsy 
during the early luteal phase of the equine estrous cycle in the 
control group (Treatment B) agrees with the findings of others 
(Hurtgen, 1975; Hurtgen and Whitmore, 1978; Hurtgen and Ganjam,
1979; Baker et al., 1981). Presumably, uterine biopsy caused release 
of uterine prostaglandin resulting in luteolysis and return to estrus 
in these mares.
From the results of the present experiment and those previously 
reported from this laboratory, it is proposed that phenylbutazone 
will cause inhibition of prostaglandin synthesis with a consequental
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blockage of luteolysis only in those mares with an existing acute 
uterine inflammatory reaction. These previous experiments also 
demonstrate that the synthesis and cyclic release of uterine prosta­
glandin from a nonpathological equine uterus appears to be unaffected 
by parenteral treatment of the mare with phenylbutazone.
EXPERIMENT IV
Effect of Chronic Administration of Phenylbutazone 
on Fertilization, Embryo Size and Embryo 
Prostaglandin Synthesis in Mares
INTRODUCTION
Results of Experiment II showed that parenterally administered 
phenylbutazone accumulated in detectable amounts in mares exhibiting 
an inflamed uterus. Results from Experiment III suggested that phen­
ylbutazone accumulated in the equine uterus that had been stimulated 
by biopsy on day 4 post-ovulation and effectively inhibited uterine 
prostaglandin synthesis that is necessary for luteolysis.
It is proposed that biopsy illicites an inflammatory response. 
Vasodialation is a major feature of inflammation (Higgins and Lees, 
1984; May et al., 1987). Vasodialation is also a prominant response 
of pregnancy. Ford (1985) reported a 2 to 3-fold increase in uterine 
blood flow to the gravid uterus of the cow, sow and ewe during the 
late luteal phase of early pregnancy coinciding with maternal 
recognition of pregnancy. It was proposed that pregnancy will 
sequester parenterally administered phenylbutazone to the uterus in 
adequate concentrations to inhibit uterine and embryo prostaglandin 
synthesis and consequently inhibit equine embryo development.
In Experiment I, 1 viable embryo was recovered from a phenylbu­
tazone-treated mare. This result demonstrated that fertilization and 
embryo viability were possible in phenylbutazone-treated mares. 
Further investigation was deemed necessary to determine if fertility 
and embryo viability were inhibited in phenylbutazone-treated mares.
An extensive literature search showed no method previously
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established for preparing the equine blastocyst for quantification of 
embryo prostaglandin synthesis.
OBJECTIVES
The objectives of this experiment were to (1) test the 
hypothesis that increased blood flow to the gravid equine uterus will 
increase the accumulation of phenylbutazone that will interrupt 
uterine prostaglandin synthsis and therefore affect early embryonic 
development; (2) test if phenylbutazone daily administered to preg­
nant mares will interrupt conceptus prostaglandin synthesis; (3) to 
substantiate previous data from our laboratory regarding fertility 
and embryo viability in mares treated with phenylbutazone; (4) to 
develop an acceptible method to collect and process the equine 
blastocyst for extraction of embryo synthesized prostaglandins.
MATERIALS AND METHODS 
Fourteen mares of mixed breeding (averaging 450 kg body weight) 
between 4 and 6 years-of-age were used in this experiment. Mares 
were maintained from May to September on a grass pasture at the 
Louisiana State University School of Veterinary Medicine with miner­
alized salt free-choice and supplemented with 8 liters mixed grain/ 
mare/day. Mares were teased daily by a stallion and ovulation was 
determined using daily rectal palpation once a day at mid-morning. 
Mares were mated by natural service once or twice a day after detect­
ing a follicle > 30 mm in diameter. Treated mares were administered 
2 g phenylbutazone (Butazolidin ; D-M Pharmaceuticals, Kansas City, 
MO.) intravenously (Treatment A). Control mares were similarly
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treated with 10 ml physiological saline (Treatment B). Treatment A 
or B started on the first day of estrus and continued daily there­
after until the day of embryo collection. Non-surgical embryo col­
lection was performed as described (Imel e_t al., 1981) starting on 
days 8, 9 or 10 post-ovulation (day 0 = palpation day of follicle 
rupture). Dulbecco's phosphate-buffered saline (PBS) with 1% fungi­
zone and antibiotic was used the as flushing medium (Appendix Table
I.)
Recovered embryos were immediately placed into a sterile petri 
dish containing =6 ml flushing medium (Appendix Table II). The 
embryo was then examined for morphological development under the 
stereomicroscope. Embryos were then photographed at 6x, 12x, 25x and 
50x using a 35 mm Nikon camera attached to a Wild M5D light micro­
scope. Each embryo was then transferred to a capped tube containing 
6 ml sterile PB-1 holding medium at room temperature for transport to 
the laboratory. Embryos were then prepared by one of 3 different 
methods for prostaglandin synthesis determination by RIA.
The first method was labeled homogenization, incubation and 
extraction (HIE). The embryo was transferred into a glass homogen­
izing vial filled with 10 ml PB-1 holding medium and placed on ice. 
Embryos were homogenized in each method by 10 strokes of a glass 
teflon homogenizing apparatus attached to a hand drill. One ml 
aliquots of homogenate were put into plastic tubes and incubated for 
0, 5, 10, 20, 30, 40, 50 and 60 minutes in a 37°C shaking water bath. 
The incubation was stopped by the addition of 20 pi of 5% formic 
acid. Then, 5 ml of ethyl acetate was added to each tube to extract 
prostaglandins. The solution was allowed to stand at room tempera-
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ture for 30 minutes and the extraction phase was then repeated. The 
tubes were then evaporated in a stream of reconstituted in 2 ml
phosphate buffered saline-gel and sonicated, Aliquots of 600 pi from 
each incubation time (set of 3 tubes) were covered and stored at 
-20°C until assayed by RIA (Hwang, 1985) for PGE2 , PGF2 «x and 6-keto- 
PGF^a (the PGI2  metabolite).
The second method was labeled intact embryo incubation and 
extraction (HE). One day 8 embryo was put in 10 ml flushing medium 
in a sterile covered embryo collection dish and incubated in a 37°C 
incubator for 5, 24, 48 and 72 hours. Another day 8 embryo was incu­
bated in a sterile capped glass vial containing 4 ml PB-1 holding 
medium in a 37°C water bath for 0, 6, 12 and 18 hours. One ml ali­
quots of medium were drawn off at the prescribed times, extracted and 
frozen as previously mentioned.
The third treatment was homogenization (H). The day 10 embryo 
was homogenized in 4 ml PB-1 holding medium. The homogenate was not 
extracted but rather frozen in 600 pi aliquots.
Uterine flushing medium recovered along with each embryo was 
also assayed for prostaglandin concentrations. One ml aliquots from 
every embryo collection medium were extracted and frozen.
Embryos from control mares were assayed for prostaglandins by 
RIA as described by Hwang (1985). Results showed a distinct PGE2  and 
PGI2  peak at 5 minutes of incubation for the day 9 HIE embryo. A day 
10 HIE embryo peaked at 60 minutes for PGE2 . Consequently, serial 
incubation time for future HIE embryos was stopped at 30 minutes.
The day 8 IIE embryos had a PGE2  and PGI2  peak at 24 hours, but the 
concentration was one-third less than the 5 minute HIE peak. The
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homogenized (H) embryo showed a very high PGE2  content compared with 
HIE and IIE embryos. Results suggested that in order to stay safely 
within the RIA assay standard curve, day 9 embryos should be collect­
ed and processed as HIE for the remainder of Experiment IV.
Three more control and 4 treated embryos were collected on day
9 post-ovulation, processed as HIE, frozen and assayed. Another day
10 control embryo was collected and homogenized (H) but this time in 
10 ml PB-1 instead of 4 ml in order to study an appropriate tissue 
dilution factor. One uterine flushing sample was assayed from all 5 
control and 4 treated HIE embryos. All these embryos and uterine 
flushings were assayed by RIA.
Data was tested for significance using SAS (SAS Institute,
1988) analysis of variance with a split plot design. Data was tested 
for significance using SAS (SAS Institute, 1988) Student's unpaired 
t-test.
RESULTS
The 4 embryos from the phenylbutazone-treated mares demonstrat­
ed a standard zona pellucida and capsule reaction under microscopic 
examination (12x). All cellular aspects of the blastocysts appeared 
normal. However, embryos from the phenylbutazone-treated mares were 
noticeably smaller and more fragile than embryos from control mares.
Embryos from control mares had a thick white capsule, but the embryos
from the phenylbutazone-treated mares had a thin translucent capsule. 
One embryo from a phenylbutazone-treated mare broke apart simply 
being drawn into the transfer pipette.
Results of the RIA assays for prostaglandins are presented in
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Tables 13, 14 and 15. The prostaglandin peak in Table 13 for a day 9 
HIE embryo at 5 minutes incubation in the preliminary prostaglandin 
assay was not demonstrated by any other embryos.
Incubation time was not significant, but there was a highly 
significant difference of prostaglandin synthesis between embryos 
from phenylbutazone-treated mares and embryos from saline-treated 
control mares for PGE2  (P < 0.0001), PGF2 «x (P < 0.0001) and P G ^  (P < 
0.0004). Three of 4 (75%) embryos from phenylbutazone-treated mares 
synthesized no detectible amounts of PGF2 <x or PG^* Prostaglandin E2  
appeared to be the dominant prostaglandin synthesized by the day 9 
blastocyst from phenylbutazone-treated mares. Data of embryos from 
control mares shows PGE2 and PGF2a were produced in approximately 
equal concentrations and PGI2  approximately two-thirds less. A 
summary of means for the prostaglandin assay is present in Table 17.
Data of embryos from control mares shows another prostaglandin 
synthesis pattern (Table 14). The day 9 HIE embryo synthesized 
higher concentrations of PGI2  than PGE2 . Day 8 H E  embryos had 
synthesis of PGI2  dominanting between 0 to 18 hours, but PGE2  was 
dominant at 24 to 72 hours. The control day 10 H embryo showed 
another pattern with PGF2 <x being dominant at near double the concen­
tration of approximately equal concentrations of PGE2  and PG^- 
The 3 prostaglandins assayed were also detected in uterine 
flushings. There was no significant difference in prostaglandin 
concentration between uterine flushings recovered from phenylbuta­
zone-treated and saline control mares for all 3 prostaglandins 
evaluated in this experiment (Table 16).
Results in Table 13 show a peak PGE2  and PGI2  at 24 hours for
day 8 H E  and a much higher prostaglandin synthesis for day 10 HIE 
than day 9 HIE. A review of the methods and summary of results is 
presented in Table 14. Homogenization produced a high prostaglandin 
concentration. It remained undetermined if it was the procedure or 
the embryo itself that produced the high prostaglandin concentration.
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Table 13. Results of preliminary radioimmunoassay for prosta­
glandins E„ and ^  synthesized by equine embryos recover­
ed from saline-treated control mares on days 8, 9 
or 10 post-ovulation
Daya
u p g e9 P GH
Treatment Time0 ng/ml ng/ml
9 HIE 0 minutes 0.62 0.00.
5 8.95 18.50
10 0.16 0.13
20 0.13 0.12
30 0.11 0.10
40 0.12 0.11
50 0.13 0.18
60 0.17 0.44
10 HIE 0 3.41 _d
5 4.14 -
10 4.34 -
20 4.83 -
30 6.47 -
40 7.63 -
50 7.49. -
60 10.54 —
8 IIE 0 hours 0.13 0.37
6 0.29 0.62.
12 0.00 0.71
18 0.30 0.43
8 IIE 5 °-03* 0.11
24 3.06 0.82
48 2.95 0.56
72 2.78 0.51
10 H - 13.13 -
^Number of days ovulation to embryo collection 
Treatment to prepare embryo for assay
HIE = Homogenized, Incubated, Extracted 
H E  = Intact embryo, Incubated, Extracted 
H = Homogenized 
^Incubation time 
Assay not run 
*Peak prostaglandin concentration
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Table 14. Equine embryo treatment groups and peak prostaglandin 
E2  concentrations from Table 13
Day of 
cycle
Treatment 
of embryo
Incubation time 
of peak PG
PGE„
(ng/ml)
8 IIEa 24 hours 3.06
9 HIEb 5 minutes 8.95
10 HIE 60 minutes 10.54
10 HC 0 minutes 13.13
aIIE = intact embryo incubated and medium extracted
bHIE = homogenized embryo, medium incubated and then extracted
H = homogenized embryo (no incubation or extraction)
Table 15. Prostaglandin synthesized by day 9 post-ovulation 
embryos recovered from physiological saline (PS) and phenylbutazone 
treated mares. Embryos were homogenized, incubated and extracted.
Mare
number
Incubation
time
(minutes)
Prostaglandin (ng/ml)
pge2 X PGF2a X p g i2 X
Saline
28 0 0.10 0.13 0.02
5 0.12 0.15 0
10 0.12 0.12 0.14 0.15 0.04 0.01
20 0.13 0.13 0
30 0.15 0.18 0.009
23 0 0.17 0.16 0.09
5 0.15 0.15 0
10 0.17 0.16 0 0.11 0.04 0.03
20 0.15 0.12 0.04
30 0.16 0.10 0
24 0 0.18 0.21 0.007
5 0.21 0.20 0.07
10 0.21 0.19 0.22 0.20 0.22 0.11
20 0.19 0.18 0.11
30 0.18 0.18 0.13
Phenylbutazone
28 0 0.14 0 0
5 0.15 0 0
10 0.14 0.16 0 0 0 0
20 0.19 0 0
30 0.16 0 0
32 0 0.05 0 ■ 0
5 0.14 0 0
10 0.15 0.12 0 0 0 0
20 0.13 0 0
30 0.14 0 0
29 0 0.13 0.04 0.001
5 0.08 0.06 0.05
10 0.11 0.11 0.05 0.05 0.002 0.01
20 0.14 0.06 0
30 0.09 0.03 0
27 0 0 0 0
5 0 0 0
10 0.13 0.06 0 0 0 0
20 0.10 0 0
30 0.07 0 0
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Table 16. Prostaglandin concentrations for uterine flushings 
recovered with day 9 equine embryos
Prostaglandin (ng/ml)
Mare _ _ _
treatment group P * ^  X p^F2a X X
Physiological 0.11 0.20 0.02
saline 0.09 0.07 0
0.07 0.07 0.69 0.22 0 0
0.06 0.06 0
0 0.06 0
Phenylbutazone 0 2.32 0.45
0.10 0.04 0.02 0.60 0 0.11
0 0.02 0
0.07 0.02 0
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Table 17. Mean prostaglandin concentrations for equine uterine
flushings and day 9 equine embryos from phenylbutazone 
(PBZ) treated and physiological saline (PS) control mares
Sample Treatment n PGE?
ng/ml
p g f9«
ng/ml
p g i7
ng/ml
Uterine
flushing3 PS 5 0.066 ± 0.010 0.216 + 0.121 0.004 + 0.004
PBZ 4 0.043 ± 0.025 0.595 ± 0.575 0.113 ± 0.113
Embryos** PS 3 0.159 + 0.007° 0.150 ± 0.007° 0.052 + 0.008c
PBZ 4 0.112 ± 0.006 0.012 ± 0.006 0.002 ± 0.007
?Mean (± SEM)
Least-Squares Mean (± SEM) 
cTreatment significantly different (P < 0.001)
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DISCUSSION
Results suggest that fertilization was not impaired by 
parenteral treatment of mares with phenylbutazone. Analysis of 
embryo photographs suggests that treatment did not affect the zona 
pellucida reaction and other standard morphological developments. 
Embryos recovered from phenylbutazone-treated mares appeared viable, 
but less likely to survive compared with embryos from control mares.
Most of the embryos from phenylbutazone-treated mares were 
difficult to locate in the flushing medium without a microscope while 
embryos from control mares were easily visible. Inhibition of embryo 
expansion appeared to occur in phenylbutazone-treated mares similar 
to the results reported for the embryos of indomethacin-treated 
rabbits (Hoffman et al., 1978). Because embryos were not systemati­
cally photographed in this experiment to determine diameter, this 
observation was not statistically evaluated. It was then decided to 
photograph every embryo in the subsequent experiment to determine its 
diameter. This apparent size difference also generated interest in 
determining whether embryo protein content was affected by phenylbu­
tazone treatment of the mare. Thus, future embryos were also to be 
prepared for the Lowry protein assay.
Results from this experiment suggest that phenylbutazone 
administered to pregnant mares significantly inhibited embryo synthe­
sis of prostaglandins F^a, and This finding may have been the
cause of inhibition of ovum transport, blastocyst hatching, blasto­
cyst expansion, embryo implantation, fetal development and live birth 
rate reported by other researchers (see Table 6).
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The dominant prostaglandin synthesized by equine embryos 
changed with age of the embryos. This finding concurs with Hwang 
et. al. (1988) who reported transitional changes in prostaglandin 
synthesis by bovine embryos at different developmental stages.
PGF2 <x was the dominant prostaglandin detected in uterine 
flushings, PGE2  was intermediate and PGI2  was the lowest concentra­
tion (Table 16). The dominance of PGF2 « is in agreement with 
Bergland et al. (1982) and Sharp et al. (1984), who reported a 
significant increase of uterine luminal PGF2 <x synthesis and/or 
secretion in pregnant mares due to transcervical lavage stimulation 
in the presence of a prostaglandin antagonist.
Results showed no significant difference in uterine prostaglan­
din synthesis between phenylbutazone-treated and saline control 
mares. However, phenylbutazone treatment did significantly affect 
embryo prostaglandin synthesis. Therefore, the effect of phenylbuta­
zone on diminished size appears to associate with the embryo itself 
rather than the uterine environment.
The PGE2  and PGI2  peaks at 5 minutes incubation for the HIE 
embryo was not demonstrated by any other embryos. However, this 
embryo produced PGE2  concentrations for the other incubation times 
falling within close range to those assayed at the end of the 
experiment (Table 15). Therefore, it was concluded that the peak was 
caused by a laboratory error.
Comparison of the day 10 H embryos in Table 13 and Table 15 
homogenized in 4 ml and 10 ml PB-1 holding medium, respectively, 
suggests that 4 ml is too concentrated and 10 ml is too dilute in 
order for the embryo prostaglandin concentrations to fall within the
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standard curve of the assay. It was concluded that future embryos 
should be placed in 6 ml PB-1 holding medium for incubation.
Due to overall laboratory time, the HIE method was discarded. 
Day 10 embryos appear to synthesize the 3 prostaglandins investigat­
ed. A decision was made to collect day 10 embryos and incubate them 
for 24 hours in 6 ml PB-1 holding medium in the subsequent experi­
ment.
Natural service breeding at =6:00 P.M. daily appeared to be 
more effective than A.M. artificial insemination every other day.
When stallion power was available, natural service was conducted 
twice a day (A.M. and P.M.) for any mare with a > 45 mm follicle.
Damaged embryos were found in the filter apparatus attached on 
top of the 2 liter collection cylinder after flushing 3 mares on 3 
separate attempts. When a mare strongly contracted her abdomen, the 
flushing medium was expelled so forcefully through the tubing that 
the embryos broke apart when they hit the filter screen. Therefore, 
the filter was removed. Outflow tubing was placed directly into the 
2 liter cylinder and then embryos gently sank to the bottom of the 
collection cylinder. The top portion of the medium was then poured 
off and the lower portion slowly poured through the filter to trap 
the embryo. Both modifications thereafter enhanced embryo recovery 
rates and were utilized in the subsequent experiment.
EXPERIMENT V
Effect of Chronic Administration of Phenylbutazone 
on Fertilization, Embryo Diameter, Embryo Prostaglandin 
Synthesis and Total Embryo Protein in Mares
INTRODUCTION
Results from Experiment IV substantiated results from 
Experiment I demonstrating that fertilization and embryo viability 
were observed in mares being chronically treated with phenylbutazone.
Results of Experiment IV also showed that mare phenylbutazone 
treatment appeared to inhibit embryo expansion and embryo prostaglan­
din synthesis. It was proposed to conduct a subsequent experiment 
utilizing the same protocol as Experiment IV except to also determine 
embryo diameter and embryo total protein. Methods investigated in 
Experiment IV that appeared to be the most appropriate were utilized 
in Experiment V.
OBJECTIVES
The objectives of this experiment were to (1) substantiate 
data from Experiment IV; (2) determine embryo diameter; (3) quanti­
tate embryo prostaglandin synthesis; (4) quantitate total embryo 
protein; (5) use the experimental protocol designed from results 
of Experiment IV.
MATERIALS AND METHODS
Test mares and all experimental procedures were the same as 
Experiment IV except that all embryo collections were performed on 
day 10 post-ovulation, a Bivona equine uterine flushing catheter
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(Bivona Inc., Gary, IN.) was used to accommodate the larger embryo 
and modifications were made in embryo processing. Within 15 minutes 
after embryo collection, the embryo was placed in a sterile petri 
dish and photographed at 6x, 12x, 25x and 50x magnifications. Embry­
os were transferred via sterile pipette to a capped sterile glass 
tube containing 6 ml PB-1 holding medium and incubated in a 37°C 
water bath for 24 hours. Then, 3 aliquots (1 ml) of medium were 
transferred to 3 parafilm covered glass vials and stored at -20°C 
until assayed for prostaglandin content by RIA. The embryo was homo­
genized in the remaining 3 ml of medium with a glass teflon homogen­
izing apparatus attached to a Dayton Workshop bench-top drill press 
(Model 4Z660A) and frozen for Lowry protein determination.
First, 6 embryos from control mares were collected. Then, 
mares were treated with 2 g phenylbutazone intravenously and 6 embry­
os were collected from these mares. Because embryos from phenylbuta­
zone-treated mares appeared smaller than those from control mares and 
it was thought perhaps the diminished size was due to advanced breed­
ing season rather than treatment, additional control embryos were 
collected, 3 to 4 months after the first embryos were collected from 
control mares.
Embryo diameters were measured with a Wild stereomicroscope 
equipped with a 35 mm camera and micrometer to measure across the 
embryo from zona pellucida border to zona pellucida border with a 
transparent metric ruler. First, a micrometer was placed under the 
microscope where the embryos were photographed on top of a 35 mm 
slide. Slide length and width gradations were counted at 6x and 12x 
magnifications.
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Homogenized embryo samples were thawed at room temperature and 
assayed according to modified Lowry protein determination (Cooper, 
1977). A standard curve was determined using 0 to 250 yg bovine 
serum albumin (Fraction-V; Sigma Chemical Co.) as standard protein. 
Samples were diluted 1:40 with 0.1 N NaOH. One-half ml phenol 
reagent (IN) was added to each tube. Absorbance was read at 540 nm 
on a Baush and Lomb Spectronic 2000. Data were tested for signifi­
cance using SAS (SAS Institute, 1988) Student's unpaired t-test.
RESULTS
Evaluation of embryo photographs showed that parenteral 
maternal phenylbutazone treatment did not affect fertilization or 
blastocyst viability. Morphological development appeared typical.
Results of embryo diameters determined at both 6x and 12x 
magnifications are presented in Table 19. The embryos from phenylbu­
tazone-treated mares were SI mm smaller than embryos from control 
mares. Mean (± SEM) embryo diameters at 6x and 12x magnifications 
were 2.54 ± 0.56 mm and 2.42 ± 0.20 mm for embryos from control mares 
and 1.41 ± 0.18 mm and 1.80 ± 0.27 mm for embryos from phenylbuta­
zone-treated mares, respectively. Embryos from phenylbutazone-treat­
ed mares were significantly (P < 0.05) smaller at both 6x and 12x 
than embryos from controls mares.
Embryo total protein results are presented in Table 19.
There was no significant difference in total protein between embryos 
from phenylbutazone-treated and saline control mares. However, 
embryos from phenylbutazone-treated mares tended to contain more 
protein (mean + SEM) (28.01 ± 0.94 yg) than those from control mares
(25.17 + 1.25 yg). Data suggested that as the breeding season 
advanced, the trend was for protein content to increase whether in 
embryos from phenylbutazone-treated or saline control mares. 
Therefore, a linear regression analysis was used to determine if a 
relationship existed between embryo collection dates throughout the 
experimental season and protein content. Days of embryo collection 
were numbered 1 to 117 starting with the first to last embryo 
collection. There was a highly significant (P < 0.0007) (r = 0.66) 
correlation between advancement of breeding season and increased 
embryo total protein content.
Results of prostaglandin embryo synthesis are presented in 
Table 20. There was no significant difference between embryos from 
phenylbutazone-treated and saline control mares for prostaglandin 
synthesis, although PGF^a approached significance (P = 0.06). A 
comparison of mean prostaglandin concentration presented in Table 21 
suggests reduced concentrations of all 3 prostaglandins synthesized 
by embryos from phenylbutazone-treated mares as compared with those 
from control mares.
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Table 18. Diameter at 6x and 12x magnifications and total protein 
(TP) of embryos recovered on day 10 post-ovulation from 
physiological saline control and phenylbutazone-treated 
mares
Embryo Mare# Treatment 6x(mm) 12x(mm)
TP yg/ 
embryo
A 135 C 2.19 2.74 22.83
B 139 C 1.17 1.71 23.10
C 135 C 2.04 2.23 24.23
D 88 C 2.19 2.57 23.45
E 2 C 2.34 2.57 24.87
F 39 C 1.46 1.89 25.37
M 88 C 2.63 3.26 32.37
N 88 C 6.28 _ * _ *
G 88 P 1.02 1.20 23.71
H 46 P 1.46 1.89 30.01
I 2 P 1.61 1.97 28.87
J 139 P 1.17 1.37 28.96
K 39 P 1.02 1.37 27.12
L 3 P 2.19 3.00 29.39
C = saline-treated control mares 
P = phenylbutazone-treated mares 
TP = total protein (yg)
* Embryo too large a diameter to fit in field at 12x and was
broken when transferred to the incubating vial in the laboratory.
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Table 19. Prostaglandin synthesis of intact incubated equine 
embryos recovered on day 10 post-ovulation from 
physiological saline control and phenylbutazone-treated 
mares
Prostaglandin (ng/ml)
Embryo Mare Treatment pg e2 PGF2a pg i2
A 135 C 36.00 4.31 1.58
B 139 C 9.24 0.70 0.26
C 135 C 17.58 1.84 0.74
D 88 C 4.20 1.02 0.16
E 2 C _* 4.39 2.34
F 39 C 8.18 0.70 0.26
M 88 C 1.85 0.61 0.10
G 88 P 0.70 0.13 0.08
H 46 P 12.39 0.46 0.19
I 2 P 1.83 0.23 0.11
J 139 P 3.56 0.50 0.16
K 39 P _ * 0.27 0.11
L 3 P 12.65 1.14 0.59
C = saline-treated control mares 
P = phenylbutazone-treated mares 
* = high concentration and off standard curve
Table 20. Mean concentrations (± SEM) of prostaglandin
synthesized by day 10 equine embryos recovered 
from physiological saline (PS) control or phenylbut­
azone-treated mares
Prostaglandin (ng/ml)
Treatment n PGE2 PGF2a FGI2
PS control 6 12.84 ± 5.12 1.94 + 0.64 0.78 ± 0.32
Phenylbutazone 6 6.23 + 2.60 0.46 + 0.15 0.21 + 0.08
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DISCUSSION
Results of Experiment V substantiated results from Experiment IV 
regarding fertilization, embryo viability, embryo development and 
embryo prostaglandin synthesis. As in Experiment IV, most of the 
embryos from phenylbutazone-treated mares were difficult to locate 
with the naked eye in flushing medium while embryos from control 
mares were clearly visible.
Embryo photographs showed that fertilization and blastocyst 
viability were not impaired by mare phenylbutazone treatment.
Embryos from phenylbutazone-treated mares appeared to be viable, but
less likely to survive compared with embryos from control mares. It
appeared that embryo expansion was inhibited. Embryos from phenyl­
butazone-treated mares were smaller (P < 0.05) at both 6x and 12x 
magnifications than embryos from control mares.
The diminished diameter of the embryos from phenylbutazone- 
treated mares compared with the diameter of the embryos from control 
mares coincide with the findings of other researchers (Hoffman, 1978; 
Hoffman et al.,1978; Lacroix and Kann, 1982). Blastocyst diameters 
from female rabbits receiving 8 mg indomethacin/kg subcutaneously 
twice daily on days 4 to 6 of pregnancy were significantly smaller 
than the diameter of control embryos (Hoffman et al., 1978). Also, 
when 8 mg indomethacin/kg was administered subcutaneously twice daily 
to rabbits on days 4 to 7 of gestation nearly complete inhibition of 
fetal development resulted (Hoffman, 1978). The number of fetuses 
that survived to day 14 were smaller than controls and their associ­
ated decidual and placental tissues weighed less. A lower dose of 3 
mg indomethacin/kg administered subcutaneously twice daily on days 4
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to 7 of gestation likewise reduced fetal, placental and decidual 
weights.
Lacroix and Kann (1982) treated ewes on days 7 to 22 of 
gestation with 300 mg indomethacin resulting in diminished embryo 
weights on day 23 of treated (67 + 14 mg) compared with embryo 
weights of the controls (90.5 ± 28 mg). These results suggest that 
parenteral maternal treatment with prostaglandin antagonists inhibit 
embryo development.
Theoretically, embryo diameters at 6x and 12x should be the same 
size. However, diameters in Table 19 show 12x larger than 6x. 
Possibly, magnification values differed due to distortion through 
medium in the petri dish where the embryo was floating when photo­
graphed and/or the lens system in the camera and microscope.
Four embryos did not follow the trend of embryos from control 
mares being =1 mm larger than embryos from phenylbutazone-treated 
mares. Variances from the mean were possibly due to the true age of 
the embryo. It was possible that some embryos may have been as much 
as 12 hours older than others due to ovulation palpating error, hour 
of ovulation, time on day 10 of embryo collection and/or date of 
embryo collection. For example, if a mare ovulated at 2300 day -1 
and was collected day 10 late in the afternoon, the embryo would be 
at a more advanced growth stage compared with an embryo from a mare 
that ovulated at 0700 hours on day 0 and was collected at noon day 
10.
Witherspoon and Talbot (1970) reported most mares tend to 
ovulate at night between 2300 and 0700. Neely (1983) reported once 
the equine embryo enters the uterus, it increases rapidly in size to
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SI mm diameter by day 8. By day 9, the vesicle diameter is =2 mm 
(Ginther, 1979). Possibly, the mares producing the smaller control 
embryos B and F ovulated early in the morning on day 0. They were 
collected at 1145 and 1245, respectively. Embryos L, M and N were 
collected in September at 1200, 1230 and 1700 hours, respectively. 
Embryos M and N from control mares were the last and largest embryos 
collected and embryo L was the last and largest embryo collected from 
a phenylbutazone-treated mare. The larger size of these 3 embryos 
may have been due to an extra half-day growth when compared to those 
embryos collected early in the day.
Day 10 embryos from phenylbutazone-treated mares were approxi­
mately the same size as a normal day 8 embryo. It appeared that as 
the breeding season advanced, embryos were larger for both treated 
and untreated mares. However, there was no significant correlation 
between season and embryo diameter. Perhaps late summer hot ambient 
temperatures advanced ovulation to early day -1. It is proposed that 
parenteral maternal phenylbutazone treatment rather than season was 
the cause of diminished size of embryos from phenylbutazone- 
treated mares.
Results suggest that maternal phenylbutazone treatment may 
inhibit embryo prostaglandin synthesis. Results showed reduced 
concentrations of PGF2 (x, PGE2  and PGI2  by embryos from phenylbuta­
zone-treated mares compared with those from control mares. The 
diminished synthesis of prostaglandins in embryos from phenylbu­
tazone-treated mares compared with those from control mares was not 
significant in Experiment V. However, the difference was highly 
significant in Experiment IV. The reasons for this discrepancy may
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have been due to age of the embryo (day 9 versus day 10) and/or the 
difference in methods utilized to prepare the embryo for quantifica­
tion of prostaglandin production.
From these data it appears the prostaglandin synthesized in 
highest quantity by the day 10 equine embryo is with PGF2 OC
being intermediate and P G ^  the least synthesized. This finding 
concurs with those from Hwang et al. (1988) who reported bovine 
embryos < 12 days of age followed the same pattern of prostaglandin 
synthesis.
In summary, results of this study suggested parenteral maternal 
phenylbutazone treatment may inhibit embryo expansion and prostaglan­
din synthesis, but does not affect fertilization, embryo viability 
and total embryo protein. There is a significant correlation between 
chronological advancement (June to October) of breeding season and 
increase in total embryo protein.
SUMMARY OF CONCLUSIONS
In Experiment I, 36 estrous cycles of mares chronically treated 
with phenylbutazone were evaluated and compared with the reported 
normal mare estrous cycle range of 18 to 24 days. The majority of 
cycles (58.3%) were within the average mare estrous cycle range. 
Cycles that did not fall within the standard range were slightly 
longer (27.8%) or were very prolonged (8.3%). Three cycles were 
shorter than usual. The mean (± SEM) estrous cycle length for all 36 
estrous cycles evaluated was 23.6 ± 0.98 days. This mean cycle 
lengths value concurred with previous experiments conducted by 
Archbald et al. (1983). These researchers used the same mares under 
the same experimental conditions as Experiment I and reported mean 
cycle length to be 23.1 ± 0.24 and 20.7 ± 0.28 for phenylbutazone- 
treated and saline-treated control mares, respectively.
Mean length of the estrous cycles was at the high end of the 
established mare estrous cycle range. This is likely due to the 
experimenal period including winter months and the early spring 
transitional phase when cycles are usually longer than normal rather 
than due to phenylbutazone treatment. However, it should be consi­
dered that phenylbutazone may have had an effect on extending some of 
the estrous cycles. Perhaps phenylbutazone would have inhibited 
luteolysis in an experimental group housed in the northern latitudes 
where seasonality has a pronounced effect on mare cyclicity.
Thirty-eight ovulations that included 4 double ovulations were 
recorded for the same 36 estrous cycles evaluated. Follicular 
development and ovulation appeared normal. These findings suggest 
that chronic phenylbutazone treatment of mares did not inhibit
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follicular development and ovulation.
After these 36 cycles were evaluated, mares were mated by 
artificial insemination. A viable embryo was recovered in 75% of the 
saline-treated control mares. One viable embryo from 5 (20%) phenyl­
butazone-treated mares was recovered. The pyometra exhibited at 
embryo collection may have been due to contaminated semen collection 
and insemination equipment. These same mares were used in Experiment 
IV but were mated by natural service from a different stallion and 
did not exhibit any pyometra.
Results from Experiment I could have been substantiated by 
having control mares for the cyclicity part of the experiment and by 
more breeding cycles in a switchback design. This was not possible 
due to lack of both available mares and time to breed and collect 
embryos before these mares were to be used for another purpose.
Experiment II results determined that phenylbutazone 
parenterally administered to mares accumulated in detectible levels 
in uterine flushes recovered from inflamed uteri of mares exhibiting 
either a high or low concurrent peripheral progesterone concentra­
tion. There was a trend for phenylbutazone positive uterine flushes 
to be from mares with a corresponding low progesterone concentration, 
as determined in 7 of 9 of the phenylbutazone positive secretions. 
Treated mares exhibiting a nonpathological uterine environment had no 
detectible phenylbutazone levels in uterine fluids.
Results suggest that phenylbutazone treatment enhanced (P < 
0.001) the incidence of uterine infection. Possibly the pyometra 
exhibited in Experiment I was potentiated by the phenylbutazone 
treatment.
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Experiment III results suggested that phenylbutazone treatment 
will cause inhibition of prostaglandin systhesis and blockage of 
luteolysis only in those mares with an existing uterine inflammatory 
reaction. The synthesis and cyclic release of uterine prostaglandin 
from a nonpathological equine uterus appears to be unaffected by 
parenteral treatment of the mare with phenylbutazone.
Results of Experiment III established a workable model to test 
the effect of other NSAID or corticosteroids on luteolysis.
Experiment IV results suggested that fertilization was not 
impaired by parenteral treatment of mares with phenylbutazone. 
Cellular aspects of the blastocysts recovered from phenylbutazone- 
treated mares appeared typical; however, the embryos were noticeably 
smaller and appeared more fragile than those from control mares.
Assay results suggested that phenylbutazone significantly inhibited 
embryo synthesis of prostaglandins.
Results of Experiment IV suggested methods modifications to be 
used to design Experiment V. The embryo collection filter was 
removed from the collection system because embryos broke when the 
conceptus hit the filter screen. Results of the prostaglandin assay 
led to the decision to collect day 10 embryos and incubate them for 
24 hours in 6 ml PB-1 holding medium. It was decided to subsequently 
photograph future embryos to determine diameter. A homogenization 
procedure was added to prepare embryos for the Lowry protein assay.
Results of Experiment V showed there was no significant 
difference between embryos from phenylbutazone-treated and saline 
control mares for prostaglandin synthesis; however, synthesis of 
PGF2 <x by embryos collected from phenylbutazone-treated mares compared
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with embryos from saline control mares approached significance (P = 
0.06). There was a reduced concentration of all 3 prostaglandins 
synthesized by embryos from phenylbutazone-treated mares as compared 
with embryos from saline control mares. Results suggested that 
maternal phenylbutazone treatment may inhibit embryo prostaglandin 
synthesis and embryo expansion, but it apparently does not affect 
fertilization, embryo viability and total protein. There was a 
significant correlation between an increase in the length of the 
breeding season as it progressed from June to October and an increase 
in total amount of protein/embryo. This phenomenon may have been due 
to loss of embryo protein during the longer storage time of embryos 
collected early in the season compared with those collected in the 
fall. However, this may also have had a physiological basis.
Results of all experiments suggest that it would be acceptable 
to chronically treat a breeding mare exhibiting a nonpathological 
uterus with phenylbutazone until conception. After fertilization, 
however, the phenylbutazone may affect embryo development. Further 
studies are needed to access the affect of chronic treatment of 
pregnant mares with phenylbutazone on embryo development.
NOTES
Experiment I was published in Veterinary Medicine/Small Animal 
Clinician, January, 1983, Volume 78, pp. 83-85.
Appendix III was published in Theriogenology, December, 1986, 
Volume 26, pp. 779-793 as part of a validation of this assay for 
general veterinary use.
Experiment II was presented at the 36th Annual Meeting of Animal 
Disease Research Workers in the Southern States, March, 1983.
Appendix IV was published in the Journal of Veterinary 
Pharmacology and Therapeutics 9, 227-229, 1986.
Experiment III was published in Theriogenology, 23, 381-387,
1985.
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APPENDIX I
Ingredients of modified Dulbecco's 
Phosphate-Buffered Saline Solution
Ingredient Amount (g)
CaCl2.2H20 1.325
MgCl2.6H20 1.00
NaCl 80.00
KC1 2.00
Na2HP04 11.50
k h2p°4 2.00
Glucose 10.00
Streptomycin sulfate 0.50
Na pyruvate 0.36
Penicillin G, sodium (1,000,000 IU)
Fetal calf serum 200 ml
Distilled H20 q.s. to 10 liters
Adapted Imel et al. (1981)
APPENDIX II
Ingredients of one liter PB-1 embryo holding medium
Ingredient Amount
Stock Solution
Dulbecco's Phosphate Buffered Saline (PBS) 1 liter
Bovine Serum Albumin (BSA) 4 g
Glucose 1 g
Sodium pyruvate 0.036 g
Phenol red 1 ml
The following ingredients were added to the stock solution 
just prior to use.
Fetal Calf Serum (FCS) 
Penicillin (IU/ml) 
Streptomycin (wg/ml)
10%
100
100
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Val|g^tion of a new commercial, solid-phase, no-extraction 
I progesterone radioimmunoassay kit for monitoring 
luteal function in the mare
OBJECTIVE
125To validate a new commercial, solid-phase, no-extraction I 
progesterone radioimmumoassay kit for monitoring luteal function in 
the mare.
MATERIALS AND METHODS
On December 1, 1980, and daily thereafter, a heparinized blood 
sample was collected from each mare in Experiment I via jugular 
venipuncture. Samples were immediately placed on ice for storage 
until transfer to the laboratory. Samples were then centrifuged. 
Plasma was poured into plastic vials and stored at -20°C until 
assayed.
During the sampling interval, mares were monitored via rectal 
palpation and teasing to detect ovulation and behavioral estrus.
All samples (n = 547) were assayed by 2 different assay 
procedures. First, plasma samples were assayed for progesterone 
using a modified procedure of a previously validated RIA method as 
described by Abraham et al., 1971. Nano-grade petroleum ether was 
used for plasma extraction. Separation of free from bound steroid 
was accomplished with dextran-coated charcoal. The specific antiser­
um used was CSU No. 337 (Colorado State University, Fort Collins,
CO). The intra- and inter-assay coefficients of variation were 9 and 
10%, respectively, for a plasma pool averaging 8 ng/ml of progester-
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one.
Secondly, a 100-pl volume of plasma was assayed using the 
commercial kit assay (Coat-A-Count No-Extraction Progesterone Assay, 
Diagnostic Products Corp., Los Angeles, CA), which had been 
previously developed for human serum. Seven progesterone standards 
(0.0, 0.1, 0.5, 2, 10, 20 and 40 ng/ml in human serum) were furnished 
with the kit assay for construction of the standard curve. In 
addition, a second set of standards was diluted with stripped equine 
plasma to determine if plasma components would interfere with the 
binding of the labeled hormone to the antibody.
A correlation analysis was utilized to evaluate relationships 
between the 2 assay methods.
RESULTS
An example of plasma progesterone levels from 2 cyclic mares 
(No. 1 and 3) from Experiment I using both the extraction assay and 
direct no-extraction assay methods are presented in Figure I.
Results from the direct method are regressed against those from the 
extraction method for the same 2 mares in Figure II. For all 9 mares 
and all cycles used in the study there was good agreement for proges­
terone levels up to 2 ng/ml using both assay methods (Figure II). 
Above that level, the direct method resulted in increasingly higher 
progesterone values than the extraction method. Correspondingly, the 
slope of the regression line relating the 2 methods was not the same 
for all mares (Figure II). One mare in the group (No. 8) had higher 
progesterone values over the full range of sampling when monitored by 
the direct method (Figure II). The reason for this could not be
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ascertained.
A total of 547 plasma samples from 9 cyclic mares was assayed 
by both methods. When all data were included, the formula best 
describing the relationship between the 2 progesterone data sets was 
exponential with a correlation coefficient of 0.938. The resulting 
equation was y = 1.27(x^*®^), where y was the result of the direct 
method and x was the result of the extraction method.
When the human serum standards were diluted 1:1 with stripped 
mare's plasma, the percent bound hormone was reduced to an average of 
8.1% below the standards of equal progesterone concentration fur­
nished with the kit (Figure III). When this diluted standard curve 
was used, the progesterone values for plasma samples were similar to 
those resulting from the extraction assay. These findings suggest 
that the 2 assays would have been closer in agreement if the stan­
dards were diluted in stripped equine plasma.
Plasma samples with progesterone values ranging between 20 and 
28 ng/ml using the direct method were then diluted 1:1 with zero 
standards furnished with the kit and sebsequently reassayed. When 
the results were corrected for the dilution, values were within 11.3% 
of the undiluted values, indicating that the assay did provide 
reproducible progesterone values in this range for mares.
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Figure I. Plasma progesterone profile for 2 cyclic 
■ares (No. 1 and 3) assayed by both an extraction, 
liquid-phase assay and the no-extraction, solid-phase 
assay. Estru6 and ovulation in these aares were 
determined by teasing and rectal palpation of ovarian 
structures.
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Figure II. Results from a direct assay regresssed 
against results for the same samples assayed by an 
extraction assay. Data from two mares (No. 1 and 3, 
see Figure I) were pooled. Values from one mare 
(No. 8) are plotted separately because the plasma 
showed exaggerated values across all concentrations 
compared with other mares.
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Figure III. Logit-log plot demonstrating the effect 
of adding stripped mare plasma at a ratio of 1:1 to 
the standards on binding of the radioactive progest­
erone to the antibody.
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DISCUSSION
Results of the extraction, liquid-phase progesterone assay 
validated the use of the new, commercial, no-extraction solid-phase 
Coat-A-Count progesterone assay kit when exact concentrations are not 
necessary above 2 ng/ml. The extraction, liquid-phase method 
presented lower progesterone concentrations when compared with the 
Coat-A-Count kit.
The direct, solid-phase RIA kit offers a fast, convenient and 
acceptable method for monitoring luteal function during the estrous 
cycle of mares. The direct-assay progesterone concentrations may not 
be in complete agreement with those obtained by the extraction, 
liquid phase method, especially during diestrus. If absolute values 
for progesterone are required, an extraction step may be desirable 
with the direct RIA method. The practice of diluting the kit stan­
dards with stripped equine plasma may be an acceptable alternative.
The kit is of potential use to the equine industry for (1) 
detecting estrus in shy breeders who do not display estrual behavior; 
(2) to plan ahead for appointment breedings; (3) to confirm diestrus 
progesterone levels and then plan to feed a commercial progesterone 
supplement in order to prevent competition mares from coming into 
estrus during the meet.
The kit appeared to be acceptable for use in future experiments 
when mare cyclicity was to be evaluated rather than absolute proges­
terone concentrations.
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APPENDIX IV
Effect of sodium heparin and ethylenediaminotetraacetate 
(EDTA) anticoagulants on phenylbutazone levels in equine 
plasma detected by high performance liquid chromatography
OBJECTIVE
The objective was to determine whether the anticoagulant used 
(sodium heparin or EDTA) alters the results from high performance 
liquid chromatography (HPLC) analysis for phenylbutazone in equine 
plasma.
MATERIAL AND METHODS
Plasma samples were obtained daily via jugular venipuncture at 
approximately the same time each morning before feeding. A 15 ml 
vacutainer (Becton-Dickinson, Rutherford, NJ) containing 286 USP 
units of sodium heparin was filled and detached and then an EDTA-K^ 
(Becton-Dickinson, Rutherford, NJ) tube was placed on the same 20 
gauge needle and filled. The vacutainers were immediately placed on 
ice. After the plasma samples were obtained, each treated mare was 
given 2 g phenylbutazone intravenously. Within 1 hour the vacutain­
ers were centrifuged in a refrigerated centrifuge for 10 minutes at 
2000 rpm. The plasma was immediately poured into sterile vials and 
stored at -20°C until analysis. Visual inspection revealed that all 
samples were free of hemolysis.
Concentrations of phenylbutazone in all plasma samples were 
determined by HPLC as described by Taylor et al., (1981), with minor
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modifications. The organic extraction solvent was removed in a stream 
of air in place of nitrogen (Appendix V). The HPLC solvent (80:20 
mixture of n-hexane:tetrahydrofuran containing 0.002% glacial acetic 
acid) was delivered at a flow rate of 2 ml/minute rather than 100 
ml/hour. The same HPLC instrumentation was used as in Experiment II.
Peaks were measured with an ultraviolet absorbance detector at 
240 nm and 0.1 absorbance units full scale using a strip chart re­
corder. The phenylbutazone and hexoestrol (internal standard) peaks 
were measured to the nearest mm by hand from the strip chart record­
er.
Forty-two paired heparin and EDTA plasma samples were selected 
for analysis. Each sample was processed in duplicate. Pairs were 
extracted on the same day, dried under an air stream, covered and 
stored overnight at room temperature. The extracted samples were 
reconstituted and subjected to chromatography the next day. Extracts 
of the heparinized sample were always chromatographed first followed 
by the corresponding EDTA sample.
The phenylbutazone concentration was determined both by using 
the internal standard method, and by reference to an external 
standard curve of phenylbutazone alone. A paired Student's t-test 
(Snedecor and Cochran, 1980) was performed to determine if any 
difference existed between the mean EDTA and heparin plasma 
phenylbutazone concentrations by either the internal or external 
standard methods. Linear regression analysis (Snedecor and Cochran, 
1980) contrasting the paired values for the 2 anticoagulants was 
performed. The regression equation for the internal standard method 
was:
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[phenylbutazone-EDTA] = 0.862[phenylbutazone-heparin] -0.142yg/ml.
For the external standard method the equation was:
[phenylbutazone-EDTAJ = 0.819 [phenylbutazone-heparin] -0.002yg/ml.
When the highly significant difference between plasma phenylbu­
tazone levels in samples collected at the same time using different 
anticoagulants was observed, a subsequent study was conducted. Plas­
ma samples, either EDTA or heparin, collected from untreated mares 
were separately pooled. Phenylbutazone was added to aliquots of both 
the plasma pools at 15 known concentrations. The plasma samples were 
frozen, stored, processed and analyzed as in the first experiment. 
Peak height ratios and phenylbutazone peak heights of the paired sam­
ples at the 15 known concentrations were evaluated using the Stu­
dent's paired t-test.
RESULTS
Using either the internal or external standard methods, the 
heparinized samples gave in higher phenylbutazone values (P < 0.01). 
Mean plasma phenylbutazone concentrations, calculated with the use of 
the internal standard, were 5.49 and 4.59 ug/ml for heparin and EDTA, 
respectively, and 4.98 and 4.07 ug/ml by use of the external standard 
method. For both the internal and external standard methods, a high­
ly significant (r = 0.96, P < 0.01) linear relationship was noted 
between the phenylbutazone concentrations of paired heparin and EDTA 
plasma samples.
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Results of the subsequent study using pooled mare plasma spiked 
with phenylbutazone showed no significant differences between the 
phenylbutazone levels for the heparin or EDTA plasma pools for either 
the internal or external standard methods (Table I).
Table I. Peak height ratios and peak heights of pooled equine
plasma spiked at 15 known phenylbutazone concentrations
Peak height ratios t-test value
Internal standard method
Heparin 0.313 + 0.06a 0.452
EDTA 0.311 ± 0.06 (NS)
External standard method
Heparin 2.522 + 0.40 1.007
EDTA 2.340 + 0.40 (NS)
a Mean (± SEM)
DISCUSSION
The initial study demonstrated an apparent difference in plasma 
phenylbutazone concentrations dependant on the anticoagulant used 
during blood collection. Heparinized plasma consistently yielded 
higher values than EDTA plasma. For several pairs of samples phenyl­
butazone was detected in the heparin sample, but trace levels or no 
phenylbutazone was detected in the EDTA sample. However, when pooled 
plasma was spiked with phenylbutazone to make standard curves, no 
differences were detected. For both EDTA and heparin plasma, the 
limit of detection was 0.03 yg/ml of plasma. Therefore, the differ­
ence does not appear to be attributable to anticoagulant effects on
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the extraction or assay procedure. It has been reported (Taylor et 
al., 1983) that hemolysis reduces phenylbutazone concentration in 
plasma. No visible hemolysis was detected in any of the plasma 
samples used for these studies and does not appear to have been a 
factor. An area which remains unexplored is the effect of the 2 
anticoagulants on erythrocytes which could allow sequestration of 
phenylbutazone by the erythrocyte. Apparently the erythrocyte and 
its separation from the phenylbutazone containing plasma is critical 
to this phenomenon, but no explanation is offered at this time.
The research investigator or regulator of performance horses 
and the veterinary practitioner should use heparinized plasma for 
phenylbutazone analyses, or at least specify which anticoagulant was 
used. Differences observed in absolute levels were significant and 
the potential failure to detect phenylbutazone in an EDTA plasma 
sample when it would be detected in heparinized plasma sample must be 
considered.
APPENDIX V
Preliminary high performance liquid chromatography 
procedures and modifications used to determine if the 
published method could be used in Experiment II
Preliminary studies were conducted to determine if the same 
analysis method described by Taylor et al. (1981) could be success­
fully used in this experiment to determine the concurrent concentra­
tions of phenylbutazone in peripheral plasma and uterine secretions 
of mares.
Standard solutions were prepared exactly as the published 
method and injected several times into the HPLC system. The standard 
phenylbutazone concentration versus the peak height in centimeters 
(cm) resulted in a linear relationship as reported. Then, 10 pi of 
the same standards were used to spike 2 ml aliquots of pooled mare 
plasma collected in EDTA vacutainers. The exact extraction procedure 
was carried out, specifically removing the solvent in a stream of 
nitrogen at room temperature as described. A relatively linear rela­
tionship resulted for aliquots with up to 15 yg phenylbutazone/ml 
plasma. These results indicated that the plasma procedure was 
successful.
At this time it was decided to see if the same results could be 
obtained by removing the solvent in a stream of air rather than ni­
trogen because (1) a limited supply of nitrogen was available at the 
time; (2) nitrogen was too expensive to buy on a limited budget; (3)
1 extraction alone consumed about one half a nitrogen tank; (4) it 
would be difficult to keep a large supply of nitrogen on hand consi­
dering the number of samples to be analyzed for this experiment.
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Duplicate 2 ml aliquots of EDTA plasma were spiked with 10 pi of 4.0 
mg/ml, 2.0 mg/ml or 0.4 mg/ml phenylbutazone standards. One set was 
dried with air and the other with nitrogen. The results indicated 
that there was little difference in peak height and that the possi­
bility of using air instead of nitrogen should be further explored 
(Table II).
Table II. First results of plasma phenylbutazone (PBZ) standards 
dried in either a stream of ^  or air
Peak Height (cm)
Plasma Std. Cone. 
(ygPBZ/ml plasma) Air Nitrogen
20.0
10.0
2.0
4.45
1.09
2.07
5.45
1.06
2.07
Next, the lowest and highest standard phenylbutazone 
concentrations were analyzed either dried in air or nitrogen (Table 
III).
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Table III. Second results of plasma phenylbutazone (PBZ) standards 
dried in either a stream of air or
Peak Height (cm)
Plasma Standard Concentration
(ygPBZ/ml plasma) Air_________ Nitrogen
2.0 1.60 1.50
1.65 1.15
1.95 1.15
1.75 * 1.20
deleted 1.10
Statistics
Mean = 1.74 1.22
SEM = 0.15 1.61
CV = 8.91% 13.20%
t-test = 4.8808 (P < 0.005)
df = 7
Technical error
20.0 4.80
4.15
5.30
5.00
4.70
4.50
5.10
5.35
4.91 
0.38 
7.80%
t-test = -0.3225 (NS)
df = 6
Mean = 4.81
SEM = 0.49
CV = 10.10%
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These results indicate that at the lower phenylbutazone 
concentrations there is a significant difference between drying with 
air and nitrogen, with the mean peak height of the air samples being 
greater than the nitrogen samples. At the higher phenylbutazone 
concentrations, no significant difference between the 2 drying 
processes was demonstrated. Considering the circumstances and these 
results, it was decided to air dry at room temperature all future 
samples.
Another standard curve was run with all samples being dried in 
a stream of air. Two ml aliquots of pooled EDTA mare plasma were 
spiked with 10 pi of the standard solutions. The standards were made 
in August, 1982, and this data was collected in December, 1982. It 
had been reported by previous researchers that the standards could be 
kept in the refrigerator for at least a month without significant 
degradation (Burns et al., 1953). Even though peak height versus 
phenylbutazone concentration resulted in a linear relationship (r = 
0.9942) it was decided to avoid contamination and dilution effects 
(caused by opening and closing the standard vials) by discarding 
these standards and making new ones. In the future, new standards 
were to be made and used for only approximately a month.
APPENDIX VI
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High performance liquid chromatography preliminary 
procedure to determine if phenylbutazone concentrates in 
supernatant or sediment of uterine fluids
Purulent yellow uterine flushing secretions collected from 
control mares were pooled, measuring 250 ml. The solution was 
stirred with a magnetic stirer for 20 minutes. Then, 800 pi of 0.05 
mg/ml phenylbutazone standard was added and the mixture was stirred 
for 30 minutes. Then, it was centrifuged at 2800 rpm for 20 minutes. 
The supernatant was poured off in 20 ml aliquots into 6 tubes. The 
sediment pellet was resuspended in the remainder of the supernatant, 
measuring 125 ml.
The supernatant and resuspended sediment pellet solutions were 
divided into 25 ml aliquots and were analyzed in duplicate as 
described in Experiment II. An unpaired Student's t-test comparing 
chromatographic phenylbutazone peak heights of the supernatant and 
the sediment determined that phenylbutazone concentrates in the 
supernatant (P < 0.05) of uterine secretions.
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APPENDIX VII
High performance liquid chromatography interassay, 
intrassay and limit of detection study
Determination of Reproducibility and Standard Curve
An interassay and intrassay study utilizing pooled plasma 
spiked with the standard phenylbutazone solutions was conducted in 
triplicate. Discrepancies were minimized in each assay by taking all 
samples from the same plasma pool, using only the fresh standards, 
and running the whole set of samples from the same batch of mobile 
phase. Each time, the samples were extracted one day and allowed to 
sit covered overnight at room temperature and were assayed the next 
day. Three sets of triplicate samples were assayed. Two ml of 
pooled EDTA mare plasma was spiked with 10 yl of standard solutions 
of 0.00, 0.05, 0.10, 0.20, 0.40, 1.0, 2.0 or 4.0 mg phenylbutazone 
/ml. Three samples of each concentration were analyzed in each 
assay.
Determination of Limits and Percent Recovery
The next study was to determine the extraction limit of 
detection, the HPLC instrument limit of detection and the percent 
recovery from both EDTA and heparin plasma samples. All samples were 
again extracted one day, and assayed the next day.
Both EDTA and heparin plasma samples were assayed together 
under the same experimental conditions to compare results. Two 
separate plasma assays were conducted. Each plasma sample contained 
2 ml aliquots of pooled heparin or pooled EDTA plasma plus a known
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amount of a single, 0.1 mg/ml standard solution. Both the EDTA and 
heparin samples were run in duplicate spiked with 2, 4, 8, 10, 12,
14, 16, 20, 22, 25, 30, 40, 45 or 50 pi aliquots of 0.1 mg/ml 
standard. Hamilton syringes were used to spike the samples. All 
plasma residues were reconstituted with 150 pi tetrahydrofuran and 10 
pi were injected into the HPLC instrument. An instrument limit of 
detection was conducted at the same time as the extraction limit of 
detection in order to determine the percent recovery. All samples in 
each assay were run with the same batch of mobile phase. Care was 
taken to maintain the same experimental conditions for all plasma and 
instrument samples within an assay.
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APPENDIX VIII
High performance liquid chromatography preliminary 
uterine flushing study
The amount of uterine flushing from phenylbutazone-treated 
mares necessary to elicit a positive response was determined by trial 
and error. A standard curve and a spiked uterine flushing sample 
were run with each assay to confirm that the extraction procedure 
worked. Two, 3, 4 and 5 ml aliquots of uterine flushings were 
assayed from mares giving a phenylbutazone positive plasma sample.
The uterine samples were extracted and analyzed the same as plasma.
All cloudy uterine samples from untreated mares were negative 
for phenylbutazone. Flushings from 2 treated mares which appeared 
yellow and contained a sediment of purulent material were assayed in 
duplicate using 1, 4 and 8 ml aliquots. Plasma samples were phenyl­
butazone positive, but all uterine flushings were negative. Next, 
six 25 ml aliquots of flushings classified as clear (2), cloudy (2) 
or yellow purulent (2) were extracted. The extraction procedure was 
the same as plasma with the following exceptions (1) 2 ml HCL was 
used to deproteinize; (2) the residue was reconstituted with 50 yl 
tetrahydrofuran. All corresponding plasma samples were phenylbuta­
zone positive. The 4 clear or cloudy flushes were negative, but the 
2 purulent yellow flushes were phenylbutazone positive, one eliciting 
a phenylbutazone peak of approximately 40 parts per billion (ppb) and 
the other 120 ppb. It was then decided that all uterine flushings 
would be extracted as above in 25 ml aliquots because a positive 
response was obtained and it was a convenient size considering the
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centrifuge and other laboratory equipment available.
The uterine flushing limit of detection and percent recovery 
study was conducted with pooled uterine flushings from the control 
mares. Twenty-five ml aliquots of flushings were spiked with 2, 4,
8, 10, 14, 16, 20, 22, 25, 30, 35, 40, 45 or 50 yl of 0.1 mg/ml 
standard solution. The residue was reconstituted with 50 yl of 
tetrahydrofuran and 10 yl of each sample were injected into the HPLC 
machine.
Next, an interassay and intraassay coefficient of variation was 
conducted on the uterine secretions. Four separate assays were run 
with 4 samples of 20, 25, 30 or 35 yl of 0.1 mg/ml standard solution 
in 25 ml aliquots of pooled flushing. Again, the residue was 
reconstituted with 50 yl tetrahydrofuran and 10 yl of each sample was 
injected into the HPLC instrument.
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